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Overview of Chapters 
Chapter 1 
Chapter 1 provides the relevant background information about the pathology, aetiology and current 
pharmacological treatments of asthma. It also explores the potential mechanisms of the action of 
magnesium and the evidence for its efficacy and introduces possible explanations for the 
heterogeneity of its effect. 
Chapter 2 
This laboratory study was designed to illustrate the potential mechanism of the effect of magnesium 
in acute asthma, by assessing the effects of magnesium on β-2 agonist-induced cAMP in human 
peripheral lymphocytes. This study demonstrated a reduction in β-2 agonist responses in acute 
asthmatics relative to non-asthmatics and suggests that there are intrinsic sex differences in 
susceptibility to down-regulating influences on β-2 responses. These differences corresponded with 
apparent sex differences in the efficacy of magnesium and support an effect of magnesium on agonist 
responses. 
Chapter 3 
This chapter is a clinical trial designed to optimize the selection of acute asthmatics presenting with 
exacerbations, who would benefit the most from magnesium treatment as an adjunct to standard 
treatment. The sample size was insufficient to draw any conclusions regarding the efficacy of 
magnesium. This study showed that the Asthma Control Questionnaire (ACQ) score was a significant 
predictor of an outcome of admission to hospital. 
Chapter 4 
This chapter is a re-analysis of the 3M clinical trial of magnesium in asthma. A sub-set of Caucasian 
asthmatics aged between 18 and 50 years old, who received intravenous magnesium vs. placebo, was 
analysed. The findings in this sub-set suggest a sub-group benefit limited to males and those with 
severe exacerbations. 
Chapter 5  
This chapter reviews the findings and provides a rationale for guidelines on the use of magnesium in 
adult asthma and explores the possibilities for future research in this area. It also discusses the further 
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Asthma is a common respiratory condition that affects adults and children. Treatment options for 
acute exacerbations are limited. Magnesium could provide additional benefit when used in 
conjunction with β-2 agonists however, the evidence for its efficacy is lacking. Meta-analysis 
suggests that severity is an important factor in response to magnesium. The results of published 
clinical trials are heterogeneous, suggesting that individual factors may influence response to 
treatment with magnesium. The literature also shows that there are sex differences in aetiology of 
asthma which could influence treatment response. Phenotypes also vary with ethnicity and atopy and 
these factors could also influence treatment response. 
The aims of the thesis were; to examine the effects of magnesium on β-2 agonist stimulation of the β-
2-adrenergic receptor (β-2AR) on lymphocytes collected from asthmatics and compare these effects 
with non-asthmatics in vitro, and to determine if cellular responsiveness to magnesium is altered by 
asthma severity and patient sex or other factors such as atopy; to examine effects of the addition of 
intravenous magnesium to optimal standardised treatment in acutely exacerbating adult asthmatics in 
the emergency department; and to re-analyse 3M trial data to examine the effects of magnesium 
between severity subgroups and in relation to patient sex.  
The interpretation of the results of the in vitro studies is limited by small sample sizes. The in vitro 
studies suggested that there are sex differences in β-2AR function which could influence treatment 
response. The in vitro studies found that β-2ARs in lymphocytes of healthy females were more 
responsive to agonist stimulation relative to healthy males however, lymphocytes of asthmatic 
females were less responsive to agonist stimulation relative to asthmatic males. Magnesium was more 
effective in male asthmatics relative to female asthmatics, in augmenting β-2 agonist stimulation of 
the receptors, as indicated by the difference in cAMP elevations. This suggests that magnesium may 
be more effective in improving β-2AR responsiveness in males. The sample size was too small to 
assess the effects of atopy on β-2AR responses and the effects of magnesium on those responses. 
I was unable to determine a benefit from the use of magnesium for the treatment of acute asthma 
relative to standard care alone, due to the small numbers recruited to the trial. The small sample 
prevented me from determining any subgroup benefits.  
In my re-analysis of the 3M trial data, I found that there was a benefit from magnesium in those with 
severe asthma, as defined by PEF 33-50% predicted. The data also showed that there were sex 
differences in response to magnesium. Magnesium’s effect on reducing admission rates compared to 
placebo was greater for males relative to females. When the sexes were assessed separately, the 




Individual differences in β-2AR responses may account for differences in efficacy of magnesium. 
These may relate to differences in sex, and possibly atopic status and ethnicity, with potential 
interactions between sex and atopy. Further study may be warranted to confirm the initial findings and 
to further explore the effects of sex-atopy and ethnicity in a larger sample of asthmatics. It is likely 
that magnesium is a safe and inexpensive optional addition to the treatment of acute asthma in those 
patients failing to respond to standard treatment however, its utility and effectiveness may be limited 





Chapter 1: Introduction: background and rationale for 
the research 
 
1.1 Asthma Overview 
1.1.1 Definition and diagnosis 
There is no gold standard or universally agreed or accepted definition of asthma. The term asthma, 
describes a group of disorders that share the common clinical manifestations of recurrent episodes of 
wheezing, often accompanied by cough, chest tightness and breathlessness. These symptoms are due 
to bronchial or airway hyper-responsiveness (AHR) which causes episodic attacks of airways 
obstruction. The episodes either resolve spontaneously or require treatment [1]. This type of wheezing 
is distinct from chronic obstructive pulmonary disease, where the symptoms and the obstruction are 
persistent and less responsive to treatment. International and national asthma guideline definitions 
incorporate such descriptions [2-4].  
The universal clinical characteristic used in all definitions, is that of airway hyper-responsiveness 
(AHR) with reversible airflow obstruction [1] and the exclusion of other causes of wheezing, such as 
cystic fibrosis and alpha-1-antitrypsin deficiency. These conditions have distinct pathophysiological 
and aetiological causes. There are no universally agreed gold standard criteria for asthma diagnosis. 
National and international respiratory disease authorities, including the International Classification of 
Diseases Registry (ICD-10), The Global Initiative for Asthma (GINA), British Thoracic Society 
(BTS) and the National Asthma Council Australia (NACA), list various criteria for diagnosis. 
Recommendations for diagnosis are a combination of history, clinical features and lung function 
measurement, with or without provocation tests. Central to the diagnosis, is the history of episodic 
symptoms and demonstration of reversible airways obstruction.  
Airways obstruction can be demonstrated during the measurement of a forced expiratory manoeuvre, 
(after a full inspiration to total lung capacity), such as a peak expiratory flow (PEF). The use of PEF  
measurements for asthma diagnosis, are no longer recommended [2]. Alternatively, the volume of air 
expelled in one second during forced expiration (FEV1), can be measured against the total volume 
that is expelled during forced expiration (FVC). This produces an FEV1/FVC ratio that can be used to 
demonstrate obstruction. A fixed ratio of less than 0.7 in adults, suggests airflow limitation [4]. More 
recently, the use of this ratio has been discouraged and the use of an age-related ratio is 
recommended, as this ratio varies with age [5]. A ratio below the lower limit of normal for age, 
ethnicity and sex, is recommended to diagnose the presence of lung disease [5]. A bronchodilator 




accepted as a prerequisite for a diagnosis of asthma [2-4, 6]. Demonstration of reversibility may 
distinguish asthma from other forms of obstructive airway disease, such as emphysema and chronic 
bronchitis, but there can be overlap of these diagnoses [7].  
For patients where a clinical diagnosis is made but spirometry is normal, measurement of airway 
hyper-responsiveness (AHR) may assist with diagnosis. AHR is measured by the concentration of 
inhaled agonist (methacholine or histamine) that induces a decrease in FEV1. It is defined as the 
provocative concentration to cause a 20% fall in FEV1 (PC 20). The sensitivity and specificity of the 
PC 20 result depends on the concentration of agonist [8]. Patients breathe incrementally increasing 
concentrations of the agonist until a fall in FEV1 of 20% is reached. If a patient tolerates a 
concentration of 16mg/mL, this excludes asthma with reasonable certainty. If a patient has a PC 20 of 
1mg/mL, the specificity and positive predictive value for the presence of AHR is close to 100%. A 
positive result does not confirm the diagnosis, as patients with other forms of obstructive lung disease 
may demonstrate AHR. Alternatively, a provocative dose of the inhaled agonist to cause a 20% fall in 
FEV1 (PD 20) may be used to measure AHR. A PD 20 of 100 µg is equivalent to a PC 20 of 
1mg/mL. 
The presence of AHR is not limited to asthmatics or those with lung disease, as AHR has been found 
to occur in healthy children, in the absence of other features of asthma [9]. The lack of a gold standard 
diagnosis and an absolute definition of the disease asthma can create difficulties when attempting to 
assess asthma prevalence and the results of clinical studies. 
 
1.1.2 Prevalence, distribution and burden of disease 
Much of the information on worldwide trends in the prevalence of asthma has been derived from 
surveys of atopic wheeze in children, therefore, is not applicable to all asthmatics. These large multi-
centre studies have used self-reporting/parental reporting of symptoms of wheeze, as well as 
physician diagnosed asthma [10, 11]. Although this method of assessment is valid [12-16], under-
reporting [15, 17, 18] and disparities between the methods of surveys [19] have been shown to occur. 
National medical databases have also been used to determine prevalence [20]. These databases are 
arguably a more accurate method of assessment however, they are reliant on clinician diagnosis of a 
condition without gold standard diagnostic criteria.  
Given these limitations in data collection, asthma is estimated to be responsible for 1% of the total 
global disease burden and responsible for 250,000 deaths annually worldwide [3]. It is also the 24th 
most common cause of lost productivity due to disability worldwide [21]. Its prevalence has increased 




The prevalence of asthma tends to vary depending on geographic location and socio-economic status. 
Asthma prevalence in children is highest in the developed world, with up to 15-fold differences in 
prevalence rates between countries [23]. English-speaking countries and Latin America have the 
highest prevalence. Under-developed regions of South East Asia and the Indian subcontinent have the 
lowest asthma prevalence however, this varies between regions and is highest within their affluent 
populations. Prevalence studies in adults show a similar trend [10]. Within geographic regions, further 
variation in asthma prevalence is associated with the degree of urbanization [24, 25], with a lower 
prevalence of asthma in children raised on farms compared with urban centres [26, 27]. Meta-analysis 
of epidemiological studies suggests that the prevalence of asthma symptoms in adults and children is 
increasing [28] and is reflective of increases in urbanization around the world. 
Asthma in Australia 
The statistics from Asthma Australia, as obtained from the Australian Bureau of Statistics, show that 
2.7 million Australians (1 in 9) have a diagnosis of asthma [29]. The prevalence of asthma is twice as 
high for indigenous Australians relative to non-indigenous Australians. In 2015, an estimated $1.2 
billion was spent on asthma treatment, with the largest portion on prescription medicines (50%) and 
hospital admissions accounting for 20% of the cost [30]. Deaths due to asthma are relatively few, with 
less than 500 per year in 2017 or less than 1 per 5000 asthmatics. Asthma deaths are more likely to 
occur in those living in remote areas, in those of low socio-economic status and in indigenous 
Australians [31]. 
Self-monitoring of symptoms, appropriate use of disease controlling medications and early 
management of exacerbations are important in managing asthma [32]. Formal written action plans are 
recommended for all those with asthma [32] however, only 21% of adults and 57% of children with 
asthma have formal action plans [31]. Increasing the proportion of asthma sufferers with formalized 
action plans and appropriate prescriptions of preventer medications, through better awareness and 
education, could reduce exacerbations and hence, reduce hospital presentations/admissions [33]. 
Improved disease control, through novel treatments for chronic symptoms and acute exacerbations, 
could also contribute to improved outcomes and reduced financial costs [34].  
 
1.1.3 Aetiology and pathogenesis 
There is no single aetiologic factor that has been found to be solely responsible in the development of 
asthma within an individual. Many different environmental factors interact with an individual’s 
genetics to influence development of the disease. An International Epidemiological Survey (ISAAC) 
found significant positive associations between asthma and the gross national product per capita 




have implied a genetic influence [36, 37] however, not all those who suffer from asthma have a 
positive family history. Genetics can also affect the severity of illness in childhood asthma [38].  
Multiple minor mutations in a variety of genes, affecting differing aspects of the asthma phenotype, 
act synergistically to influence the expression of the phenotype. These genes are influenced by 
environmental factors [39]. The risk of developing asthma may be modified via genetic 
polymorphisms [40, 41], as was illustrated in the Childhood Study of Asthma (COAST) study of 
genetics of asthma. This study found that the same genes could confer an increased or decreased risk 
of asthma, depending on the environmental exposure [42]. It was also found that none of these genes 
alone, nor environment alone, had a significant effect on the phenotypes.  
Although there are more than 170 genes on 15 chromosomes thought to be associated with asthma 
[43], these associations are not consistent. Variation in allele frequencies between different 
populations [44], sex differences [45] and ethnicity [46], have been shown to influence phenotypic 
expression. For example, the GPR154 gene located on chromosome 7p, linked to the G-protein 
coupled receptor present in smooth muscle and epithelium, was associated with AHR in an Asian 
population [47]. The ORMDL3 gene located on chromosome 17q21, was specifically associated with 
childhood asthma and asthma across three non-Caucasian populations [48]. Thus, in addition to 
environmental influences, genetic and ethnic influences on asthma expression appear to be 
population-specific. 
Theories of asthma pathogenesis 
There are three main theories of asthma pathogenesis. The first two pertain to early immune 
exposures, while the third postulates an intrinsic dysfunction of the β-2AR within the airway [49]. 
None alone explains the disease, as there are numerous different phenotypes with varying associated 
inflammatory patterns. 
The role of inflammation in the pathogenesis of asthma is debated, as there is evidence from human 
biopsy specimens to show that certain types of inflammation can be dissociated from AHR [50-52]. 
Eosinophilic bronchitis is a condition that is associated with eosinophilic inflammation of the airways 
however, there is no associated AHR [50, 51]. A study of asthmatic patients showed that the degree of 
inflammation, as determined by sputum, bronchial lavage or lung biopsy, was not correlated with the 
degree of AHR, as determined by methacholine inhalation [52]. At the same time, inflammatory 
mediators have been demonstrated to alter airway smooth muscle (ASM) properties [53], induce AHR 
in normal ASM [54], and exacerbate AHR in mild asthma [55].  
Inflammation has a role in promoting exacerbations [56], contributes to the severity of symptoms[57] 
and influences long-term lung function [58, 59]. Variation in the pattern of inflammation and 




structural alterations associated with asthma [61]. Thus, the pattern of inflammation influences the 
clinical features. 
The Thymic lymphocyte is the primary immune cell associated with asthma, and when activated, 
induces clonal expansion of T-cell sub-sets. These sub-sets are classified as helper (TH) cells and 
regulate the acquired immune response. The two main pathways of inflammation differ in their 
cytokine profiles and cell types recruited and activated. The TH1 pathway, is associated with 
neutrophilic inflammation and the TH2 pathway of eosinophilic inflammation, is associated with both 
atopic and non-atopic variants of asthma [62, 63].  
The atopic theory, proposes that early sensitisation to inhaled antigens stimulates eosinophilic/TH2 
inflammatory pathways, resulting in eosinophilic inflammation in the lungs and consequently, AHR. 
Although allergen inhalation induces eosinophilic inflammation and bronchoconstriction in 
asthmatics [64], the presence of eosinophilic airways inflammation in humans, has been shown to 
exist in the absence of AHR [50, 51, 65]; thus, atopic sensitisation as a mechanism for atopic asthma 
in humans remains controversial. Atopy has been shown to modulate the disease process [66]. 
Reduced sensitization to antigens improves symptoms [67] and influences the frequency/severity of 
exacerbations. Atopic status may be an important factor in influencing or modulating asthma 
phenotype. 
The ‘hygiene hypothesis’, postulates that ‘un-hygienic’ contact with infection, or early exposure to 
microbes, may stimulate innate (TH1) pathways and down-regulate acquired or TH2 pathways, and 
that this contact may be protective against atopic sensitisation and asthma [68]. Prenatal exposure, 
specifically to endotoxin, has been associated with lower asthma rates [26, 27]. Childcare attendance 
in the first six months, or households with multiple siblings, are also protective against developing 
asthma in childhood [69]. These outcomes suggest microbial exposure may be protective against 
atopic disease.  
 
 
1.2 The Pathology of Asthma 
1.2.1 Overview 
As with the aetiology, asthma pathology is diverse. Although all forms of asthma share a similar 
pattern of functional and structural alterations within the airways, there is variation in the severity of 
these changes, as well as the underlying or driving inflammatory processes. Human lung is composed 




the lung, that histopathological abnormalities are found. In addition to these visible changes in lung 
tissue of asthmatics, there are dynamic changes in the properties of ASM.  
There are several inflammatory cell types involved, and the predominating infiltrate varies between 
individuals. These inflammatory cells are derived from the pool of lymphocytes known as T-helper 
cells (TH), which are derived from Thymus tissue. Within the airways, are increased cellular 
infiltrates with T lymphocytes and varying numbers of eosinophils, neutrophils and macrophages 
[70]. Eosinophils predominate in allergic/atopic asthma [70, 71], while non-atopic asthmatics have a 
more mixed population of inflammatory cells [62]. Inflammation drives exacerbations [56] and 
contributes to severity of symptoms [57], and in the long term, reduces lung function [58, 59]. 
Variations in these inflammatory patterns are responsible for the phenotypic variations previously 
described [60].  
The pathology of asthma also involves structural changes in the lung tissues. Structural changes that 
can be seen histologically, involve the sub-epithelial or basement membrane (BM), the extracellular 
matrix (ECM) and the smooth muscle. These changes are referred to as remodelling. Thickening of 
the BM is only observed in the presence of eosinophilic inflammation [71, 72]. Mechanical factors are 
also thought to be significant contributors to these changes, due to the observation in vivo, that 
thickening of the BM was stimulated by methacholine challenge in asthmatic patients, independent of 
any additional recruitment of eosinophils [64]. Remodelling also involves an increase in both the size 
and number of smooth muscle cells, with hypertrophy predominating in the small airways and 
hyperplasia in the larger airways [73]. The ASM mass is increased proportionately to eosinophilia and 
mast cell numbers [74, 75]. In cultures of human airway smooth muscle (HASM), mechanical strain 
has been observed to induce the proliferation of HASM cells [76]. Increased ASM mass has been 
associated with asthma severity [77, 78], treatment resistance in paediatric asthma [79], and fatal adult 
asthma [80]. 
 
1.2.2 Airway smooth muscle and asthma 
Regulation of airway smooth muscle tone 
To maintain airway patency and adapt to the constantly changing loads imposed during the cycle of 
breathing, HASM tone is regulated by the balance of excitatory and inhibitory influences. This is 
largely regulated by input from the parasympathetic nerves of the autonomic nervous system, onto 
muscarinic receptors on the muscle membrane [81, 82]. The major neurotransmitter is acetylcholine 
(ACH), which causes bronchial smooth muscle contraction via activation of muscarinic receptors 
(M3) [83]. Noxious stimuli mediate the release of various neuropeptides, including Neurokinins, 




adrenergic receptors. These receptors are of the beta-2(β2) subtype [84] and are activated via 
endogenous β-adrenergic agonists in the blood [85]. The β-2 adrenergic receptor (β-2AR), is the only 
β-adrenergic receptor sub-type in airway smooth muscle, and the density of these receptors increases, 
as the diameter of the airway lumen decreases [84]. In contrast, the density of parasympathetic 
ganglia is greatest at the proximal bronchi [86].  
Molecular mechanisms of ASM contraction 
Activation of the M3 receptor in ASM and activation of its associated G-protein by ACH, causes 
ASM contraction via the production of second messengers. These second messengers regulate many 
down-stream events. Contraction/relaxation of ASM involves the formation and activation of the 
actin-myosin cross-bridge, like that of skeletal muscle, however, there is an additional process that 
involves polymerisation of cytoskeletal actin and myosin and re-arrangement of specialised filaments. 
This is dependent on and initiated by increasing intracellular calcium levels, which are regulated via 
release of intracellular calcium stores [87]. Unlike other smooth muscle types, membrane 
depolarisation and voltage gated calcium channels are not generally considered to be involved in 
ASM contraction [88].  
The release of intracellular calcium is achieved via activation of muscarinic receptors of the M3 sub-
type [82, 83], which stimulates its associated G-protein α sub-unit to activate the enzyme 
phospholipase C [89]. Phospholipase C (PLC) catalyses the production of the second messenger 
inositol-1-4-5 triphosphate (IP3) [90], via the IP3 receptors that are associated with calcium channels 
on the membrane of the sarcoplasmic reticulum (SR) [91]. Phospholipase C also effects the release of 
calcium from the SR that surrounds the myo-filaments [92-93]. Calcium is returned to its stores at the 
end of the contraction via sarcoplasmic reticulum/endoplasmic reticulum ATPase (SERCA), which is 
a calcium pump located on the surface of the SR [94].  
The intracellular increase of calcium occurs as a series of oscillatory waves [92]. The frequency of 
these oscillations are modulated in response to agonist concentrations and highest at the initiation of 
contraction [95]. The amplitude and frequency of these oscillations, influences ASM behaviour. An 
increase in oscillation frequency is associated with an increase in contraction [96]. 
The contractile apparatus 
In all muscle, the basic unit of contraction is formed by a thick filament composed of myosin and a 
thin filament composed of actin [97]. These filaments are arranged to overlap and form cross-bridges 
between the thin filament and the ‘head’ of the thick myosin filament [98]. The head contains the 




enzyme acto-myosin-ATPase [99]. The thin filament is primarily formed by a double stranded helix 
of filamentous actin (F-actin) [101] and the associated regulatory actin-binding proteins [102]. 
A contraction is produced by the shortening of the muscle fibre that occurs when myosin activation 
creates a sliding of actin on the myosin [98]. This ‘sliding filament’ theory was proposed by H. E. 
Huxley in 1969 [103] and is based on early studies in the skeletal muscle of animals [97, 98, 104]. 
Myosin is activated by an increase in intracellular calcium [105]. In the presence of calcium, actin 
binds to the myosin head, along with ATP, and the enzyme acto-myosin-ATPase is activated. This 
results in hydrolysis of ATP [106]. The energy released by ATP hydrolysis causes the tilting of the 
actin heads which are attached to myosin via cross-bridges [103] and results in shortening and 
stiffening of the muscle. A cross-bridge cycle of attachment-detachment occurs, as each ATP 
molecule is hydrolysed [107]. Muscle tension can be maintained for a time after the initial stimulus. 
This is thought to be due to the ‘latch state’ in which the cross-bridges remain attached but are not 
cycling [108]. 
Acto-myosin ATP-ase activity is dependent on the phosphorylation status of the MLC20 [109-111], 
which is regulated by intracellular calcium, in a process known as calcium sensitization [112-114]. 
This process is regulated by the two opposing enzymes, myosin light chain kinase (MLCK) and 
myosin light chain phosphatase (MLCP) [115]. MLCK is activated through its binding of calcium and 
increases MLC20 phosphorylation [116]. MLCP decreases MLC20 phosphorylation, independently of 
calcium concentration [109]. MLCP activity is inhibited by M3 receptor activation through activation 
of Rho-GEF [117] which in turn activates of Rho-A [118].  
The role of the cytoskeleton in contraction of ASM 
In ASM, ‘stiffness’ or isometric tension can be uncoupled from active contractile force [129]. In 
sheep trachea, acetylcholine-induced stiffness was shown to be modulated by Rho-kinase, 
independently of calcium and myosin light chain phosphorylation [131]. This stiffness was found to 
be calcium dependent, and increasing intracellular calcium was found to augment the degree of 
stiffness [132]. Thus, the acto-myosin cross-bridge activation and cytoskeletal modifications regulate 
ASM tone and contractility, and the cytoskeleton can be regulated independently of acto-myosin 
cross-bridges.  
ASM contraction requires polymerisation of cytoskeletal actin [119], together with the re-arrangement 
of other cytoskeletal proteins and filaments, such as soluble of G-actin, for force development [120]. 
Cholinergic M3 stimulation of ASM leads to polymerisation of G-actin, which is also regulated by 
Rho-A [121].  
F-actin is anchored at dense bodies or focal adhesion complexes (FAs), which are located throughout 




integrin proteins [122] which are anchored to the surrounding ECM [123]. These structures provide a 
structural framework for the transmission of force between cells and throughout the smooth muscle 
tissue [124]. Contractile activation stimulates recruitment of dense bodies and association with 
integrins at the cell membrane [122]. This is regulated by Rho-A [125]. 
The cytoskeleton is also involved in the maintenance phase of a contraction or ‘stiffness’. Ex vivo 
studies in animal airway muscle, demonstrate cytoskeletal modulation of ‘stiffness’ of the muscle at 
different lengths [126-128]. Transfer of the load to the cytoskeleton by re-arrangement of the 
filaments, is thought to be responsible for the maintenance of force, while allowing the actin-myosin 
unit to re-initiate the contraction [129, 130]. 
Relaxation of human airway smooth muscle  
The β-2 adrenergic receptor 
The β-2AR is a prototypical member of the family of G protein coupled receptors. The mechanism of 
β-2AR activation is well defined. Activation of its stimulatory subunit (Gsα) results in the activation 
of adenylate cyclase (AC), a membrane bound enzyme which catalyses the production of cAMP 
[133]. It is initiated via β-2 agonist binding which then promotes association of the receptor with the 
Gsα sub-unit of the G-protein [134]. This coupling activates GTPase of the Gsα and dissociation of 
the sub-unit from the G-protein [134]. Adenylate cyclase (AC) is activated by hydrolysis of GTP on 
the Gsα subunit [135]. The Gsα sub-unit has spontaneous AC activating abilities however, β-2 agonist 
binding to the receptor is catalytic in the activation of AC by several fold [136], as it can couple with 
multiple G-proteins [137]. 
To explain receptor activation by agonist, a computer-generated model of ligand efficacy, the 
“Ternary complex model” of activation, was derived [138]. This model predicted that agonist ability 
to bind receptor and stabilize the receptor -G-protein complex, determined the degree of response. 
Full and partial agonists are defined in this model, by the relative abilities of the ligands to stabilize 
this complex and maintain the “active” state of the receptor. The use of NMR spectroscopy permitted 
the observation of different conformational states and provided further information regarding β-2AR  
dynamics [139-142]. When un-liganded or inverse agonist bound, two inactive conformations of the 
receptor exist in dynamic equilibrium [139]. The agonist alone is insufficient to stabilize a fully active 
state of the receptor and requires the presence of the Gsα protein [141, 142] or an intracellular G 
protein mimetic [139, 140]. Agonists shift the equilibrium toward a conformation capable of coupling 
to Gsα, although there is heterogeneity in the conformational changes, resulting in the coexistence of 
inactive, intermediate and active states [140]. When bound by agonist, an intermediate state is the 
most populated state of the receptor [139]. Efficacy is related to the population of active 




Agonist stimulated production of cyclic AMP results in phosphorylation of the receptor and 
uncoupling from its Gsα sub-unit. This process is rapid and reversible and is part of the normal 
process of regulation and maintenance of receptor function [143]. This functional uncoupling is 
followed by removal of receptor from the surface, otherwise known as sequestration. Receptor 
sequestration transiently reduces the population of surface receptors, but recycling occurs rapidly 
within minutes [144] and is an important step in re-sensitisation of the receptor’s responses [145, 
146]. Long-term exposure to β-2 agonist stimulation however, results in a down regulation of β-2AR 
numbers, as determined by radio-ligand binding studies [147-150]. 
Molecular mechanisms of relaxation 
Beta-2 adrenergic receptor activation of animal and HASM causes a reduction in active tension in 
vitro [151]. Relaxation of ASM via β-2 agonist stimulation is generally accepted as an important 
mechanism of relaxation in human and animal tissues [85, 152].  
In HASM, the model of β-2AR mediated relaxation involves the second messengers cAMP and PKA, 
which reduce intracellular calcium via several mechanisms [85]. In HASM, cAMP is rapidly 
degraded by the enzyme phosphodiesterase 4D (PDE4D) [153] therefore, the effect of β-2 stimulation 
on cAMP production is short.  
The suggested mechanisms by which cAMP may affect relaxation have been demonstrated in animal 
tissues via reduction in intracellular calcium and calcium sensitivity [154]. This β-2 agonist 
cAMP/PKA pathway has been shown to inhibit calcium entry via SOCCs [155], to inhibit calcium 
release via IP3 inhibition [156], reduce frequency of calcium oscillations [157] and increase re-uptake 
of calcium via stimulation of the internal calcium pump (SERCA) [151]. Studies in animals suggest 
that β-2 agonist mediated increases in cAMP, also induce relaxation due to alterations in calcium 
sensitisation, calcium sensitivity via MLCK inhibition [151], enhanced activity of MLCP [151, 158] 
and de-phosphorylation of MLC20 [159]. It is possible that other mechanisms independent of MLCK 
phosphorylation may regulate long-term calcium sensitization via direct G protein stimulation [160]. 
Animal studies have also shown that in the absence of de-phosphorylation of MLC20, an increase in 
cAMP is insufficient to relax animals’ ASM [159], emphasising the importance of de-phosphorylation 
of MLC20.  
The relevance of these mechanisms in human tissue is not clear. In HASM, β-2 agonist mediated 
cAMP/PKA mechanisms have been shown to be involved in relaxation of pre-contracted tissue via 
the inhibition of receptor-activated calcium influx [161]. The involvement of PKA was challenged 
due to the discovery of an alternative cAMP activated exchange protein (Epac), which was found to 




while PKA inhibition abolished β-2 agonist induced relaxation [161]. These data suggest that PKA 
rather than Epac activation, is involved in β-2 agonist mediated relaxation. 
Animal studies in intact bronchial segments, demonstrated that β-2 agonists act synergistically with 
oscillatory strain to induce relaxation [163]. This suggests that the cAMP/PKA pathway may also be 
involved in regulating ASM cytoskeletal dynamics. Previous studies in cultured HASM cells found 
heat shock protein 20 (HSP 20) was phosphorylated via β-2 agonist induced PKA, and in animal 
ASM, this phosphorylation of HSP 20 resulted in relaxation via depolymerisation of F-actin [164, 
165]. Evidence from cultured HASM, suggests that both PKA and PKA independent pathways are 
involved in β-2 agonist regulation of cytoskeletal dynamics [166, 167].  
The details of the mechanisms of a β-2 agonist effect on calcium sensitisation in HASM remains to be 
defined. It may involve additional pathways independent of PKA, such as the inhibition of Rho-kinase 
as a means of reducing calcium sensitisation [168] or via Myosin light chain kinase (MLCK) 
phosphorylation [169]. 
Stretch induced relaxation and the behaviour of ASM in vivo 
The mechanisms of ASM contraction and relaxation are largely derived from experimental 
observations in static models and isometric contractile states of ASM. Historically, the property of 
length adaptation has been attributed to ASM, based on in vitro studies on isolated ASM strips in 
animal tissues [130, 170] and comparative studies in humans and animals [171]. Contraction in 
response to stretch has been observed in cultured HASM [172], mediated via a stretch receptive 
calcium channel that is usually stimulated by changes in osmolality [173]. A contractile response to 
stretch has also been observed in an in vitro study in an intact animal lung [174]. In contrast to these 
findings, the property of length adaptation is not evident when physiological conditions are imitated 
in animal ASM [175] or in HASM in vitro[176], nor in in vivo human systems [177]. The response of 
HASM in vivo, is relaxation. Despite this, some argue that stretch does not induce relaxation of  
HASM [178]. 
The more recent models of ASM behaviour, recognise the property of stretch-induced relaxation or 
force-fluctuation-induced re-lengthening (FFIR), actin-myosin cross-bridge detachment cycling and 
cytoskeletal re-organisation, as important events in regulating the contractility of ASM [179-183]. 
Recently, experimentally derived mathematical equations have been constructed which describe the 
relationship between force and length [127, 179]. These equations predict force-length relationships 
that cannot be accounted for by rates of cross-bridge cyclic alone, further supporting the role of the 





The properties of ASM have been likened to that of soft glassy materials. Although the explanation 
for the behaviour of these materials in not well understood, soft glassy materials are observably ‘scale 
free’, in that there is no absolute alteration in force per unit change in length or direct relationship 
between stiffness and rate of any internal process [180]. These observations are consistent with the 
predictions of the afore described mathematical models of ASM dynamics. As ASM displays these 
same properties, it is suggested that analogous to glass, where plasticity is modulated by internal 
temperature, ASM plasticity is modulated via remodelling of its cytoskeletal structure [180]. 
Integrating the roles of the cross-bridge and the cytoskeleton in the mechano-sensitivity of ASM 
Early studies in animal ASM provided some preliminary data on the mechanisms of mechano-
sensitivity. Stretch-induced changes were shown to involve actin-myosin cross-bridge interactions 
[184, 185]. Stretch was also shown to induce changes in actin-cytoskeletal-integrin interactions, 
whereby stretch down-regulated the cross-linking of these filaments [127]. Focal adhesion kinase 
(FAK) was found to be involved in both the regulation of intracellular calcium and MLC20 
phosphorylation [186], suggesting that the two processes are inter-dependent. Using a cultured human 
non-smooth muscle cell line transfected with contractile proteins, a model was developed which 
demonstrated a mechanism of interaction of contractile elements and the regulation of the assembly of 
cytoskeletal components, in response to mechanical factors [187]. The study showed that focal 
adhesion complexes (FAs) are regulated by acto-myosin generated forces, and inhibition of acto-
myosin generated tension leads to FA disassembly. Different filaments of the FA (paxillin, vinculin 
and zyxin) showed different response times. 
Subsequently, and most recently, further details consistent with these findings were obtained via in 
vitro study of animal fibroblast cells [188]. This study observed heterogeneous responses of zyxin, 
vinculin, paxillin and FAK, to Rho-associated kinase (ROCK)-mediated perturbations of actin-myosin 
contractility. The responses of the FAs were determined by their location, size, filament composition 
and length history. The effects of these ROCK-imposed mechanical perturbations in different focal 
adhesions, had distinct paths. Within different focal adhesions, the protein exhibiting the strongest 
response to ROCK perturbations also varied. 
These findings explain the ability of ASM to behave in a ‘glassy’ fashion in response to mechanical 
stress. Disruption to these pathways may underlie the dynamic abnormalities observed in asthmatic 
ASM. 
The effects of asthma on the behaviour of ASM 
Airway hyper-reactivity is manifested as an increased but reversible bronchoconstriction response to 




also accompanied by an alteration in the ASM dynamic response to mechanical stimuli, wherein the 
property of the ASM itself is altered. 
Dynamic abnormalities 
The human lung in vivo is subject to dynamic alterations in load/tension, such that there is no static 
equilibrium between contractility/relaxation. More relevant to the function of ASM in health and 
disease, is how these properties of the muscle are dynamically related and regulated. Studies of intact 
healthy human systems in vivo have shown that a deep inspiration induces relaxation [177]. 
Furthermore, increasing length, as in a deep inspiration (DI), reverses bronchoconstriction [189, 190] 
and protects against contractile stimuli [191, 192]. Thus, the normal response of ASM to dynamic 
changes in length and tension that occur with the respiratory cycle, allows the muscle to adapt to these 
changes and maintain airway patency over a wide range of lung volumes, as occurs during tidal 
breathing and deep inspiration. This mechanism is impaired in asthmatic ASM.  
It was noted as early as 1859, that there are dynamic abnormalities in the function of asthmatic ASM 
[193]. Since then, few studies have examined the dynamic behaviour of asthmatic ASM in vivo. In a 
recent ex vivo comparative study of ASM strips in healthy controls and asthmatics, asthmatic ASM 
was observed to have greater passive stiffness at longer lengths relative to non-asthmatic ASM. The 
ability of the ASM to relax after stretch was reduced by almost 50% in asthmatic ASM relative to 
non-asthmatic ASM [194].  
Studies of broncho-motor responses to DI, as measured by plethysmography [195-197] and later 
direct imaging of the airways [177], have shown that asthmatics have a bronchoconstriction response 
to deep inspiration relative to healthy non-asthmatics. Studies of the effects of a DI on pre-constricted 
lungs as measured by PEF or FEV1, showed that the ability of a DI to reverse constriction is impaired 
in asthma relative to non-asthmatics [189, 190, 192, 197]. Spirometry evaluations and direct imaging 
of the airways of asthmatics, showed impairment of DI-induced bronchodilation after constriction 
with methacholine occurred in those whose FEV1 was <75% predicted [198]. The ability of a DI to 
reverse bronchoconstriction was positively correlated with airway distensibility in the large and 
medium-sized airways. Thus, an increase in ‘stiffness’ was associated with impaired ability to relax in 
response to stretch. The ratio of residual lung volume to total lung capacity (RV/TLC) was negatively 
correlated with airway distensibility and the ability of a DI to reverse bronchoconstriction. 
Distensibility was dependent on RV/TLC, and not an independent predictor of the ability of DI to 
reverse bronchoconstriction. These relationships were lost after bronchodilation with a β-2 agonist.  
These data show that this impaired ‘stretch-relaxation’ response and increased ‘stiffness’, contribute 
to the obstructive defect in asthma and suggest a functional abnormality in asthmatic ASM. This 




tracheal muscle, in which no significant qualitative or quantitative differences were found in the sub-
cellular structure between asthmatics and non-asthmatics [199]. 
A comparative study of asthmatics and non-asthmatics, using forced oscillations to measure minimal 
airway resistance following maximal inspiration R (min), showed that R (min) is greater in asthmatics 
relative to non-asthmatics, and performed better than PEF or FEV1 in detecting AHR as determined 
by methacholine challenge [200]. This study supports a reduction in airway distensibility as a 
contributing factor in AHR and demonstrates a non-invasive method of predicting AHR, that may be 
very useful in assessing and diagnosing asthma. 
Changes in distribution of ventilation 
Studies of asthmatic lungs show that bronchoconstriction is associated with, and results in, ventilation 
heterogeneity [201-203]. Using MRI, it was demonstrated that at baseline, ventilation heterogeneity is 
proportionate to the reduction in FEV1, and that methacholine and exercise challenges increase, while 
β-2 agonists decrease heterogeneous ventilation. Non-asthmatics did not develop any regions of 
heterogeneous ventilation in response to these challenges [201]. Another study, using a histamine 
challenge and multiple-breath-washout (MBW) to measure heterogeneity of ventilation, showed that 
reduction in FEV1 followed the degree of in-homogeneity of ventilation that occurred in the 
conducting zones of the lung. The degree of in-homogeneity in the non-conducting/gaseous exchange 
zones or acinar zone, corresponded to the degree of AHR, i.e. those with a decrease of FEV1>20% in 
response to histamine had a higher baseline acinar in-homogeneity of ventilation relative to those with 
<20% reduction in FEV1 [202]. In another study of asthmatics, using MBW, baseline heterogeneity 
was found to predict AHR, independent of airway inflammation [203]. These data illustrate that 
ventilation distribution and inequalities thereof, are important determinants of AHR and may 
determine the severity of the disease. In a comparative study of larger areas of lung with normal and 
poor ventilation, using Positron Emission Tomography (PET), heterogeneity of ventilation was also 
demonstrated. Within segments of poorly ventilated lung, there were greater numbers of smaller 
‘units’ of poorly ventilated lung, while within normally ventilated segments, there were few poorly 
ventilated ‘units’[204]. This suggests that small clusters of poorly ventilated areas, resulting from 
constriction of the small airways, can impact on larger areas of the surrounding lung. The images 
obtained in this study are also consistent with airway closure from bronchoconstriction of small 
airways, as the mechanism of loss or reduction in ventilation [201]. 
The cause of this abnormal bronchoconstriction and the factors responsible for these alterations in 
dynamic ASM properties, are not known. Abnormalities in contractility via alterations in calcium 
handling and calcium sensitivity, have been postulated as mechanisms of increased response to 
otherwise non-constricting stimuli, as a potential cause of AHR. Changes in the dynamic properties of 




receptor function may impair relaxation and contribute to AHR. There may be an interaction between 
the presence of inflammation and alterations in intracellular calcium. 
Potential mechanisms of abnormal smooth muscle behaviour 
Mechanical/structural abnormalities 
In  non-asthmatics, AHR as measured by sensitivity to methacholine, was able to be induced by 
inhibiting DIs [205]. Another study of similar methodology failed to demonstrate this [197], 
suggesting that more than just mechanical factors are required for the development of AHR. 
Structural alterations associated with remodelling have been proposed as a cause of altered dynamics 
[206] and are considered to have a significant impact on clinical disease expression [207, 208]. These 
changes may be indicative of functional disorder, rather than the cause.  
A comparative study of the ultra-structural features in post mortem ASM tissue of asthmatic and non-
asthmatics, failed to detect any large or statistically significant differences in ASM cell cross-sectional 
area, thick or thin filament density or aggregation of dense bodies [199]. In asthmatics, there was 
evidence of remodelling, as demonstrated by an increase in the ASM area, a near significant 
difference in BM thickness (p=0.09), together with active eosinophilic inflammation relative to non-
asthmatics [199]. This data suggests that functional changes may be more important than structural 
ones. 
Abnormal calcium handling 
Some associations between calcium handling and cytokines associated with airway inflammation in 
asthma, have been demonstrated. These cytokines may be responsible for the AHR observed in 
asthma. The most commonly implicated cytokines, IL13 and TNF-α, as well as being associated with 
asthma exacerbations, have been observed to increase intracellular calcium by a variety of 
mechanisms. In ex vivo non-asthmatic  HASM, IL-13 and TNF-α were shown to increase SERCA 
expression and decrease the rate of fall of [Ca2+]I [209], increase calcium responses to agonist [210] 
and increase Ca2+ influx and the expression of the regulatory Na+-Ca2+ exchanger [211]. In cultured  
HASM cells, IL-13 was shown to increase agonist stimulated calcium responses and maximal force 
generation [212]. These data suggest a mechanism whereby, altered calcium handling may lead to 
AHR and potentially increased contractility and ‘stiffness’. In ex vivo human tracheal smooth muscle 
cells, TNF-α was found to produce increased intracellular calcium responses to contractile agonist 
[213] and to induce AHR, in non-asthmatic ASM [214]. Levels of TNF-α are also increased via 
increases in intracellular calcium [215] hence, there is a positive feedback effect interaction between 




Altered calcium sensitivity has been observed in asthmatic HASM. Biopsies of lung tissue showed 
maximal shortening velocity and capacity were increased in asthmatic ASM relative to non-asthmatic 
ASM and coincided with an increased expression of MLCK [216]. This may explain the increase in 
airway contractile responses observed in asthma. 
Beta-2 receptor abnormalities 
In 1962, Andor Szentivanyi proposed the ‘β-adrenergic theory of the atopic abnormality in bronchial 
asthma’, on the basis that atopy alone cannot account for the disease process, and he proposed that the 
disease was due to an abnormality in the β-2AR itself [49]. There is evidence that suggests 
dysregulation of β-2AR function occurs in asthmatics, however, it is difficult to distinguish between 
intrinsic differences and the effect of regular β-2 agonist use.  
Genetic polymorphisms could account for observed differences in responsiveness to β-2 agonist, 
among asthmatics. A mutation in the catalytic domain of Adenylate Cyclase (AC) type 9 was shown 
to confer reduced basal and β-2 agonist stimulated cAMP activity [217]. A polymorphism in the 
peptide encoded by the 5LC region of the β-2AR gene, has been shown to influence receptor 
synthesis [218]. This peptide has a polymorphism at position 19 Arginine (Arg)/ Cysteine (Cys). In 
HASM cells natively expressing β-2AR, the Cys19 polymorphism was associated with a two-fold 
greater expression of receptors relative to the Arg 19 genotype. These data show that innate β-2AR 
responsiveness is influenced by genetic factors, which may contribute to the asthma phenotype. These 
data also show that genetic factors could contribute to β-2 agonist responses independently of the 
asthma phenotype.  
There is evidence that inflammation can contribute to impaired relaxation responses to β-2 agonist. 
Interleukin-13 has been shown to reduce β-2 agonist ability to relax HASM cells [219]. Interleukin-1β 
has also been shown to alter β-2AR function in HASM via uncoupling of the receptors from Gsα 
[220, 221]. Tumor necrosis factor-α has been shown impair β-2 agonist induced relaxation in cultured 
HASM [222] and to be synergistic with IL-1β in reducing β-2 agonist induced relaxation [223]. The 
Cysteine-leukotriene LTD4, has been shown to reduce maximal isoprenaline stimulated cAMP in 
cultured HASM and inhibit β-2 agonist induced relaxation in ex vivo HASM [224], suggesting 
desensitisation of receptor responses. A study of cultured HASM, found that asthmatics expressed 
twice the level of PDE4D relative to non-asthmatics [225]. Inhibition of PDE4D in both asthmatics 
and controls, gave a similar response in terms of β-2 agonist induced cAMP production. In theory 
however, increased PDE4D levels could lead to a more rapid decline in β-2 agonist stimulated cAMP 






Altered regulation of cytoskeletal dynamics 
Cytoskeletal dysfunction as a mechanism of AHR, has recently been supported [226]. In this study, 
the model for the mechanism was first developed in mice. Subsequently, post-mortem airway smooth 
muscle tissue from those with fatal asthma was examined. Zyxin has been identified and characterised 
in human smooth muscle [227]. It is a zinc binding protein that is widely expressed in human tissues 
and forms part of focal adhesions (FA), via binding to actinin, in association with mature complexes, 
and is important for microfilament organisation [228]. It is the primary mechanosensitive filament of 
the FA [229]. Asthmatics that died from asthma, had increased accumulation of zyxin relative to those 
who died from other causes and non-asthmatics. These data strongly implicate altered cytoskeletal 
function mediated by zyxin in the pathogenesis of asthma. 
Summary of the asthmatic ASM 
In summary, ASM function may be altered by factors that influence calcium sensitivity and 
cytoskeletal dynamics. Calcium sensitivity, regulating actin-myosin cross-bridge cycling, may be 
altered in asthma via increase in MLCK expression therefore, magnifying intracellular calcium 
increases.  
Rho-A/ROCK activation potentiates MLCK driven increase in contractility via inhibition of MLCP, 
the counter-regulator of MLC20 phosphorylation. Cytoskeletal fragility in response to mechanical 
stress is the normal response, however, this response may be altered in asthma via increased zyxin 
expression. Rho-A/ROCK activation promotes cytoskeletal reinforcement via actin, actinin and 
paxillin accumulation however, this process is also regulated by cross-bridge cycling which is 
mechanosensitive. Both processes are influenced by Rho-A/ROCK pathways hence, they are a 
common denominator in the regulation of ASM function. The most commonly implicated cytokines 
in asthma pathogenesis, TNF-α and IL-13, have been demonstrated in animal and HASM, to up 
regulate Rho-A/ROCK pathways [230-232]. Oral corticosteroids inhibit IL-13 induced up regulation 
of Rho-A [233].  
Pro-contractile influences mediated by Rho-A/ROCK, are also opposed via cAMP/PKA pathways. 
These pathways involve inhibition of MLCK, de-phosphorylation of MLC20 and depolymerisation of 
F-actin via phosphorylation of HSP 20. Increase in expression of PDE sometimes associated with 
asthma, could limit the effect of cAMP elevation on relaxation. Beta-2 agonists mediate cAMP/PKA 
pathways but can also inhibit actin polymerization, Rho-A/ROCK pathways and MLCK, via PKA 





1.2.3 Role of inflammation in asthma 
Leukocyte pathways and inflammatory mediators 
Inflammatory mediators are involved in acute exacerbations of asthma, and more than one of the 
immune pathways may be involved [234]. The main cytokines produced by TH cells are; interleukin-
13 (IL-13) [235, 236], which activates mast cells and stimulates allergic inflammation [237], 
interleukin-5 (IL-5), which activates eosinophils [238], tumour necrosis factor (TNF-α), which is 
associated with both allergic and non-allergic asthma [239, 240] and interleukin-8 (IL-8), which is 
associated with non-allergic asthma [241]. Both TNF-α and IL-8, activate and recruit neutrophils 
[242, 243], while TNF-α is also a common denominator in both T-helper pathways described. It is 
also increased in asthmatic airways when compared to healthy controls [239, 240], and TNF-α gene 
expression is increased in severe asthmatics [240]. Monocytes and macrophages from asthmatics have 
also been shown to have increased IL-8 and TNF-α production in vitro [244]. The production of 
nuclear transcription factors that promote inflammation, such as NF-kappa-B (nuclear factor-kappa-
B), are also increased by TNF-α [215]. In non-asthmatics, TNF-α has been shown to induce AHR and 
induce sputum neutrophilia [54] and increase severity of AHR mild asthmatics [55].  
More recently, another T-lymphocyte pathway, TH17 and its associated cytokine IL-17A, have been 
identified in allergic asthma [245]. The cytokine was first identified in T-lymphocytes infected with 
herpes virus [246] and was subsequently identified in high concentrations in sputum and broncho-
alveolar lavage fluid in asthmatics relative to controls [247]. Interleukin-17A was associated with IL-
8 and neutrophilic inflammation and asthma severity [248] and was demonstrated in vitro in both 
animal and HASM, to increase contractile force in response to methacholine [249]. It was shown to 
reduce the efficacy of budesonide on TNF-α induced IL-8 inhibition, through induction of changes in 
gene expression, thereby blocking potential pathways for corticosteroid inhibition of cytokine 
production [250]. The cytokine IL-17A is now recognised as an important mediator of airway 
inflammation and its resistance to treatment with corticosteroids. 
Recently discovered is another class of immune cell, a non-B/non-T lymphocyte, which is designated 
as an innate lymphoid cell. It has similar properties to T-helper cells, in that it also influences the 
behaviour of other inflammatory cells. These cells, found in the sputum of asthmatic patients but not 
healthy controls, produced IL-13 and IL-5 [251]. These immune cells, therefore, can stimulate allergic 
inflammation and recruit eosinophils.  
Cystyl-leukotrienes (LTs) are a group of inflammatory mediators associated with allergy and 
anaphylaxis. They are produced in all leukocytes by the metabolism of arachidonic acid (AA) within 
the cell membrane. The AA pathway is implicated in asthma, as inhibition of the receptors for LTs 




The mast cell 
The mast cell was one of the first cell types to be associated with asthma. Mast cell degranulation was 
first implicated in asthma pathogenesis in the 1960s [254] and became the target of asthma treatment 
with mast cell stabilisers [255]. Subsequently, inhaled corticosteroids replaced these treatments as 
first line for prevention of asthma symptoms [256]. More recently, the mast cell has been recognised 
as a key mediator of several aspects of asthma pathology. Studies of bronchial washings in asthmatics 
showed mast cells to be increased in asthma relative to non-asthmatics [257]. In both eosinophilic and 
non-eosinophilic asthma, mast cells are seen to infiltrate ASM [71, 75]. Mast cells are a source of the 
cytokines IL-4 [239, 258] and IL-5 [239] which are involved in the recruitment of eosinophils. 
Interleukin-13 [258] and TNF-α [239], which are important inflammatory mediators in asthma, are 
also produced by mast cells. 
Mast cell numbers in ASM correlate with the severity of the disease [259]. Recently, a specific mast 
cell sub-type was identified as a major source of IL-17A [260]. This mast cell sub-type was associated 
with increased AHR [261], eosinophilic inflammation [261, 262] and resistance to corticosteroid 
treatment [262]. 
 
1.2.4 Clinical features  
General features 
Asthma symptoms are caused by the physiological abnormality of hyper-responsiveness of ASM. In 
response to a variety of contractile stimuli, there is an abnormal contractile response, which results in 
a state of prolonged/excessive contraction or “bronchospasm”, resulting in airflow obstruction. 
Inflammation within the airways is often present to varying degrees and can precipitate and modify 
the hyper-excitability of the airways. Inflammation also causes swelling to the airways, which further 
contributes to the obstruction. These abnormalities are experienced as episodic bouts of 
wheezing/coughing and/or chest tightness and associated breathlessness. The bouts are usually brief 
and self-resolving but may be persistent or recurring. When persistent, these episodes are often 
relieved with an inhaled bronchodilator. 
Frequency and severity of exacerbations varies between individuals and may be influenced by the 
type and amount of inflammation present. In many cases, the degree of inflammation correlates with 
the severity and frequency of exacerbations [56]. The obstruction caused by bronchospasm is 
reversible, but with time it may become fixed due to alteration of the muscle structure and properties. 
This may occur when inflammation is difficult to control and symptoms persist, leading to a decline 




inflammation, there is persistent AHR which leads to the development of rapidly progressive fixed 
obstruction [264].  
Asthma symptoms can progress at any time in to a much more acute condition, in which the 
bronchospasm is persistent and there is a rapid worsening of airways obstruction and a decline in lung 
function. The exacerbation is usually due to increased inflammation as the result of a respiratory tract 
infection or an environmental trigger but can occur without an identifiable trigger [265]. Severity and 
frequency of exacerbations tends to reflect the activity of the disease. Exacerbations may be 
unavoidable and difficult to manage and may occur abruptly and without warning.  
The severity of an exacerbation varies greatly in terms of degree of obstruction and respiratory 
distress. Response to treatment can also be variable, with some responding well to emergency 
treatment and being discharged home, while others requiring hospital admission and intensive 
treatment. Exacerbations can be life-threatening and even fatal [266]. Death results from closure of 
the small airways and complete obstruction to airflow. This leads to respiratory arrest, followed by 
eventual cardiac arrest from hypoxia. Exacerbations of such severity are often termed ‘status 
asthmaticus’ [267] and are difficult to manage.  
Classification of severity varies between guidelines [2-4] but generally indicates severity on a scale of 
mild to near-fatal. Mild exacerbations are generally classified as those without hypoxia and increased 
work of breathing, while increased work of breathing, increased respiratory effort and reduction in 
oxygen saturation, indicate more severe exacerbations. The degree of distress or respiratory effort 
determines the severity of the exacerbation which, if life-threatening, is usually accompanied by 
significant reduction in oxygen saturation. A saturation of <92%, with or without supplemental 
oxygen, is a feature of a life-threatening exacerbation [4]. Exhaustion may intervene and is a sign of 
impending respiratory arrest and death. Guidelines include the use of PEF to assess severity in acute 
asthma exacerbations. Both BTS and GINA use a PEF <50% predicted to classify an exacerbation as 
severe [4, 268]. BTS classifies a PEF <33% as life-threatening [4]. 
Diversity within the asthma phenotype 
Those with a diagnosis of asthma share the common features of AHR and airways inflammation, 
together with a clinical pattern of acute paroxysms of bronchospasm in isolation and/or acute 
exacerbations, superimposed on chronic airflow limitation. Despite these general similarities, there 
are individual differences in clinical patterns of disease. Patients with similar disease patterns can be 
“grouped” based on phenotypes and endotypes however, there are other individual factors that can 





Intrinsic vs. extrinsic asthma 
Traditionally, asthma has been broadly classified into two sub-types, as determined by the presence or 
absence of specific IgE antibodies to common allergens or triggers [269]. Patients with specific IgE 
antibodies against aeroallergens or positive skin prick tests (SPTs), were classified as having extrinsic 
or allergic/atopic asthma, whereas those without IgE markers or positive SPTs, were classed as 
intrinsic or non-allergic/non-atopic.  
Clustering of asthma phenotypes 
Classification of asthma sub-types is useful, as there are differences in inflammatory phenotypes and 
underlying aetiology which influence the clinical expression of the disease, therefore, also the 
treatment response. The optimal method of classification would predict best treatment and treatment 
responses, which no classification predicts perfectly. The ‘clustering’ approach of sub-grouping 
asthma expands on the traditional intrinsic/extrinsic classification. It is based on common 
inflammation patterns, clinical features and treatment response. It distinguishes inflammatory types 
by the presence or absence of one inflammatory cell type, the eosinophil, which is often associated 
with allergy.  
Atopic asthmatics have early onset disease, eosinophilic inflammation and are more responsive to 
inhaled steroids. This ‘cluster’ represents the ‘extrinsic’ asthma type and is described by several 
authors [270-272]. A separate cluster of late onset asthma is like the ‘extrinsic’ phenotype in being 
atopic, eosinophilic and corticosteroid sensitive, but symptoms appear in adulthood [270, 271]. The 
other phenotypes are characterised by non-eosinophilic inflammation or a mixed inflammatory 
pattern. These include one cluster characterised by late onset of symptoms, obesity, predominantly 
female sex and a neutrophilic inflammatory profile [270, 273, 274]. Patients in this group have more 
severe symptoms, poor response to an inhaled steroid and a greater degree of fixed obstruction.  
Endotypes  
The recently developed concept of endotypes, recognises asthma sub-types with a demonstrable 
aetiology and distinct pathological mechanisms, such as occupational, aspirin-sensitive asthma and 
exercise-induced asthma [271]. Such classification allows identification of those with specific 
treatment requirements and allows avoidance of triggers for improved symptom control. 
Occupational asthma refers to asthma that occurs in the absence of pre-existing airways disease and is 
a direct result of occupational exposure. It can be irritant-induced, otherwise known as reactive 
airways dysfunction syndrome (RADS) [275-277]. This occurs immediately upon exposure to irritant 
and without immunological sensitization. Alternately, it can be immunologically mediated due to 




asthma may be exacerbated by environmental factors at work and is considered as a separate entity 
known as labelled Work Exacerbated Asthma (WEA) [275].  
Aspirin-sensitive asthma refers to a triad of asthma, nasal polyposis and exacerbations that are 
precipitated by exposure to non-steroidal anti-inflammatory medications or aspirin. In susceptible 
asthmatics, these medications enhance the synthesis of cystyl-leukotrienes (Cl-T) which induce mucus 
production and bronchospasm [278]. It is estimated, that 10% of asthmatics without prior use of 
aspirin/ NSAID may be sensitive to these medications, and it is generally advised that all asthmatics 
avoid these medications [279]. 
Asthma in elite athletes occurs in the absence of pre-existing disease. The condition has been 
observed in competitive swimmers and skiers and responds to a reduction in the intensity, or the 
cessation of training [280]. Release of inflammatory mediators triggered by drying of the airways is 
believed to be the mechanism, and the mast cell is believed to be the source of these mediators. 
Hyper-responsiveness of the airways is accompanied by neutrophilic and sometimes eosinophilic 
inflammation. Sodium cromoglycate, a mast cell stabiliser, is very effective in this group of 
asthmatics if taken immediately prior to exercise [281] however, it is less effective when taken alone 
than in combination with an inhaled β-2 agonist [282]. 
Recently, blood biomarkers and gene clusters have been correlated with specific endotypes in a group 
of 146 children [283]. These genes were involved with immune cell function and inflammatory 
patterns. The clinical markers included obesity and atopy, identifying profiles like that previously 
described in the endotype models [271]. There was no correlation between the type of medication or 
amount of medication used and the endotype. Larger studies may be able to correlate these endotypes 
with treatment requirements, otherwise the utility of such biomarkers is largely academic. 
Sex differences 
There are significant sex differences in several aspects of asthma. For example, the prevalence of 
asthma in childhood is greater in males relative to females. This is reversed in adult asthma [284]. The 
change in the sex ratios in asthma prevalence from childhood to adulthood, is not correlated with the 
stage of puberty [284]. This, and other data, suggest more than just an effect of hormones.  
Some of these sex differences have implications for treatment, including differences in the phenotypic 
expression of asthma. Severity of the disease follows opposite sex trends in childhood asthma relative 
to adult asthma. In childhood asthma, males have greater severity and admission rates relative to 
females [285-288]. In adult asthma, women have more severe symptoms and frequency of 
exacerbations relative to men [285, 289-294], are more likely to have difficult to treat asthma [295], 
use oral corticosteroids [291] and are more likely to be admitted to hospital with an exacerbation 




Women had longer hospital stays relative to men, yet men were more likely to die during admission 
[292]. In this study, females were more likely to be Caucasian (37.9%) relative to men (34.2%). This 
data suggests that asthma in women is more persistent and chronic relative to asthma in men, while in 
men, asthma may be a more acute life-threatening event.  
In studies of the immunological cell lines in asthmatics, sex differences in the immune responses of 
TH1 and TH2 pathways were found. The differences in immune response patterns may explain the sex 
differences in the severity patterns that have been described. Interleukin 2 (IL-2) is a cytokine that 
induces clonal expansion of T-cells [297]. In an ex vivo study, it was used to stimulate proliferation of 
TH1 (IFN-γ+) and TH2 (IL-13+) cells. Stimulation of a population of peripheral lymphocytes, resulted 
in a greater increase in IL-13 and IFN-γ producing cells in asthmatics relative to non-asthmatics 
[298]. The increase in IL-13 (TH2) producing lymphocytes was dependent on sex, with a significant 
increase in the number of IL-13 producing cells occurring in female asthmatics only. There were no 
sex differences in the number of IFN-γ (TH1) producing cells. The increase in T-lymphocytes was 
found to be due to an increased lymphocyte survival and not an increase in proliferation. This 
suggests that asthmatic females have a greater TH2 response relative to asthmatic males. Inhaled 
corticosteroid (ICS) had no effect on the production of cytokine producing lymphocytes in either sex. 
Sex differences in immune responses have also been found in relation to the β-2AR. In a study of 
healthy non-asthmatics, the effect of β-2 agonist on the function of neutrophils was assessed [299]. 
There were almost three times more β-2 binding sites on neutrophils of females relative to males. The 
β-2 agonist isoprenaline, increased non-directional locomotion (chemokinesis), stimulated release of a 
chemotactic factor from neutrophils of females, but had no effect on neutrophils from males. 
Isoprenaline also inhibited IL-8 induced chemotaxis in neutrophils of females only.  
The β-2AR is also important in asthma as the target of β-2 agonist bronchodilator treatment. 
Stimulation of the β-2AR on ASM cells results in an increase in cAMP production and consequently, 
relaxation of the muscle and relief of bronchospasm. Beta-2 receptor-stimulated cAMP in 
lymphocytes of healthy females, during the luteal phase of the menstrual cycle (when oestrogen and 
progesterone levels are highest), has been shown to be greater relative to males [300, 301]. This 
variation in cAMP was related to hormonal influences on receptor density [300]. Paradoxically, 
female asthmatics have been shown to down-regulate β-2 responses in response to cyclic changes in 
hormones relative to non-asthmatic females [302]. This may account for the increase in symptoms 
that some asthmatic women experience prior to menses [303, 304]. 
Atopy 
Atopy is another factor influencing asthma phenotype. The effect of atopy on phenotype was 




and non-atopic asthmatics have also been described in the literature. Non-atopic asthma was 
associated with more frequent requirement for ICS preventers, greater use of intermittent oral 
corticosteroid (OCS) [305] and more severe and persistent symptoms [305, 306] relative to atopic-
asthmatics. These differences may relate to the differences in inflammation patterns as previously 
described, thus, atopy may be an important determinant of disease expression and treatment response. 
Sex vs Atopy 
The effects of sex on asthma outcomes may be in part related to the effects of atopy. The incidence of 
non-atopic asthma is higher in females relative to males in all age groups [307]. Non-atopic 
asthmatics are more likely to be female, have lower FEV1 values, require ICS and OCS for control of 
symptoms and have higher severity scores relative to atopic asthmatics [305]. These differences may 
be due to an interaction between atopic status and sex, that influences the development of asthma in 
adults.  
Female sex was associated with an increased risk of asthma in adulthood relative to males (OR 1.99; 
CI 1.54-2.57) p<0.05 [294]. There was also an increased risk of asthma in atopic relative to non-
atopic individuals (OR 3.04; CI 2.40-3.85); however, the effect of atopy on asthma incidence was 
greater in males (OR 4.9; CI 3.29-7.30) relative to females (OR 2.28; CI 1.68-3.08), and the effect of 
sex on asthma incidence was greater in non-atopic individuals (OR 3.2; CI 2.12-4.85) relative to 
atopic individuals (OR 1.4; CI 1.02-2.02). In the same study, the risk of asthma in atopic females 
decreased with age, but the risk did not decrease in men. Other studies have found a decrease in the 
incidence of asthma [308] and a decrease in atopy [309], in post-menopausal relative to pre-
menopausal women. The effect of menopause on asthma was lost when oestrogen replacement was 
given [308]. Thus, atopy is a greater risk factor for adult onset asthma in males relative to females, 
and the decrease in risk of asthma with age in females (unless hormone replacement is given) is due to 
a decline in the prevalence of atopy. In the absence of atopy, the female sex is a greater risk for adult 
onset asthma relative to the male sex.  
Ethnicity 
Differences in asthma phenotypes between African Americans and “white” populations have been 
described. One USA study found that among asthmatic adults presenting to an emergency department, 
African-Americans had a greater degree of airways obstruction, as measured by PEF values and were 
more likely to have PEF <50% and PEF <35% predicted, relative to Caucasians [310]. Atopic disease 
and asthma among relatives were higher in African Americans relative to “whites” and Hispanics 
[311]. Differences in endotypes between African American and “white” children with asthma have 
recently been identified. Eleven cytokines, including IL-4, IL-5, IL-13 and IL-17A, were found to 




significant factor in symptom control and severity in non-African American children [312]. In acute 
care facilities, where a high proportion of those presenting with acute asthma exacerbations are 
African-Americans, there are disparities in asthma outcomes, with African-Americans having the 
highest frequency of presentations to emergency, admissions and asthma-related deaths compared 
with ‘whites’ [313, 314]. These differences are independent of socio-economic status [315]. Genetic 
variation in the β-2AR gene and higher rates of atopic sensitization relative to “whites”, are thought to 
contribute to these disparities in outcomes [316]. 
 
 
1.3 Management of Asthma 
1.3.1 Overview of asthma management 
The principles of asthma management are to control the underlying inflammation and relieve the 
airway obstruction caused by the hyper-responsiveness of the airways. Long-term treatment aims to 
minimise the frequency and severity of acute exacerbations, while the aim of treatment of acute 
exacerbations is to prevent deterioration in respiratory function and death. National and international 
guidelines have similar recommendations for the management of asthma symptoms and acute 
exacerbations [2-4]. Management of asthma involves pharmacological treatment, directed towards 
reducing the frequency of symptoms and preservation of lung function, by relieving 
bronchoconstriction and controlling inflammation. A variety of types of medication are available to 
manage the underlying pathological processes.  
A short acting inhaled β-2 agonist (SABA), either via a metered dose inhaler (MDI) or via wet 
nebulization, is used to treat the symptoms of bronchoconstriction such as wheezing or cough. The 
main pharmacological treatment used, to control inflammation and maintain symptom control, is an 
inhaled corticosteroid (ICS), either alone, or in combination with a long-acting β-2 agonist (LABA). 
Oral corticosteroids (OCS) are sometimes required to treat an acute exacerbation and may also be 
required to assist in long-term control of symptoms. Other add-on treatments are also available for 
long-term management of symptoms. 
Good asthma management also includes self-monitoring, avoidance of triggers, abstinence from 
cigarette smoking and early recognition of and management of acute exacerbations. It also includes 
regular review by the general practitioner to ensure the prescription of appropriate medications and to 





1.3.2 Management of asthma symptoms 
Beta-2 agonists 
The β-2 agonists are proven to dilate human airways [317]. They are, and have remained, the 
mainstay of bronchodilator treatments since their introduction in the 1960s and are used primarily to 
relieve the symptoms of wheeze, cough or breathlessness. They are the only agents to relax ASM 
regardless of the contractile stimulus [318] and are therefore, an effective treatment of broncho-
constriction in asthma regardless of the trigger. They stimulate the production of the second 
messenger cyclic adenosine monophosphate (cAMP), which is believed to effect smooth muscle 
relaxation. Beta-2 agonists are classified as short acting (SABA) or long acting (LABA), dependent 
on their respective durations of action. Beta-2 agonists also reduce airways hyper-responsiveness 
(AHR) as demonstrated by an increase in the PD 20 for histamine [319]. Long acting β-2 agonists are 
also effective in reducing AHR as defined by provocation challenges [320-322]. The β-2 agonists also 
display intrinsic anti-inflammatory effects [323] and have synergistic effects on inflammation when 
combined with corticosteroids [324]. In clinical trials in both adults and children, the addition of 
LABA to ICS therapy provides a modest improvement in symptom control relative to ICS alone 
[325]. 
Short acting β-2 agonists such as salbutamol and terbutaline, are the primary pharmacological agents 
to relieve episodes of bronchoconstriction and wheeze. They are available in a metered dose inhaler 
(MDI), and the dose can be titrated to effect. They are also available in a solution that can be 
delivered via an air or oxygen driver nebulizer. The long acting β-2 agonists, formoterol and 
salmeterol can be used as relievers. Due to concerns about increased mortality and life-threatening 
events, particularly in African-Americans [326, 327], they are only used in combination with ICS, 
when ICS alone is insufficient. 
Beta-2 agonists can also have adverse effects. Regular SABA use has been shown to increase AHR in 
atopic asthmatics [328]. With chronic excessive administration, β-2 agonist can interfere with the 
anti-inflammatory actions of corticosteroids and contribute to worsening of asthma symptoms [329, 
330]. 
Other bronchodilators 
Ipratropium and tiotropium are muscarinic antagonists that induce bronchodilation by inhibiting the 
effect of acetylcholine at the muscarinic receptors (M3) in the airways. Tiotropium is a long acting 
muscarinic antagonist that was first used in chronic bronchitis. It has been shown to be effective as 
add-on therapy in those whose symptoms are not well controlled on the combination of LABA/ICS 




Although still considered an optional add-on treatment in chronic asthma management [4], 
theophylline and others in its class are rarely used. Theophylline and its soluble salt aminophylline are 
inhibitors of phosphodiesterase, the enzyme responsible for the breakdown of cAMP. They are 
presumed to relax airway smooth muscle through increases in the intracellular content of cAMP via 
inhibition cAMP breakdown and are also believed to have some mild anti- inflammatory properties 
[332]. 
Anti-inflammatory treatment 
Corticosteroids with glucocorticoid activity are the mainstay of anti-inflammatory treatment. By 
reducing inflammation, they reduce AHR and airways reactivity, thereby reducing the number and 
frequency of episodes of bronchoconstriction and obstruction. Due to their efficacy, they remain the 
first line anti-inflammatory treatment. 
Corticosteroids cross the plasma membrane and bind to the glucocorticoid receptor (GR) in the cell 
cytoplasm. The hormone receptor complex is then transported to the nucleus where it binds to DNA 
on glucocorticoid response elements (GRE) [330, 333]. The anti-inflammatory action is thought to be 
dual. GRE-GR complexes can increase the transcription of anti-inflammatory mediators and directly 
inhibit inflammatory gene expression via inhibition of nuclear transcription factors such as nuclear 
factor-κβ [330].  
The inhaled corticosteroids (ICS) are effective in controlling symptoms in adults and children, when 
taken regularly [334, 335]. An inhaled corticosteroid is more effective when combined with a long 
acting β-2 agonist than when taken alone [325]. This may be due to the additional properties of β-2 
agonists as anti-inflammatory agents [336, 337] and modulators of remodelling [338], and synergism 
with corticosteroids in inhibiting remodelling [337]. Prednisolone is an oral corticosteroid that can be 
used in short bursts to stabilise chronic asthma symptoms [4]. 
Additional agents for maintenance therapy 
Leukotriene receptor antagonists (LTRA) are antagonists of leukotrienes, another class of 
inflammatory mediator. They are less effective than ICS [339] and are used as second line medication 
in controlling asthma symptoms. They can improve control as ‘add-on’ therapy to ICS [340] and are 
effective in aspirin intolerant asthma [253].  
Sodium cromoglycate and nedocromil sodium are both structurally different but have similar 
mechanisms of action. They are administered as an inhalation. They inhibit cough, mast cell and 
eosinophil activation and other pathways in allergic responses via chloride channel inhibition [341]. 
They are less effective in controlling asthma symptoms relative to ICS, but useful in allergic/atopic 





Monoclonal antibody therapy is a more recently available option for those with difficult to control 
symptoms, in place of ongoing oral corticosteroids. They have very specific indications for use in 
those with difficult to treat allergic asthma, and prescription is limited to those over the age of 12 who 
are under respiratory specialist care. Monoclonal antibodies block interleukin signalling, so can be 
effective in treating the persistent eosinophilic inflammation by reducing the production and 
recruitment of eosinophils.  
Omalizumab is an anti-IgE antibody and mepolizumab, benralizumab and reslizumab are anti-IL5 
antibodies. They are given as a subcutaneous injection monthly. These agents have been shown to 
reduce the frequency of exacerbations, improve lung function and reduce asthma symptoms as 
measured by ACQ scores [344-346]. Anti-IL13 antibodies have been developed but are not yet 
available for use [347]. 
 
1.3.3 Management of acute exacerbations 
The treatment of an acute asthma exacerbation is directed at maintaining adequate oxygenation of the 
blood and reducing work of breathing by relieving airway obstruction. Mechanical support of 
respiratory function may be necessary in extreme situations, to prevent death from respiratory failure 
due to severe obstruction and the resultant fatigue. Treatment is tailored to the severity of the 
exacerbation. 
Pharmacological treatments 
Despite the variety of agents available and the recent pharmacological developments in the 
management of chronic symptoms, no new pharmacological agents have been developed for 
management of acute asthma exacerbations. There are also few agents with proven clinical efficacy 
and hence, treatment options for the management of acute exacerbations are limited. 
Supplemental oxygen 
Supplemental oxygen is indicated where oxygen saturation is <94% and is titrated to maintain an 
oxygen saturation between 94-98% [4]. Oxygen can be delivered via nasal prongs to a flow rate of up 
to 4 litres per minute. Higher flow rates may be delivered via a mask, a non-invasive ventilator or 







Short acting β-2 agonists such salbutamol and terbutaline are used to alleviate bronchospasm and are 
the mainstay bronchodilators used in the treatment of acute exacerbations of asthma. They can be 
given as an inhalation via a metered dose inhaler (MDI) or via wet nebulisations. They are very 
effective in relieving airway obstruction via either route [348]. Inhaled β-2 agonist is given initially as 
‘rescue treatment’ in bursts of three nebulisations during the first hour but can be given continuously 
for as long as is required [2, 4, 268]. Once breathing has improved, the frequency of inhalations can 
be titrated according to need, with the aim of reducing the frequency of inhalations and eventually 
weaning β-2 agonist treatment over two to three days, depending on the severity of the attack.  
Inhalation via MDI is suitable for initial treatment of mild to moderate exacerbations. Guidelines 
recommend 400-1200mcg salbutamol inhalation via a holding chamber or spacer, every 20-30 
minutes, until there is an effect [2]. Absorption of β-2 agonists via the inhaled route can be variable, 
dependent on airway calibre. Greater degrees of airway obstruction are associated with reduced 
systemic absorption and reduced bronchodilating effect, necessitating higher doses [349].  
The nebulised route is preferred for the more severe exacerbations and should be used in clinical 
situations where supplemental oxygen is required [2, 4, 268]. Salbutamol nebulisations of 5mg can be 
given intermittently at 20-minute intervals [2]. Continuous nebulisations are more effective than 
intermittent nebulisations, in reducing admission to hospital and improving obstruction and are 
recommended for severe and life-threatening exacerbations [350]. Although the intravenous route has 
been utilised for severe/acute exacerbations, it is now discouraged, as it has been shown to have an 
adverse side-effect profile without any clinical benefit over nebulised treatment [351]. Its use is 
reserved for patients where inhalation/nebulisation is unreliable [4].  
Excessive or high dose β-2 agonist use in acute cases, can lead to biochemical disturbances such as 
lactic acidosis [352, 353] and hypokalaemia [354]. Lactic acidosis may contribute to increased 
respiratory effort [355] and complicate assessment of severity, leading to inappropriate further high 
dose use of β-2 agonist [353]. Although hypokalaemia may predispose to adverse cardiac events, a 
direct link between hypokalaemia and asthma morbidity/mortality is difficult to establish [354]. 
Ipratropium has been shown to be an effective adjunct in the treatment of acute asthma in children 
and adults. When administered with initial treatment of inhaled or nebulised β-2 agonist, as a single 
inhalation or nebulisation, ipratropium was found to improve airways obstruction and reduce 
admission rates relative to β-2 agonist alone [356-358]. The greatest improvements in airways 
obstruction were found in those with the lowest initial FEV1 or PEF values [357]. Ipratropium can be 
administered via inhalation or wet nebulisation, concurrently with β-2 agonist. Guidelines vary in 




single initial dose with rescue treatment, followed by repeated dosing 6 hourly until resolution of 
symptoms [4]. The Australian guideline advises 500mcg nebulised concurrently with salbutamol, for 
three doses at 20-minute intervals for the first hour [2].  
Corticosteroids 
Oral corticosteroids, such as prednisolone, are effective in treating acute exacerbations [359], 
reducing hospital admissions [360] and preventing relapse [361]. Hydrocortisone is a corticosteroid 
that can be given intravenously where oral administration is not practical, i.e. life-threatening 
exacerbations and mechanically ventilated patients. Guidelines recommend 50mg of oral prednisolone 
within the first hour of treatment, regardless of asthma severity [2, 4, 268]. If the intravenous route is 
preferable, hydrocortisone can be given intravenously at 100mg 6 hourly [2, 4, 268]. Corticosteroid 
treatment should be continued daily for at least 5 days, or until recovery, for up to 10 days [2, 4, 268].  
Optional add-on treatments  
If there is no response or insufficient response to the above treatments, then there are no clinically 
proven and few guideline-recommended additional treatment options. The use of magnesium in acute 
asthma is discussed in detail in the following section. 
Aminophylline 
In those not already taking oral theophylline, aminophylline is given as a 5mg/kg loading dose 
infusion over 20 minutes, followed by a continuous infusion of 0.5-0.7 mg/kg/hour [4]. When 
compared with intravenous salbutamol [362] or added to high dose inhaled β-2 agonist [363, 364], 
aminophylline provided no clinical advantage relative to salbutamol alone and resulted in an increase 
in adverse effects, such as vomiting and abnormal cardiac rhythms [364]. Although aminophylline is 
included in the current BTS guideline, as an optional add-on treatment for those non-responsive to 
initial treatment, its use is discouraged due to the adverse side effect profile and lack of proven benefit 
in acute asthma [2, 4, 268]. 
Ketamine 
Ketamine is listed as an option in the BTS/SIGN guideline, as there is some evidence that it is an 
effective bronchodilator [365]. An intravenous bolus followed by an infusion may reverse 
bronchoconstriction, improve symptoms and prevent the need for mechanical ventilation in status 
asthmaticus and assist in the weaning of mechanical ventilation [365]. It does not appear to have any 
benefits in those with less severe exacerbations, in terms of reduced hospital admission rates or 






Heliox is a gas that is a mixture of oxygen and helium. The principle behind its use is to reduce the 
work of breathing by delivering oxygen in a vehicle with a lower airflow resistance relative to the 
nitrogen present in air. Its use alone in asthma is not recommended [4, 268, 368] however, a recent 
meta-analysis suggests that it is effective as a vehicle for delivering β-2 agonist nebulisations and 
produces greater improvements in airways obstruction and reductions in admission to hospital, in 
adults and children, relative to the standard oxygen driven methods [369]. The reviewer suggests that 
its use in routine care of acute asthma is appropriate, but this practice has not been recommended in 
the more recent guidelines [2, 4, 268]. This may relate to the necessity of specialised breathing 
circuits for the delivery of heliox.  
Treatment of respiratory failure 
Fatigue or severe obstruction, with collapse and occlusion of the small airways, results in severe 
hypoxia and ultimately death if respiratory function is not supported. Retention of carbon dioxide as 
measured on arterial blood gas, or indicated clinically by drowsiness, heralds an impending 
respiratory arrest. In this circumstance, support of respiratory function is required to prevent death [4]. 
Assisted ventilation 
Intubation and mechanical ventilation are a last resort, but necessary to prevent death from hypoxia. 
This procedure must be undertaken cautiously by those clinicians with experience in managing 
mechanically ventilated asthmatics, as there are potential adverse consequences of overexpansion of 
the lungs, raised intra-thoracic pressure and tension pneumothorax [370]. Indications for intubation 
and mechanical ventilation are drowsiness, hypoxia despite supplemental oxygen and respiratory 
arrest [4]. Once ventilated, bronchodilators may be administered via the endotracheal tube or 
intravenously.  
Non-invasive ventilation (NIV) has been used to avoid the need for mechanical ventilation. The 
efficacy of non-invasive ventilation in severe exacerbations has been reviewed in a meta-analysis 
[371]. The reviewers were unable to draw conclusions because the data was insufficient. Although 
listed in guidelines as an option for respiratory failure, it is acknowledged that there is a lack of 
evidence in support of its use [2, 4, 268].  
Pulmonary bypass 
Extracorporeal membrane oxygenation (ECMO) is an invasive method for supporting cardio-
respiratory function and was originally used during cardiac bypass surgery [372]. It can provide 
oxygenation of the blood through an external apparatus bypassing the lungs [373]. This procedure can 




supporting respiratory function in mechanically ventilated asthmatics and was effective in patients 
where mechanical ventilation was unable to provide satisfactory oxygenation [374]. No patient 
suffered adverse neurological sequelae however, the sample size in this review was only16 patients. 
This treatment is not listed in current asthma guidelines [2, 4, 268]. 
 
 
1.4 Magnesium and asthma 
1.4.1 Overview 
Magnesium is listed as an optional add-on therapy in severe asthma and in those non-responsive to 
treatment [2-4]. The evidence is limited  therefore, its use is not strongly advocated. The clinical trials 
of magnesium in asthma varied greatly in methodology, inclusion criteria and discharge criteria. This 
may be a reason for the inconsistent results however, individual factors have yet to be considered 
when assessing magnesium’s efficacy. There are several factors that may contribute to this individual 
variation in response to magnesium. These factors should be taken in to consideration when assessing 
the utility of magnesium in the treatment of acute asthma.  
There is much variation within the asthmatic population with respect to clinical phenotype, as well as 
underlying pathogenic processes and response to treatment. It would be reasonable to hypothesise that 
these differences could translate to a difference in response to magnesium and hence, there may be 
subgroups that benefit from magnesium more than others. This is the situation for treatment of asthma 
with monoclonal antibodies which are effective in those with high sputum eosinophil counts. Expert 
opinion advocates for targeted therapy based on asthma endotypes [375]. This principle could be 
relevant to the use of intravenous magnesium in acute asthma. Asthma endotypes may be important to 
the efficacy of magnesium, given the wide variations in efficacy between studies.  
 
1.4.2 Efficacy of magnesium in the treatment of acute asthma 
Overall effects of intravenous magnesium 
Although there has been anecdotal evidence from case reports, the clinical trials assessing its efficacy 
along-side standard treatments have had varied results, therefore, there is a lack of conclusive 
evidence to support the use of intravenous magnesium in acute asthma. There have been few 
published clinical trials, most of which have been small and with varied results (Table 1). 
Comparisons between studies is made difficult by the inconsistency in methodology between studies 




to detect the differences in outcomes reported [376-378]. Meta-analysis has attempted to assess 
magnesium’s efficacy [379, 380], but is limited by the factors previously mentioned. The most recent 
meta-analysis suggests that magnesium is an effective adjunct to treatment in adults presenting to 
emergency departments with acute asthma exacerbations however, the overall effect on admission 
rates is small (7%) [380]. Given the effect size, larger numbers would be required to confirm the 
utility of routine use of magnesium to treat acute asthma exacerbations. 
Severe asthma subgroups. 
Some studies have reported large significant benefits in small studies of severe asthmatics [381-383] 
and within the severe subgroups of larger studies [384]. Magnesium use was associated with a 
reduction is admission rate and greater improvements in spirometry relative to placebo; thus, the 
Cochrane group concluded that asthma severity and non-response to treatment in terms of 
improvements in airways obstruction, were factors in determining treatment response to magnesium 
[379].  
Skobeloff found that acutely exacerbating asthmatics, whose initial PEF was <200L/min and failed to 
double after 2 salbutamol nebulisations, showed a 32% improvement in absolute PEF values within 2 
hours of treatment with intravenous magnesium, while those receiving placebo showed no 
improvement in PEF [382]. In another study, intravenous magnesium was also found to reduce 
admission rates by 24% in those with a presenting FEV1 <30% predicted, accompanied by a modest 
(6%) but significantly greater improvement in airways obstruction relative to the placebo group [383]. 
Bijani et al found that for those with an initial PEF <200L/min, who failed to increase their PEF 
>200L/min after 6 hours of treatment with bronchodilators and steroids, intravenous magnesium 
produced a greater improvement in airways obstruction relative to standard care alone [385]. PEF data 
were reported as the percentage predicted, and the mean initial PEF was similar for both groups at 
<30% predicted. Those in placebo failed to increase their PEF to <50% predicted, while those treated 
with magnesium had a mean PEF >80% predicted at the end of the study period. 
Porter failed to find any benefit from magnesium in a group of severe asthmatics with an initial FEV1 
of <25% predicted [386]. Green also failed to find a benefit from magnesium in a group with an 
absolute initial PEF <150 L/min [377]. In both studies, those in placebo and treatment groups doubled 
their initial PEF values with nebulisations of β-2 agonist. These patients may have been excluded 
from the Skobeloff and Bijani studies as they responded well to initial β-2 agonist. 
Tiffany replicated Skobeloff’s study protocol, with the addition of a third group that received a 
magnesium infusion of 2g(8mmol)/hour for 4 hours. This study failed to demonstrate any difference 




magnesium and placebo groups had similar initial PEF values (120 vs. 130L/ min), and both groups 
had limited response to further β-2 agonist treatment, with PEF values remaining below 200L/min.  
Studies where patients of all severities were included, also had variable results. Silverman found that 
the use of magnesium in a subgroup of those with FEV1<25% predicted, resulted in a greater 
improvement in FEV1 predicted relative to standard care alone [384]. The effect was greatest in those 
with an initial FEV1<20% predicted. The mean baseline FEV1 was 16% predicted, and the 
administration of magnesium increased FEV1 to 41% predicted relative to 34% predicted in placebo. 
There was a smaller benefit in those with FEV1 25-29% predicted which was not statistically 
significant. The admission rate overall was not reduced however, had admission criteria of a final 
FEV1 >50% predicted been strictly applied, the use of magnesium would have resulted in a 10% 
reduction in admission rate.  
Bloch found also found that in the subgroup of those with an FEV1 < 25% predicted, magnesium 
produced a 20% greater improvement in FEV1 predicted relative to placebo [381]. Those receiving a 
placebo failed to improve their FEV1 with further β-2 agonist, despite a small initial improvement. 







Table 1. Randomised control trials of intravenous magnesium in asthma. Comparison of severity and 






In two other studies in acute asthma of mixed severities, magnesium was not shown to have any 
significant effect on admission rates or improvements in PEF relative to placebo, nor in the sub-group 
of severe/life-threatening asthma [378, 388]. Bradshaw failed to find any beneficial effect from 
magnesium on PEF or a significant reduction in admission rates in those with PEF <33% [378]. The 
Goodacre (3M) study (which included an inhaled magnesium group) also failed to find any beneficial 
effect on PEF or a significant reduction in admission rates in any sub-group analyses of severity 
[388]. The overall improvement in PEF was similar in both studies. These results contrast the 
Silverman and Bloch studies. 
Magnesium’s efficacy may be influenced by individual factors, in addition to severity and response to 
initial bronchodilator treatment, and individual variation in response is likely to be a contributing 
factor to the small overall effect. It is, therefore, important to examine these studies in detail to 
determine which factors may contribute to efficacy and to identify those more likely to benefit.  
Factors that may limit or influence magnesium’s efficacy 
Magnesium dose 
It is possible that there is a dose-response relationship between magnesium and efficacy, as 
magnesium dosing varied between the studies. However, both 1.2g(5mmol) [382] and 2g(8mmol) 
[384] were effective in small studies, while 2g was ineffective in the larger Goodacre study [388]. 
This suggests that factors other than dose may be involved. 
Ethnicity 
There may be an interaction between ethnicity and severity, in terms of bronchodilator 
responsiveness, that may also influence magnesium’s efficacy. The ethnicity of populations studied 
varied greatly, however, the results appeared to favour magnesium in populations of mostly non-
whites with “severe” asthma. Skobeloff’s study, which demonstrated the greatest benefits from 
magnesium, had a large proportion (n=34, 89%) of African-Americans. These ‘non-responders’ were 
true non-responders and failed to increase PEF in response to β-2 agonist without the addition of 
magnesium to their treatment. This study demonstrated the greatest reduction in hospital admission 
rates for magnesium over placebo (42%) of all studies to date. Studies in mixed populations of 
African Americans and non-white Hispanics [384] have had similar success from magnesium, 
although, not with the same magnitude of effect as Skobeloff. Racial demographics for the Tiffany 
and Bloch studies were not reported, limiting an assessment of the effect of race on the β-2 
responsiveness and efficacy of magnesium in these studies. Bijani, in an Iranian population [385] and 
Singh, in an Indian population [383], found benefit from the use of magnesium. Boonyavorakul’s 





Green [377], Bradshaw [378] and Goodacre [388] failed to find benefit from the use of magnesium in 
acute asthmatics of mixed severities nor in the severe subgroups. The Green study in the US, 
consisted of >60% (n=74) white, 24% (n=29) Hispanics and 7.5% (n=9) African-Americans. In this 
study, there was a doubling of PEF values overall irrespective of treatment and the overall admission 
rate was low (20%), thus the potential for magnesium to show benefit would have been limited by the 
responsiveness of the cohort to bronchodilator. The major ethnicity in the Goodacre study was white 
(90 %, n=974), with less than 1% (n=11) classified as ‘black’ or ‘black British’. The demographic of 
ethnicity was not reported in the Bradshaw study. 
Ethnic differences in response to various asthma treatments is well documented. Asthmatic African-
Americans were found to be less responsive to β-2 agonist relative to Caucasians asthmatics at 
maximal doses of inhaled β-2 agonist, but baseline lung function parameters were not significantly 
different [389]. Asthmatic African-Americans, Mexican Americans and Puerto-Ricans, were found to 
have below expected responses to β-2 agonist relative to Caucasians [390]. The same author found 
that in African American asthmatics, ICS does not increase bronchodilator response to β-2 agonist 
[391]. Clinical studies have also found that long-term LABA use resulted in increased adverse 
outcomes, including mortality, in African-Americans relative to other races [392].  As mentioned 
previously, the reason for the poorer outcomes for African Americans is thought to relate to racial 
differences in asthma phenotype and to be independent of socio-economic status [315, 316]. 
These data suggest that ethnicity is an important variable that may affect treatment response. 
Magnesium, therefore, may be more beneficial in certain ethnic groups. Further studies to investigate 
the effect of ethnicity on response to magnesium could prove African Americans to be one of those 
groups. The reason for a difference in efficacy may relate to a difference in β-2AR responses. Further 
studies in to the effect of ethnicity on outcomes related to the use of intravenous magnesium in 
asthma, may be worthwhile. 
Other potential outcome benefits from the use of intravenous magnesium in acute asthma 
Despite a lack of proven efficacy in Caucasian asthmatics overall, magnesium may have some 
benefits in terms of reduction in relapse rates and/or improvement in symptoms. Although the Green 
study failed to show any reduction in admission rate with the use of magnesium, there was an 8% 
relapse rate (n=5), requiring a return visit to the emergency department within 72 hours in the placebo 
group, while the relapse rate in the magnesium group was only 1.7% (n=1) [377]. Silverman also 
reported a difference in relapse rates, with 3% (n=4) of those in the placebo group and less than 1% 
(n=1) in the magnesium group re-admitted at 7 days [384]. These studies are small, and larger 
numbers of participants would be required to confirm such an effect on readmission to hospital. 




Although Bradshaw reported no benefits from the use of magnesium, there was a non-significant 
trend towards a reduction in the number of β-2 agonist nebulisations administered to the magnesium 
group (n=20) relative to the placebo group (n=27) [378]. The study was small (n=129) therefore, it is 
not possible to draw conclusions regarding magnesium’s effect on β-2 agonist use. Larger studies 
would be needed to further assess this. 
Intravenous magnesium and status asthmaticus 
There are no published clinical trials in which the utility of magnesium in status asthmaticus has been 
assessed. This is likely due to the difficulties in obtaining informed consent, or ethical dilemmas faced 
when withholding a potentially beneficial treatment in those patients whose life is under immediate 
threat. The only data available in the literature, is in the form of case reports and case series. Some 
studies reported that 1-2g of intravenous magnesium given as a rapid bolus, produced marked 
improvements in clinical symptoms in adults with impending respiratory failure and obviated the need 
for intubation [393, 394]. The use of 1.2g [395] and much larger doses, in the range of 10-20g (40-
80mmol), have also been reported to be successful in reducing significantly increased airway 
pressures in mechanically ventilated asthmatics, where high airway pressures had persisted despite the 
use of maximal doses of intravenous β-2 agonist [396-398]. 
These data support the use of magnesium in status asthmatics, however, this data may be biased 
towards positive outcomes, as negative outcomes are less likely to be reported or published. 
Meaningful evaluation of magnesium’s efficacy in these circumstances is limited. 
Inhaled magnesium  
There is little evidence in support of the use of inhaled magnesium in as a bronchodilator in acute or 
stable asthma in adults. Inhaled magnesium was not shown to be effective in stable asthmatics with 
chronic obstructive symptoms [399]. Nebulised magnesium was not shown to be an effective 
bronchodilator or influence airways resistance (Raw) in stable asthmatics [400]. The 3M study found 
no difference in admission rate between inhaled magnesium and placebo (79% vs. 78%) [388]. A 
Cochrane meta-analysis in 2005 supported the use of inhaled magnesium in acute asthma [401] 
however, more recent reviews are in conflict. One review found there were benefits related to reduced 
admission rates and lung function [402]. Others found no overall benefit in outcomes [403] and 
recommended intravenous over inhaled magnesium [404].  
Inhaled magnesium may be of benefit in stabilization of AHR. Inhaled magnesium has been shown to 
reduce bronchoconstriction responses and prevent bronchoconstrictor responses in stable asthmatics, 
as defined by FEV1 >80% predicted [405-407]. When bronchial provocation response in asthmatics 




PD 20/PC 20 to histamine and methacholine relative to the placebo [405-407]. The effect of inhaled 
magnesium on PD 20 to histamine was also found to be dose-dependent [406]. Inhaled magnesium 
was also shown to reverse methacholine and histamine-induced bronchoconstriction [405, 407] and 
irritant induced bronchoconstriction [408].  
The combination of inhaled magnesium and salbutamol has been effective in improving lung function 
in asthmatics [409]. A small trial showed inhaled magnesium in combination with inhaled salbutamol 
and intravenous corticosteroid, to improve airways obstruction and reduce admissions relative to 
standard bronchodilator therapy [410]. These data suggest that the addition of magnesium to standard 
bronchodilator therapy is more effective than inhaled magnesium alone. While Australian and British 
guidelines do not recommend inhaled magnesium in adults [2, 4], international guidelines (GINA) 
include inhaled magnesium as an option for dilution of salbutamol for nebulisation [268]. 
Magnesium in managing acute asthma in children 
The data in clinical trials of children are more supportive of intravenous magnesium’s clinical 
efficacy [411-416], and some recommend the use of intravenous magnesium in children to improve 
lung function and reduce admissions [402, 417]. The most recent Cochrane review was less 
supportive due to the small sample sizes in the studies reviewed [418]. Another recent review 
suggests that intravenous magnesium prevents one admission in every five children treated [419]. 
Inhaled magnesium has been shown to induce bronchodilation in children [420] however, it was less 
efficacious relative to salbutamol. The most recent review of magnesium use in children does not 
recommend the inhaled route [421].  
The differences in the apparent efficacy of intravenous magnesium between adults and children, may 
be explained by the heterogeneity of adult asthma and associated co-morbidity, relative to the often 
‘otherwise healthy’ childhood disease. Childhood onset asthma is often of the ‘extrinsic’ type which 
is associated with the presence of eosinophilic inflammation and a good response to steroids [270-
272]. Adult asthma, though sometimes the persistence of a childhood onset disease, is often its own 
entity. The adult phenotypes sometimes share features in common with childhood disease [270, 271] 
however, they are more often persistent and severe [270, 273, 274]. Adult asthma may also be 
complicated by a greater degree of fixed obstruction due to the persistence of symptoms from 
childhood [422-424], co-morbid chronic airways disease [425] and/or the effects of cigarette smoking 
[426-428], which are generally absent in children. These differences may account for differences in 




Current practice/usage in acute exacerbations 
Intravenous magnesium sulphate has been recently included in guidelines for acute asthma treatment. 
It is suggested as a second line agent for those who fail to respond to standard bronchodilator 
treatment and severe asthma as determined by PEF or FEV1 [2, 3]. Guideline definitions of ‘severe’ 
asthma suggest PEF <50% predicted signifies a severe exacerbation [4, 268], while PEF or FEV1 
<30% is classified as an indicator of a ‘life-threatening’ exacerbation [4, 268]. In contrast, early 
literature defined severe as PEF or FEV1 <30% [381-383]. Recommendations for its use in life-
threatening asthma are weak [2, 4] or absent [268]. There is also a perception of potential for toxicity 
from the use of intravenous magnesium [4] however, this does not appear to have impacted on its 
usage [429]. 
The current practice of use of intravenous magnesium in adult acute asthma, has been assessed in two 
large surveys of emergency departments in Britain [429] and Canada/United States [430]. In Britain, 
magnesium was used to treat acute asthma in 93% of emergency departments. Reported reasons for its 
use, included non-response to treatment and severe or life-threatening asthma. Lack of evidence of 
efficacy was the most commonly stated reason for not using it. In the US, although 93% of 
respondents reported magnesium was available, magnesium was only used in 2.5% of patients with 
acute exacerbations. Reported reasons for its use were older age, previous need for intubation, high 
initial respiratory rate, low PEF and failure to respond to initial β-2 agonists. A recent small survey of 
456 physicians in Turkey, found that only 48% were aware of its inclusion in the BTS, GINA asthma 
guidelines [431]. Usage was again restricted to severe and life-threatening exacerbations. 
These data show consistency between guideline recommendations and usage however, perception of 
its efficacy and awareness of magnesium as an option for treatment of acute asthma exacerbations, 
may influence its use across the world. 
 
1.4.3 Magnesium status and asthma 
Magnesium status may also be important in asthma exacerbations and lung function however, the data 
are not consistent. The role of magnesium status in asthma is not well defined and results of studies 
vary, depending on the methods of assessment used.  
Studies have not shown any differences in serum magnesium levels between asthmatics and non-
asthmatics. No difference in serum magnesium was found between exacerbating asthmatics and 
controls [432], stable asthmatics and controls [433] or between children with asthma, exacerbating or 
stable, and non-asthmatics [434]. One study reported no differences in multiple measures of 




levels were the same, there were some non-statistically significant differences, with asthmatics having 
slightly greater magnesium retention post IV loading and a slightly lower dietary magnesium intake 
relative to non-asthmatics. Low serum magnesium levels in asthmatics were associated with increased 
frequency of exacerbations and the need for preventative therapy [436]. This has also been found 
among patients with chronic airways limitation [437]. These data show that serum magnesium is not a 
surrogate marker of asthma, but magnesium deficiency may impact on disease severity in those with 
asthma.  
This is supported by studies where total and free intracellular magnesium levels were measured. In 
exacerbating asthmatics, levels of erythrocyte magnesium but not serum levels, were reduced relative 
to both non-exacerbating asthmatics and healthy controls [438]. Exacerbating asthmatics also showed 
a return to normal intracellular levels when exacerbations were controlled [438]. Significantly lower 
erythrocyte magnesium levels in stable asthmatics relative to healthy controls have also been found 
[433]. These data suggest that low intracellular magnesium concentrations may be associated with 
acute exacerbations.  
Histamine challenge in mild well-controlled asthmatics and non-asthmatics, was shown to reduce free 
intracellular erythrocyte magnesium levels without altering serum levels. The decrease in intracellular 
magnesium was not correlated with AHR [439]. Another study in asthmatics found that exacerbations 
were associated with elevated neutrophil counts, blood histamine, and inversely correlated with serum 
and red cell magnesium levels [440]. This effect was most pronounced in atopic relative to non-topic 
asthmatics. Low intracellular magnesium concentrations in neutrophils [441] and red blood cells [442, 
443] was inversely correlated with AHR as measured by methacholine challenge but not severity of 
asthma as determined by FEV1 or PEF [442]. These studies suggest that reductions in 
serum/intracellular magnesium occur during an exacerbation and may be associated with AHR. 
In adults with mild to moderate asthma, long-term (6.5 months) magnesium supplementation was 
shown to improve lung function, reduce AHR and improve quality of life, although, without 
significant changes in any of the multiple measures of magnesium status used [444]. It is also notable 
that only 2 of the 52 asthmatic patients were found to be deficient in magnesium thus, the 
improvements were independent of magnesium status. These data suggest that magnesium 
supplementation may be beneficial in terms of control of AHR, independent of magnesium status.  
Sex may influence the effect of magnesium status. Poor dietary magnesium intake in children 
between 11 and 19 years was correlated with reduced lung function as measured by FEV1, in both 
asthmatics and healthy controls [445], however, only in females was there a difference in effect 




1.5 Gaps in Knowledge 
1.5.1 Clinical benefits 
The efficacy of magnesium in asthma has not been established however, future clinical trials may 
determine whether magnesium is efficacious in the treatment of acute exacerbations. It is clear from 
the heterogeneity in the results of published trials, that large numbers of patients may be required to 
demonstrate this. 
The 3M trial is the largest clinical trial to date, yet it failed to demonstrate a significant reduction in 
admission rates or improvement lung function with intravenous magnesium (a 7% difference in 
favour of magnesium was not statistically significant) [388]. This suggests larger numbers of patients 
are needed to demonstrate an overall benefit. Additionally, there may have been other factors that 
limited magnesium’s efficacy in this study. The trial included older patients, therefore, could have 
included those with co-morbid illnesses that predispose an admission to hospital, irrespective of 
treatment responses. The inclusion of asthmatics of all severities could also potentially mask any 
benefit from magnesium. It is, therefore, important for future studies to assess the effect of severity on 
treatment response and perhaps exclude those with significant co-morbid illness that could influence 
disposition. There were no pre-defined admission or discharge criteria in this multicentre study, which 
could also have influenced outcomes. Future studies should have well-defined admission and 
discharge criteria to reduce the influence of local admission policies on outcomes. 
The heterogeneity in the results of clinical trials suggests that there is individual variation in response 
to treatment, therefore, there may be subgroups of patients more likely to benefit from the use of 
magnesium. A trial targeted towards those most likely to benefit, such as non-responders to initial β-2 
agonist, may be more successful without the need for large numbers of patients. Ethnicity and other 
individual variations could also influence outcome therefore, larger numbers may still be required to 
determine any subgroup benefits. Future studies should collect demographic data such as 
race/ethnicity and atopic status, in addition to sex and other variables, to adequately assess the effect 
of individual variation on response to magnesium. 
Whether the use of magnesium in acute asthma exacerbation may have other benefits, for example, in 
reducing relapse rates and β-2 agonist use, is yet to be determined. Outcome data should include 




1.5.2 Potential mechanism of action 
Bronchodilation 
Magnesium has been shown to have bronchodilating properties. Magnesium was used as early as 
1936, for the treatment of the bronchospasm associated with an acute asthma exacerbation, prior to 
the advent of β-2 agonists [446]. A small study of exacerbating asthmatics showed that 2g(8mmol) of 
intravenous magnesium had a direct bronchodilating effect, as shown by an improvement in FEV1 
relative to placebo, but the effect of magnesium on FEV1 was less than that of inhaled salbutamol 
[447]. Thus, magnesium has a direct effect on airway smooth muscle relaxation. This could occur via 
several possible mechanisms 
Calcium antagonism  
In arterial smooth muscle, magnesium competitively inhibits L-type voltage gated calcium channels. 
Pharmacological blockade of these channels causes vasodilation in human vascular smooth muscle 
[448].When infused intravenously, magnesium has been shown to cause vasodilation in healthy 
volunteers [449], and the action of magnesium was blocked by simultaneous infusion of calcium 
gluconate [449]. These data show that magnesium causes vascular smooth muscle relaxation via 
competitive inhibition of L-type voltage gated calcium channels.  
Inhibition of voltage gated calcium channels is unlikely to be the mechanism of HASM relaxation, as 
pharmacological blockers of L-type channels have very minimal beneficial effect on lung function in 
asthma [450], and when inhaled, they have been shown to induce bronchoconstriction in asthmatics 
[451]. The lack of effect is likely due to the voltages at which these calcium channels operate in 
HASM. These channels are not active at potentials of less than -20mV, which is outside the range at 
that occurs during HASM activity (-25mV and -55mV) [87]. The negative potential is maintained by 
potassium channels that maintain membrane polarity, despite changes in the flow of calcium [452, 
453]. These data suggest L-type channel blockade is not the primary mechanism of action of 
magnesium in HASM relaxation, and that magnesium may compete with calcium via an alternative 
mechanism. 
Lowering of intracellular calcium 
Magnesium was shown to relax porcine ASM pre-contracted with potassium chloride (KCL) and a 
muscarinic agonist carbachol in a dose dependent manner, over a concentration range of 1.2 to 9.2 
mM [454]. This was associated with a fall in intracellular calcium. Magnesium also inhibited KCL-
induced but not carbachol-induced contractions, as shown by a rightward shift of the dose response 




shown to relax rabbit ASM strips pre-contracted with acetylcholine in a concentration dependent 
manner, over a concentration range of 0.1mM to 2M [455]. The steepest decrease in contraction was 
observed at ≥10mM. Magnesium was also shown to relax resting, histamine, muscarinic agonist and 
electrically stimulated ASM in rabbits in a dose-dependent manner [456]. The lowest dose used 
(1mmol) was effective at relaxing resting ASM but not for contractile agonist or electrically 
stimulated ASM. Higher doses (≥ 5mmol) were also used and were able to relax contracted ASM. 
This relaxation was not antagonised by calcium, suggesting a different mechanism to L-type calcium 
channel antagonism. 
In canine nerve membrane preparations, an inhibitory effect on the intracellular release of stored 
calcium via IP3 gated calcium channels has been shown to occur by competitive inhibition of IP3 
binding [457]. The Na+/Ca2+ exchanger (NCX) regulates calcium influx and is present in many cells 
including ASM [458]. Magnesium acts as a competitive antagonist of calcium influx through these 
channels [459]. Magnesium competitively inhibits calcium binding to the cytoplasmic binding sites 
and alters the conformation of NCX. This prevents calcium influx and occurs at intracellular 
magnesium concentrations of 0.5 to 1 mM. Magnesium may affect relaxation of HASM via decreased 
intracellular calcium via one or both mechanisms.  
Effects on β-2 adrenergic receptor function and adenylate cyclase activation 
Increased levels of intracellular magnesium may relax ASM through enhanced ‘basal’ AC/cAMP 
production via numerous mechanisms. In isolated membranes from yeast cells transfected with Sf9 
AC, Magnesium was shown to catalyse AC in a concentration dependent manner [460]. Catalytic 
activation was observed at free magnesium concentrations of 0.1-1.0mM, which was up to 10-fold the 
normal free ionised levels. This range corresponded to the steepest part of the concentration/rate 
curve.  
In intact mouse lymphoma cells, magnesium increased basal AC and GTP stimulated AC activity, but 
this effect was abolished in the presence of β-2 agonist [461]. Beta-2 agonists have been shown to 
affect magnesium transport across intact mouse lymphoma cell membranes via the β-2AR [462] but 
independent of cAMP [463]. This process was shown to undergo rapid desensitisation which was 
reversed after 30-60 minutes [464]. Magnesium uptake without influence of a β-2 agonist was shown 
to be dependent on extracellular concentrations, with a maximal rate of uptake at 50µM to 3mM 
[465]. The effect of the administration of intravenous magnesium on intracellular levels may be 
affected by concurrent β-2 agonist use however, this effect would be short-lived.  
Inhibition of AC activity, as mediated through the Gβγ sub-unit, involves inhibition of GDP release 
and GTP binding [466]. Physiological concentrations of magnesium (1mM) caused this sub-unit to 




of GTP binding to the Gsα sub-unit [466]. These data suggest that greater than physiological levels 
may increase AC activity by antagonising the inhibitory effect of the Gβγ sub-unit.  
Magnesium has also been demonstrated to influence β-2AR affinity. In intact mouse lymphoma cells 
[461] and rat lung membrane preparations [467], concentrations of 2-3mM magnesium were able to 
induce a high affinity state of receptor for agonist. Magnesium’s effect on agonist affinity was limited 
to those receptors in the low activation state, i.e. not agonist/GTP bound. Thus, increasing 
intracellular magnesium may increase AC activity in systems not already stimulated by GTP or β-2 
agonist.  
Augmentation of β-2 agonist stimulated relaxation of ASM via enhanced production of cAMP. 
Intravenous magnesium may augment β-2 agonist induced bronchodilation. In adults hospitalised for 
asthma, a bolus of 20mg/kg (0.08mmol/kg) of magnesium followed by infusion of 10mmol/kg/hour, 
when administered simultaneously during salbutamol inhalations, caused an increase in FEV1 
responses to salbutamol relative to salbutamol alone [468]. Maximal bronchodilating response as 
measured by FEV1 was not altered however, the dose response curves were shifted to the left, which 
could reflect an increase in β-2 agonist binding to the receptor. These effects suggest that magnesium 
may augment β-2 agonist induced HASM relaxation. This may be due to an increase in agonist 
affinity for the receptor and consequently, an augmentation of cAMP production.  
In isolated frog erythrocyte membrane preparations, magnesium was shown to increase β-2 agonist 
binding. Beta-2 agonist stimulated AC activation was increased and was proportionate to the intrinsic 
activity of the agonist [469]. This effect was also demonstrated in isolated S49 (lymphocyte) 
membranes [461]. Magnesium’s effect on β-2AR affinity for the agonist was specific and not seen for 
other cations, and the effect was blocked by high levels of GTP, suggesting that this effect is limited 
to ‘inactive’ receptors. Receptor bound GTP reduces receptor affinity as a means of negative feedback 
regulation of receptor activity [470] however, in the absence of bound GTP, AC activity is low. 
Increased affinity for β-2 agonist increases nucleotide binding and exchange hence, AC activation and 
cAMP production. The relevance of this mechanism to intact human systems is not known however, 
this may be an important mechanism in maximising relaxation response of ASM to β-2 agonist 
bronchodilators.  
Reduction of AHR and symptoms via anti-inflammatory actions 
When administered intravenously, magnesium has also been shown to reduce AHR, as measured by 
bronchial provocation responses PC 20 to methacholine [471]. Intravenous magnesium resulted in 




intravenous magnesium can reduce AHR in asthmatics. The mechanism may involve inhibition of the 
release of pro-inflammatory cytokines.  
In cultured lymphocytes of asthmatic patients, magnesium has been shown to inhibit secretion of IL-5 
and IL-13 at concentrations ≥ 5mM [472]. Magnesium has also been shown to attenuate the activation 
of neutrophils in asthmatic patients at physiological (1mM) and high concentrations (5mM) [473]. 
TNF-α, which is associated with AHR [54, 55] and IL-1β, which is associated with impaired β-2 
agonist responses [223], are inhibited by magnesium. Magnesium was shown to suppress IL-1β, TNF-
α and IL-8 in neonatal cord mononuclear cells [474] and IL-6 and TNF-α from maternal mononuclear 
cells [475], at clinically achievable serum levels (2.5mM). These studies show that magnesium has 
broad anti-inflammatory properties over a wide range of concentrations and has anti-TNF-α properties 
at clinically relevant concentrations thus, anti-inflammatory activity may be an important mechanism 
of action. An anti-inflammatory effect has not been demonstrated directly in vivo and the optimal 
serum concentration required to achieve this in asthma in vivo is yet to be established. Maximal non-
toxic levels such as 2.5-3mM may be the most appropriate.  
Restoration of intracellular magnesium depletion 
The effects of an intravenous infusion of magnesium were assessed in one study of patients 
undergoing cardiac ablation. The 4g (20mmol) infusion produced an immediate increase in 
intracellular magnesium content in buccal mucosal cells, and serum concentrations remained elevated 
at 6 hours [476]. This demonstrates that an intravenous infusion of 4g magnesium is effectively 
distributed to both the intra and extracellular compartments. A definitive association between 
magnesium deficiency and acute asthma exacerbations has not been proven however, intracellular 
depletion of magnesium may impair β-2AR function and consequently, relaxation of HASM. 
Intracellular depletion may also increase inflammation. Intracellular deficiency may be restored with 
the administration of magnesium.  
Magnesium and normal β-2 adrenergic receptor function 
Magnesium has an important function in the regulation of the β-2AR. The β-2AR is the prototype of 
the family of G-protein coupled receptors (GPCRs), and receptor activation, AC stimulation and 
cAMP production, require coupling with a G-protein [133]. G-proteins are membrane bound 
transducers of receptor-activated signals, so named for the property and requirement of guanine-
nucleotide binding. Magnesium is intimately involved in the G-protein regulation of β-2AR function. 
Activation of the β-2AR is initiated via β-2 agonist binding which then promotes association of the 
receptor with a Gsα sub-unit of the G-protein [134]. This coupling activates GTP-ase of the Gsα and 




Gsα sub-unit of the G-protein [135]. The binding of β-2 agonist to the receptor is catalytic in the 
activation of AC by several fold [136].  
Magnesium is essential to normal β-2AR function. Normal physiological intracellular magnesium 
concentrations are required to produce cAMP from ATP, as Mg-ATP is the substrate for agonist 
induced activation of Gs/GTP-ase [477] and GTP binding/GDP dissociation [134, 466]. It is also 
necessary for agonist induced dissociation of Gsα from the Gβγ sub-unit [478] and detection of a high 
affinity state of receptor [479], i.e. that which promotes coupling with Gsα sub-unit. Magnesium is 
also required for basal, GTP and β-2 agonist stimulated AC activity, as demonstrated by competitive 
inhibition with Sc3+ [480].  
Magnesium and immune function 
Metabolic syndrome is characterised by insulin resistance, obesity, increased inflammation and 
oxidative stress and is associated with magnesium deficiency as determined by lower serum 
magnesium and low dietary intakes [481]. The most recent review reports that magnesium deficiency 
is a contributor to low grade inflammation, as indicated by TNF-α levels, and contributes to the 
pathogenesis of many chronic inflammatory diseases such as metabolic syndrome and coronary 
atherosclerosis [482]. Low serum magnesium levels have been associated with elevated TNF-α levels 
in obesity [483] and elevated serum levels of the inflammatory marker CRP (complement reactive 
protein), in association with lower glucose tolerance in otherwise healthy children [484]. Thus, 
magnesium has an important role in regulating inflammation and deficiency can have adverse 
consequences in human health. 
Lymphocytes and the study of β-2 adrenergic receptor function 
The β-2AR is the primary target of pharmacological HASM relaxation. In addition to a variation in 
response to magnesium in clinical studies, literature supports that there is individual variation in β-
2AR function, as already discussed. It is, therefore, important to assess if there is any effect of 
magnesium on the β-2AR and/or β-2 agonist induced bronchodilation. 
Human lung tissue may be difficult to obtain and therefore, impractical for research purposes. Human 
peripheral blood lymphocytes have abundant cell surface β-2 receptors [485] and are easily obtained, 
which makes them ideal, and is why they have been extensively used to study the function of β-2AR 
in asthma [486-496]. Studies have found the β-2AR on peripheral lymphocytes to have similar 
properties to those of HASM. Studies of the function of the β-2AR, in lung tissue and blood samples 
from patients undergoing lung resection for cancer and healthy cultured HASM tissues, have shown 





Cyclic AMP responses to isoprenaline were shown to be of similar values in lymphocytes and 
homogenised lung parenchyma [497, 498]. In both lymphocytes and homogenised lung tissue 
[497,498] and intact segments of bronchial smooth muscle [497], salbutamol displayed partial agonist 
activity relative to isoprenaline, as determined by cAMP production. These data show that the 
lymphocyte β-2AR has similar agonist affinities thus, making lymphocytes a suitable vehicle to study 
the effects of magnesium on the β-2AR. 
 
1.5.3 Safety and appropriate dosing of intravenous magnesium in acute asthma 
Magnesium exists in the body as a metal salt. It is the fourth most abundant cation and the most 
common intracellular cation after calcium [499]. It is largely found in the intracellular compartment 
bound to organelles or complexed with anions, with only 2-3% ‘free’ or ionised [500]. It is this 
ionised form that is biologically active [501]. The normal reference range for total serum magnesium 
is between 0.75-0.9mM [502]. Toxicity due to intravenous infusions may occur however, not until 
levels are above 3mM. The earliest sign of toxicity is loss of the deep tendon reflexes which precedes 
more serious events [503]. More serious toxicity includes paralysis at levels above 5mM, cardiac 
conduction abnormalities at levels above 7mM and cardiac arrest at levels above 12.5 mM [504]. 
Magnesium is almost exclusively excreted in urine, with 90% of an intravenous dose being excreted 
within 24 hours [504]. Severe fluctuations in serum magnesium levels are only seen with intravenous 
administration, and accumulation is unlikely unless there is a co-existing renal impairment. Thus, 
dosing in someone with normal renal function would be safe, as long as serum levels were kept below 
3mM. 
A systematic review of pharmacokinetic studies in women with pre-eclampsia, found that the usual 
dosing regimen (4-6g [16-24mmol] as an intravenous bolus followed by an infusion of 1-2 g [4-
8mmol] per hour) raised serum levels to approximately double the baseline [504]. In all women, 
levels were well below levels that induce any life-threatening toxicity (i.e. less than 2.5mM). In 
addition, magnesium clearance is reduced, the half-life is longer and steady state concentrations are 
higher in pre-eclamptic women relative to healthy pregnant women [505]. It could be concluded that 
if this dosing regimen is safe in pre-eclamptic women, that it is even more likely to be safe in males 
and non-pregnant females.  
A dose of 5g (20mmol) given as a bolus, has been used to treat status asthmaticus in an un-intubated 
patient without producing any clinical signs of toxicity [506]. As previously noted, much larger doses 
have been used in ventilated asthmatics. A single bolus dose of up to 20g (80mmol) given over an 




intravenous bolus dose of up to 5g (20mmol) is therefore, likely to be safe in an emergency 
department setting. 
Asthma is not a listed indication for use of intravenous magnesium (2017 NPS MedicineWise, 
https://www.nps.org.au/), and there are no formal or established guidelines on the use of intravenous 
magnesium in acute asthma exacerbations. Any guideline for intravenous magnesium dose is limited 
to the treatment of pregnant women with pre-eclampsia and eclampsia. The recommended dose of 
intravenous magnesium, in guidelines for treating acute asthma exacerbations in adults, ranges from 
2g (8mmol) [4, 268] to 2.5g (10mmol) [2]. Studies in conscious and spontaneously ventilating 
asthmatics, have reported successful outcomes from the use of magnesium in doses ranging from 1.2g 
(5mmol) [382] to 5g (20mmol) [506]. Doses of up to 20g (80mmol) have been used successfully in 
mechanically ventilated asthma patients [398]. Given magnesium’s mechanism of action is not 
defined, the serum levels at which a therapeutic response may occur is not clear. There may also be a 
dose-response effect thus, appropriate dose may vary depending on individual sensitivity to 
magnesium’s effects. Asthma guidelines may underestimate the required dose in some individuals. 
Intravenous magnesium dosing in paediatric asthma is weight-based, with early clinical trials using 
25-40mg/kg (0.1 -0.16 mmol/kg) as a single dose bolus infusion [411-416]. This would allow a dose 
of up to 2g (8mmol) to be administered to a 50kg child. A dose of 50-75mg/kg (0.2-0.3 mmol/kg) as a 
single bolus dose over an hour has also been used, with serum levels remaining below 1.8mM and no 
reports of toxicity [507]. More recently, even higher doses have been shown to be more effective. A 
small study of children with status asthmatics, showed that an infusion of magnesium at 
50mg/kg/hour for 4 hours to a total of 200mg/kg (up to10g in a 50kg child) compared with a single 
dose of 50mg/kg, was safe and more effective in reducing length of stay to less than 24 hours [508]. 
There were no reports of toxicity. 
These data suggest that higher intravenous doses than are currently recommended in the guidelines 
can be given safely to adults with an acute asthma exacerbation, and that larger dosing may be 
appropriate and safe for treating severe exacerbations within the emergency department. A dose of 5g 









1.6 Hypothesis and Aims 
 
Magnesium can improve asthma outcomes through several mechanisms including an improved 
response to β-2 agonist or directly via relaxation of airway smooth muscle. This study aims:  
1. To demonstrate the mechanism of the action of magnesium, by assessing the effect of 
magnesium on β-2 agonist stimulated cAMP, in human peripheral blood lymphocytes. 
2. To assess the effect of magnesium on hospital admission rates and bronchodilator response 
to β-2 agonist during an acute asthma attack, in patients who respond poorly to treatment, 
by comparing the addition of intravenous magnesium solution to the standard treatment 
with the standard treatment alone.  
3. To assess the safety and efficacy of a larger than guideline-prescribed dose of magnesium 
sulphate (5g/20mmol), in non-mechanically ventilated asthmatics.  
4. To identify the sub-group(s) of patients most likely to benefit from the addition of 
magnesium to standard optimal care. 
5. To demonstrate sex differences in the β-2AR to β-2 agonist and magnesium. 
 
It is hypothesised, that magnesium augments β-2 agonist induced cAMP, and that the addition of 
magnesium to β-2 agonist, will increase β-2 agonist stimulated cAMP production in human peripheral 
blood lymphocytes relative to β-2 agonist alone. 
It is hypothesised, that intravenous magnesium will improve acute asthma outcomes, as indicated by a 
reduction in the admission rate to hospital and improved lung function, relative to standard care alone. 






Chapter 2: Study of the effect of magnesium on 
lymphocyte β-2 adrenergic receptor function in vitro 
 
2.1 Methods  
2.1.1 Introduction 
Clinical studies suggest that magnesium’s mechanism of action is through augmented bronchodilator 
responsiveness [382, 468]. This could be mediated by an increase activation of the β-2AR and 
increased cAMP production, resulting in greater relaxation of airway smooth muscle. Therefore, it 
was hypothesised, that magnesium augments β-2AR stimulated induced ASM relaxation via an 
augmented cAMP response to β-2 agonist. The aim of this study was to examine whether magnesium 
augments β-2 agonist induced cAMP production and therefore, provide evidence for the possible 
mechanism of its effect.  
Given the practical difficulties in obtaining HASM specimens, animal tissues could potentially be 
used to study the behaviour of the β-2AR, however, the predominant β receptor type in animal ASM 
varies between species [509]. Unlike in HASM, where the ASM β-receptors are entirely β-2, in 
animal ASM there is a predominance of one sub-type over another. In guinea pigs 85% [510], canines 
80% [511] and pigs 70% [512] of the β receptors are of the β-2 sub-type. In rabbit ASM, β-receptors 
are predominantly β-1 [456]. It would, therefore, be difficult to extrapolate the findings in animal 
studies to HASM.  
The β-2AR present in human lymphocytes is qualitatively, but not quantitatively, the same as the 
receptor in lung tissue [497]. The validity of their usage has been discussed in section 1.5 and 
therefore, lymphocytes provide a valid method to study the effect of magnesium on β-2AR responses. 
Lymphocytes have been frequently used to study the effects of asthma and β-2 agonists on β-2AR 
responses [488, 492, 496, 513, 514]. Only one other study reported the effect of magnesium on β-2 
agonist stimulated cAMP in healthy patients [515].This is the first study to examine the effects of 
magnesium on β-2 agonist stimulated cAMP in asthmatic patients.  
 
2.1.2 Study design  
Selection of patients 
Acute asthmatics were recruited from patients presenting to the Lyell McEwin Hospital Emergency 




An amendment was made to the clinical trial [TQEH/LMH Approval No: 2010076] to allow 
collection of blood for processing of lymphocytes from those patients recruited to the clinical trial. 
Patients who were retrospectively excluded from the clinical trial and those with a post-rescue 
treatment FEV1 ≥ 70% predicted, were also included. Healthy volunteers were recruited from the 
Lyell McEwin hospital staff. Stable asthmatics were recruited from Lyell McEwin hospital staff and 
from asthmatic patients presenting to outpatients for their routine visit at the Mater Hospital Brisbane. 
They were selected if they had medically diagnosed asthma and were not symptomatic at the time of 
recruitment. Males and females were selected in the same manner.  
This study was approved by the Human Ethics Research Committee of the Lyell McEwin and Queen 
Elizabeth hospitals [Approval HREC/13/TQEHLMH/283] and [TQEH/LMH Approval No: 2010076]  
Classification of patients 
Healthy controls were defined by the absence of any medical condition, acute or chronic and not 
restricted to respiratory conditions. Asthma was defined by reversible airways obstruction 
demonstrated clinically and diagnosed by a medical practitioner, symptoms of asthma at any time 
during the patient’s lifetime whether diagnosed or not (e.g. a patient giving a history of recurrent 
cough and wheeze but who had not sought medical assistance previously) or patients on asthma 
treatment as prescribed by a doctor. This treatment included regular inhaled corticosteroid, as needed 
inhaled salbutamol, or another bronchodilator. 
Acute asthma 
An acute attack was defined by the onset of symptoms in previously asymptomatic patients, acute 
worsening of symptoms irrespective of treatment or acute respiratory distress due to asthma.  
Stable asthma 
Stable asthma was defined by two criteria: an FEV1 >80% predicted or best if known and an Asthma 
Control Questionnaire (ACQ) score of ≤ 1.5. Both criteria were required for inclusion in to the study. 
Inclusion criteria 
Inclusion criteria were age 18–50 years and able to give written consent to participation. Patients who 
did not meet the above criteria or were unable to provide written consent or perform spirometry were 
excluded. 
Withdrawal criteria 




Testing and treatment before consent. 
Prior to consenting for inclusion in the study, an information sheet was given to patients and the study 
and its requirements explained. All asthmatics were assessed with an ACQ score to assess asthma 
control and spirometry to assess degree of airway obstruction.  
Spirometry was performed with the EasyOne® hand held spirometer [n.d.d Medical Technologies 
US/Zurich]. If possible, the best value of the three attempts was recorded at the time of recruitment. 
For stable asthma ≥ 80% of the predicted value from NHANES (III) values or best if known, was 
required for study entry. For acute asthmatics, testing was performed at least 15 minutes after the last 
of the three rescue nebulisations however, many of the acutely exacerbating asthmatics were unable to 
perform 3 attempts and therefore, a single attempt was accepted, if it was adequate. An attempt was 
considered adequate if the forced expiration lasted at least 2 seconds, there was a sharp early PEF and 
the patient did not cough during the first 2 seconds of the manoeuvre. Repeated attempts were 
encouraged however, in cases where this was not possible a single effort was accepted. These patients 
were then consented after spirometry was obtained. This method has previously been acceptable in 
other studies of acute asthma, where repeated attempts to obtain “quality” spirometry were not 
possible [383, 384].  
Sample collection and analysis 
After written consent was obtained, an intravenous cannula was inserted and 30mLs of blood was 
drawn. Samples were divided and a 10mL aliquot was sent to the hospital’s pathology laboratory – 
the Institute for Medical and Veterinary Sciences (IMVS), for routine blood cell counts, serum 
electrolytes and total serum magnesium. The remaining 20mL was reserved for isolation of PBMCs. 
Serum magnesium was measured using the “xylidil blue complexometric method” (MG2: Cobas-c) 
with a sensitivity 0.1-2.0mM. 
Data collection 
For each subject, base line demographic variable data (age, sex, ethnicity, BMI, smoking status and 
atopic status) were collected from all patients. Ethnicity data was not presented in the tables as all 
patients were of Caucasian ethnicity. Asthma medication use and blood for a serum magnesium level 
were collected from asthmatic patients and FEV1 was measured. An ACQ was also administered 
upon recruitment to the study as an indicator of asthma control in the past week. The questionnaire 
also provided information on the use of short acting β-2 agonist (SABA) in the preceding week. 
Atopic status was determined by self -reporting of the presence or history of eczema, hay fever or an 




Lymphocytes from individual patients were stimulated in separate experiments and data recorded 
separately for each subject. Mean cAMP values were determined from pooled data.  
Statistical analysis 
Statistical calculations were performed with IBM SPSS 24 (Statistical package software for students). 
For non-parametric data, a Mann Whitney U test was used for independent variables and a Wilcoxon 
signed rank test was used for dependent variables. To adjust for multiple comparisons, mean cAMP 
values were compared using a linear mixed effects model.  
Power calculations for the linear mixed effects model were determined post-hoc, as neither the range 
of cAMP values nor the size of any effect of magnesium on cAMP production were known prior to 
experimentation. A University employed biostatistician performed the power calculations based on 
the cAMP values produced in healthy controls.  
For salbutamol stimulated cAMP in the healthy control group (n=15), with a standard deviation = 4.6, 
intraclass correlation coefficient (ICC) = 0.286, =0.05, the study had 26% power to detect the 2nM 
difference (28%) in cAMP production observed. To have 80% power would have required a sample 
size of n=60. For isoprenaline stimulated cAMP in the health control group (n=15), with a standard 
deviation= 8.7, ICC=0.92, =0.05, the study had <50% power to detect the 1.5nM (9%) difference in 
cAMP observed. To have 80% power would have required a sample size of n=30. 
Based on these calculations, a sample size of n=15 would have had an 80% power to detect a 4.5nM 
(70%) difference in salbutamol stimulated cAMP and a 3nM (30%) difference in isoprenaline 
stimulated cAMP. The data from groups where significant differences were detected are displayed in 
tables throughout the chapter. 
The dose response graphs were constructed using mean agonist stimulated cAMP values, divided by 
the basal or un-stimulated cAMP values. The ratios of the means were then plotted on the y-axis 
against the concentration of the agonist.  
 
2.1.3 Experimental procedures 
Lymphocytes were isolated from the peripheral whole blood of healthy controls and asthmatic 
patients. Human peripheral blood lymphocytes were assessed for cAMP responses, to both a selective 
and a non-selective β-2 agonist, over a range of concentrations. The effect of a milli-molar 




Processing of lymphocytes 
Isolation and cryopreservation of lymphocytes 
For convenience, peripheral blood monocytic cells (PBMCs) were isolated by the Ficoll method, as 
detailed below, using the density gradient medium LymphoprepTM supplied by StemcellTM 
technologies. The population of the isolated monocytes is primarily lymphocytic and will henceforth 
be referred to as lymphocytes. For convenience, lymphocytes were required to be frozen immediately 
post-isolation from whole blood. Optimization experiments subsequently demonstrated that frozen 
cells provided optimal amount of cAMP. 
Twenty millilitres (mL) of whole blood in 10mL aliquots was diluted with 10mL of Dulbecco’s 
Phosphate Buffered Saline (DPBS: Sigma) and layered over 7mL of the separation medium 
(LymphoprepTM: StemcellTM technologies) in a 20mL plastic V-bottom tube. The tubes were then 
centrifuged at 850g for 20 minutes at 20ºC (Haraeus X3R Multifuge centrifuge: Thermo Fischer 
Scientific). The lymphocytes were then carefully removed using a Pasteur pipette and re-suspended in 
20mL of DPBS. The suspension was then centrifuged at 850g for 5 minutes at 20ºC. The supernatant 
was discarded, and the cell pellet was re-suspended in 20mL of DPBS, then centrifuged at 360g for 5 
minutes at 20ºC. The supernatant was discarded. 
Prior to freezing, the cell pellet was re-suspended in 950µL of freezing media, made from 50% each 
of foetal calf serum (FCS) and 30% Dimethysulphoxide (DMSO: Sigma) in plain media (RPMI: 
Sigma). Isolated lymphocytes were transferred to 1mL cryovials in 500 µL aliquots and stored in a 
Nalgene freezing container for 24 to 72 hours. Cells were then transferred to a plain container and 
stored at -80ºC for a period of up to 3 months, prior to use. 
Thawing of lymphocytes 
Plain RPMI solution (GibcoTM) and thawing media (plain RPMI with 10% foetal calf serum) were 
pre-warmed to 37ºC in a water bath. The cryovial containing the frozen lymphocytes was then 
removed from the -80ºC freezer and transferred to the water bath. The vial was held in the water until 
most of the lymphocyte suspension was liquid, but a small solid pellet remained, then 1000µL of 
warm thawing media was slowly added to the cell suspension and gently mixed. The suspension was 
then transferred to a 1500µL reaction tube and spun at 1.6g for 3 minutes at 21ºC. The supernatant 
was then discarded. The cells were re-suspended with 950µL of plain RPMI for immediate 
experimentation, or 950µL of culture medium for overnight incubation, depending on the experiment 






A cell count was undertaken prior to freezing, subsequently to thawing and prior to experimentation, 
using an automated cell counter. Samples with a cell viability of >15% were included in the study. 
One µL of cell suspension was placed in a 500µl tube and 1µl of thymidine blue was added and 
mixed with the cells. The cells were then pipetted on to a glass slide and inserted into the cell counter. 
Dead cells were identified by uptake of thymidine blue. The total number of cells, the number of 
viable cells and the percent viable were displayed and recorded.  
ELIZA assay for cAMP 
Commercially available ELIZA kits, cAMP XPTM (#4339), were purchased from Cell Signaling 
Technology Inc. The assay had a sensitivity of 0.3 to 240Nm of cAMP. 
Reagent preparation  
Phenylmethylsulfonylfluoride (PMSF) was obtained as dry powder from Sigma laboratories. To make 
stock solution of PMSF, 0.174g of dry powder was dissolved in 1mL of anhydrous ethanol and then 
diluted in 9mL of anhydrous ethanol to make 10mLs of a 100mM solution, which was stored at -20ºC. 
As per the manufacturer’s instructions, 10X cell lysis buffer was diluted to 1X in milli-Q purified 
water, to which 1mM PMSF was added. Lysis buffer was made in 2x 50mL aliquots at a time and 
stored at -4ºC for 2 weeks or until used. 
Preparation of lysate as per manufacturer’s protocol 
Cells were plated in culture medium in a 96 well plate at a concentration of 104 cells per well and 
incubated overnight in a humidified incubator at 37ºC with 5% CO2. Cells were then rinsed by adding 
200µL of warmed DPBS to each well. The plate was then spun in the Haraeus X3R Multifuge 
centrifuge for 3 minutes at 360g at 20ºC. Supernatant was aspirated and test solutions along with 
warmed DPBS were added to each well. The cells were then incubated with desired reagents for 5 
minutes. Cells were then rinsed by adding 200µL ice cold DPBS to each well and spinning and 
aspirating the supernatant as described. This step was repeated and 100µL of 1X lysis buffer was 
added to each well. The plate was then placed on ice for 10 minutes prior to cAMP assay. 
Modified method for stimulation of lymphocytes 
A modified protocol was developed, as an alternative to the manufacturer’s protocol, to optimise 
cAMP production. A 1mL aliquot of thawed cells was diluted in 15mL of warmed DPBS and 
suspended in a water bath at 37ºC for 5-10 minutes, prior to stimulation. An aliquot of cells was 
added to 1.5mL reaction tubes, sealed and incubated in the water bath along with the desired reagents, 




concentration of 105 cells per mL. The cells were incubated in the water bath for 5 minutes at 37ºC. 
Sealed reaction tubes were then immersed in an ice water bath for 5-10 minutes to terminate further 
cAMP production and minimise cAMP degradation. 
Modified method for lysate preparation 
For rinsing, the reaction tubes were spun in a small centrifuge at 1.6g for 3 minutes at 4ºC. The 
supernatants were discarded, the cell pellets re-suspended in 1mL of ice cold DPBS solution and 
centrifuged at 1.6g for 3 minutes at 4ºC. Supernatants were discarded and the procedure repeated. The 
cell lysate was then prepared by adding 450µL of lysis buffer to each reaction tube and standing on 
ice for 10 minutes. The cell lysate was frozen at -20ºC for 24 hours and the cAMP assay performed 
the following day. This was done for convenience, so that multiple samples could be processed at the 
same time. 
 cAMP Assay 
All components of the ELIZA kit were brought to room temperature. Standards for interpolation were 
prepared as per the manufacturer’s instructions. Cell lysates were prepared, except where the 
modified protocol was used, and frozen samples of lysate were thawed on ice. Lysates were assayed 
according to the cAMP XPTM manufacturer’s protocol. Plates were read at 450Nm according to the 
manufacturer’s instructions. Absorbance was recorded at 450Nm. Data were recorded in text file 
documents and Excel worksheets.  
Calculation of cAMP production 
Cyclic AMP values were interpolated from the standard curve using the Graph Pad Prism 7 program, 
and standards were distributed on sigmoidal 4pl logarithmic scale. For interpolation of the cAMP 
values, X values (standards) were transformed to logarithmic, absorbance was interpolated, and 
cAMP values transformed 10X and recorded. The cAMP values were recorded in Excel form as nM 
and then transformed to nM per 106 cells using a simple mathematical equation; 
[cAMP] per 106 cells = 106 x measured [cAMP]/ (no of cells per mL) 
Values were also expressed in ratios of cAMP over base level. Data were expressed in tabular and 
graphic form. 
One of the acute asthmatic females produced insufficient cAMP to calculate ratios for all isoprenaline 
concentrations, so her data could not be included in the analysis. It was not clear whether this was a 





Dulbecco’s phosphate buffered saline solution (x1) (DPBS) Dimethysulphoxide (DMSO) and 
Forskolin 10mg dry powder were commercially prepared and supplied by Sigma laboratories. Plain 
medium (RPMI) was commercially prepared and supplied by GibcoTM. Commercially available 
ampules of 10-3M solution of the β-2 agonists, salbutamol and isoprenaline, 2M magnesium sulphate 
and 0.9% saline for human injection, were supplied by the hospital pharmacy.  
Preparation of reagents  
Culture medium was prepared from 10% foetal calf serum in plain RPMI with 1% penicillin-
streptomycin (GibcoTM) and stored at 4ºC for up to 12 months, prior to use. 
Two hundred µL of 2M magnesium sulphate solution was diluted in 9.8 mL of 0.9% saline for human 
injection to make 10mL of 40mM solution, which was stored at room temperature. Fresh stock 
solution was made every three months. 
Stock solution of forskolin 10-2M was prepared and stored in accordance with the manufacturer’s 
instructions. Ten mg of dry forskolin powder was dissolved in 1mL of DMSO to make a 2.4 x 10-2M 
stock solution, which was stored at room temperature in the dark for up to 9 months. For each 
experiment, 10µL of forskolin stock solution was diluted in 90µL milli-Q to make 100µL of a 10-3M 
forskolin solution. This was done immediately prior to commencement of the experiments as 
forskolin is unstable in aqueous solution.  
Fresh β-2 agonist reagents were made on the day of the experiments and discarded at the end of the 
day. For each experiment, serial dilutions of the 10-3M of salbutamol and isoprenaline solution were 
performed with 0.9% saline to make 1mL of each of a 10-4M, 10-5M, 10-6M and 10-7 M solutions. For 
the experiments, 50µL of stock solution or diluted solution was added to each reaction tube to make 
final concentrations of 10-4M, 10-5M, 10-6M, 10-7 and 10-8 M.  
Optimisation  
Optimisation experiments to determine the optimal conditions for stimulation and preservation of 
cAMP, were carried out prior to formal experimentation, using the investigators’ own lymphocytes. 
Frozen lymphocytes were used initially for convenience and thawed prior to experimentation as 
previously described. The lymphocytes were frozen at an initial concentration of 2-4 x106 cells per 
mL and after thawing, had a concentration of 1-3 x106 cells per mL. Cells were incubated at 37ºC for 
5, 15 and 30 minutes with 10-4M, 10-6M and 10-8M of isoprenaline. Once the optimum incubation 




harvested fresh and frozen cells was then undertaken using the same concentrations of agonist as 
before. 
Optimisation of experimental method 
Thawed lymphocytes were diluted in a warm culture medium to a concentration of 105 cells per 
millilitre. Lymphocytes were then added in 200µL volumes to each well in a 96 well incubation plate 
to give approximately 104 cells per well. The plate was incubated overnight at 37ºC and the cells 
rinsed as per manufacturer’s protocol described previously. 
To each well, volume of warmed RPMI and isoprenaline solution was added for a final volume of 
200µL. Isoprenaline to a final concentration of 10-4M was added to the first 16 wells,10-6M to the next 
and 10-8M to the next. The plate was then incubated at 37ºC for 5 minutes to allow stimulation of 
cAMP. The cells were then processed as per the manufacturer’s protocol as previously described. 
The optimisation experiments were then repeated in a modified method, using 1.5mL sealed reaction 
tubes for each of the conditions tested for stimulation and processing of cells. Thawed lymphocytes 
were diluted in 10mLs of warm RPMI to a concentration of approximately 2.5 x105 cells per mL and 
left to stand in the water bath at 37ºC for 5-10 minutes. To each of four tubes, 900µL of lymphocyte 
suspension was added. To three of the tubes, 100µL of isoprenaline was added to a final concentration 
of 10-4M, 10-6M and 10-8M. To the remaining tube, 100µL of saline was added. The tubes were sealed 
and placed in the water bath at 37ºC for 5 minutes. At the end of the stimulation period, the tubes 
were immersed in an ice-cold water bath for 10 minutes. The cells were then rinsed and lysed 
according to the modified lysate preparation protocol, and cAMP was assayed as per manufacturer’s 
protocol described earlier. 
Optimisation of time  
The modified stimulation method described above was repeated for incubation times of 15 and 30 
minutes. The cells were then rinsed and lysed according to the modified lysate preparation protocol, 
and cAMP was assayed as per the manufacturer’s protocol. 
Optimisation of preparation of lymphocytes 
Lymphocytes were isolated according to the method previously described and re-suspended in 
thawing media. Frozen lymphocytes were thawed as described earlier. Both lymphocyte suspensions 
were then diluted in 10mL of warm plain RPMI and left to stand in a water bath at 37ºC for 10 
minutes. The approximate final concentrations were 105 cells per mL for both samples. Both sets of 




protocol described above. The cells were then rinsed and lysed according to the modified lysate 
preparation protocol, and cAMP was assayed as per manufacturer’s protocol. 
Beta-2 agonist stimulation of cAMP in peripheral blood lymphocytes 
To determine differences in receptor function, lymphocytes were stimulated with salbutamol, the 
highly selective β-2 agonist and the non-selective β-agonist, isoprenaline. There were 15 different 
experimental conditions, and five different agonist concentrations were used for each agonist; 10-4M, 
10-5M, 10-6M, 10-7M and 10-8M. The effect of agonist alone was measured against the effect of 
agonist and 1mM, and agonist and 2mM of magnesium sulphate. Forskolin, a direct activator of 
Adenylate Cyclase (AC), was used as the positive control at a concentration of 10-4M. To determine 
the baseline, un-stimulated cAMP values, measurements were taken from lymphocytes in suspension 
alone, without any additional reagent. Forskolin and baseline conditions were duplicated for each of 
the β-2 agonists, so that 34 conditions were tested for each subject. 
For both β-agonists, 100µL aliquots of the various β-2 agonist dilutions were added to the reaction 
tubes. For agonist alone conditions (5 tubes), an additional 50µL of saline was added, for agonist and 
1mM magnesium (5 tubes), 25µL of magnesium and 25µL of saline were added, and for agonist and 
2mM magnesium (5 tubes), 50µL of magnesium stock solution was added to the required tubes. One 
hundred and fifty µL of saline alone was added to one tube as the basal or negative control. To the 
remaining tube, 50µL of saline was added. The 100µL of forskolin dilution was made up just prior to 
stimulation and added to the tube after the lymphocytes were added, as forskolin was known to be less 
stable once diluted in water.  
Frozen lymphocytes were thawed as previously described and re-suspended in warmed RPMI. The 
lymphocytes were then counted and suspended in 15mL of pre-warmed plain DPBS and left to stand 
in a water bath at 37ºC for 5-10 minutes, prior to stimulation, while reagents were freshly prepared 
and added to the reaction tubes as described above. Once the lymphocytes had warmed and rested, 
850µL of lymphocyte suspension was added to the 150µL of the reagent solutions in each of the 
reaction tubes, to make a final volume of 1000µL. Lymphocytes were stimulated under experimental 
conditions for 5 minutes as per the modified method described above. Cells were then rinsed and 
lysed according to the modified lysate preparation protocol, and cAMP was assayed as per 
manufacturer’s protocol. The experiments were performed separately for salbutamol and isoprenaline 
agonists and repeated for each of the patients. For each patient, cAMP was assayed separately, but  







2.2.1 Optimisation of β-2 agonist stimulated cAMP 
Lymphocytes incubated and stimulated in the 96 well culture plates, produced an insufficient amount 
of agonist-stimulated cAMP to be detected by the assay, i.e. only basal un-stimulated cAMP was 
detected in all cells. Repetition of the experiment at different incubation times produced the same 
result. The low cAMP level was thought to be due to rapid degradation of cAMP by cellular 
phosphodiesterase. A phosphodiesterase inhibitor was considered, but not utilised, as it was known to 
alter the dose-response relationship in β-2 agonist stimulated cAMP production, which would 
confound the magnesium experimental results. Rapid cooling was thought to be necessary to avoid 
undue loss of stimulated cAMP but was technically difficult and could not be performed using the 96 
well plates.  
The optimisation experiments were repeated using 1.5mL sealed reaction tubes, as described in the 
methods above, to enable the rapid cooling of the cells by immersion in an ice water bath and reduce 
the loss of cAMP through degradation by phosphodiesterase. Lymphocytes stimulated in 1.5µL 
reaction tubes and cooled in the ice water bath, produced measurable stimulated cAMP responses and 
an appreciable increase over baseline in relation to the dose of agonist used. The 1.5mL reaction tubes 
were used in the remainder of the optimisation experiments and the final protocol. The optimal time 
for stimulation was found to be 5 minutes (Figure 1). Freshly isolated lymphocytes failed to produce 
any measurable cAMP, independent of incubation times. The reasons for this are unclear and may 
reflect contamination of cells with bacteria.  
 
                
Figure 1. Optimization of cAMP production. Concentration of isoprenaline mM (millimolar) vs. [cAMP] 
expressed as fold increase over baseline; comparison of cell-agonist incubation times at 37ºC.  




2.2.2 Beta-2 agonist stimulated cAMP production 
Lymphocytes were isolated from 15 healthy controls, 11 acute asthmatics and 14 stable asthmatics, 
and assessed for β-2 agonist responses in the presence and absence of magnesium as described in the 
methods section. Patients were all aged between 18 and 50 years-old and of Caucasian ethnicity.  
Healthy Controls 
There were 7 females and 8 males in the control group. There were no significant differences in age. 
The median age of males was 38.5 years (IQR 30-42.5) relative to 35 years for females (IQR 25-48) 
(p=0.96). There was one active smoker in each sex. Serum magnesium levels were within normal 
limits for both males and females. Baseline physiological parameters of heart rate, blood pressure, 
oxygen saturation, respiratory rate and FEV1% predicted, were not performed in healthy controls as 
they were assumed to be within the normal limits.  
Lymphocytes from healthy controls produced 105% more cAMP when stimulated with isoprenaline 
than with salbutamol (p<0.01). In the lymphocytes from healthy controls, 1mM of magnesium 
increased the mean salbutamol stimulated cAMP by 28% relative to agonist alone (Wilcoxon Signed 
Rank; p<0.001), and 2mM of magnesium increased mean salbutamol stimulated cAMP by 25% 
relative to agonist alone (p<0.001). This was accompanied by a shift to the left of the dose-response 
ratios (Figure 2a). When adjusted for multiple comparisons, these differences were not significant. 
 
       2a) 2b)  
 
Figure 2. Dose response ratios cAMP healthy controls: the effects of different concentrations of 
magnesium on responses to stimulation with β-2 agonists. Effect of magnesium on increasing 
concentrations of β-2 agonist mM (millimolar) on cAMP production expressed as fold increase in 
cAMP over baseline.     
2a salbutamol, 2b isoprenaline 




In the lymphocytes of healthy controls, 1mM magnesium increased the mean isoprenaline stimulated 
cAMP by 9% relative to agonist alone (p<0.01) and produced a shift to the left of the dose response 
ratios, while 2mM of magnesium had no significant effect on mean isoprenaline cAMP production 
(Figure 2b). 
Acute asthma 
There were 4 male and 7 females with acute exacerbations of asthma. Lymphocytes of one of the 
females was not analysed as they failed to produce any measurable cAMP, despite repeating the 
experiments. There were 6 females included in the data analysis. The small sample size limited any 
meaningful statistical comparisons. There were no observed differences in baseline physiological 
parameters (Table 2). 
 
Table 2. Baseline and demographic comparisons in acute asthmatic males and females. 
 
IQR: interquartile range, SE: standard error, BMI: body mass index, ICS: inhaled corticosteroid, 
LABA: long acting β-2 agonist, SABA: short acting β-agonist, OCS: oral corticosteroid, FEV1: forced 
expiratory volume in 1 second. 
Variables for acute asthma (n=10)
males                           
(n=4)
females                                    
(n=6)
Age, median (IQR) 40.5 (26.5-47) 31 (27-42)
BMI, median (IQR) 30 (28-37) 38 (30-43)
Current smoker, n (%) 1 (25) 4 (57.1)
Serum magnesium (mM),  mean (SE) 0.83 (.02) 0.79 (0.02)
Preventer,  n (%)
ICS only 1 (25)
ICS+LABA 2 (50) 5 (71.4)
Other medications
antibiotics 3 (42.9)
antihistamines 1 (25) 1 (14.3)
tiotropium 1 (14.3)
theophylline 1 (14.3)
SABA use mcg/day , median (IQR) 1800 (1400->1600) 1600 (1600->1600)
OCS use in 24 hours prior to arrival , n (%) 1 (25) 4 (57.1)
Asthma Control Questionairre (0-6),  median (IQR) 4.3 (3.45-4.8) 4.5 (4.5-4.6)
Borg dyspnoea scale (0-10) , median (IQR) 7 (5-7) 6 (5-8)
FEV1 % predicted, median (IQR) 69 (40-73) 48 (44-53)
Respirations  per minute , median (IQR) 23 (21-24) 28 (24-28)
Oxygen saturation %, median (IQR) 95 (93-97.5) 98 (96-98)
Pulse rate in beats per minute , median (IQR) 113 (97.5-131) 120 (101-127)
Systolic blood pressure mmHg , median (IQR) 127.5 (120-135) 125 (120-130)




Lymphocytes from acute asthmatic patients produced 74% more cAMP when stimulated with 
isoprenaline than with salbutamol (p<0.01). In the lymphocytes from acute asthmatics, 1mM 
magnesium had no effect on salbutamol stimulated cAMP and 2mM increased mean salbutamol 
stimulated cAMP by 18%, relative to agonist alone (p=0.06) however, there was no apparent 
relationship between the dose of agonist and cAMP response (Figure 3a). 
In isoprenaline stimulated cells, 1mM magnesium increased mean cAMP production by 6% 
(Wilcoxon Signed Rank; p<0.05) and 2mM magnesium by 12% relative to agonist alone (p<0.05). 
Both 1mM and 2mM magnesium, produced a shift of the dose-response ratios to the left (Figure 3b). 
When adjusted for multiple comparisons these differences were not significant. 
 
       3a)  3b)  
 
Figure 3. Dose response ratios cAMP acute asthmatics: the effects of different concentrations of 
magnesium on responses to stimulation with β-2 agonists. Effect of magnesium on increasing 
concentrations of β-2 agonist mM (millimolar) on cAMP production, expressed as fold increase in 
cAMP over baseline.  
3a) salbutamol, 3b) isoprenaline 
No added magnesium ●, 1mM added magnesium □, 2mM added magnesium ∆.  
 
Acute asthma vs. healthy controls 
There was greater variability in responses to β-agonists in acute asthmatics relative to controls. 
Lymphocytes from asthmatic patients, when stimulated with salbutamol, produced 52% less cAMP 
relative to healthy controls (Mann-Whitney-U; p<0.001). When adjusted for multiple comparisons, 
these were only significant for 1mM magnesium (Table 3). Lymphocytes from asthmatic patients 
produced 62% less cAMP when stimulated with isoprenaline relative to healthy controls (p<0.001). 




forskolin stimulated cAMP were not significantly different in acute asthmatics relative to healthy 
controls (Table 3).  
 
 
Table 3. Mean cyclic AMP production for each treatment condition by group; healthy controls 
vs. asthma (stable and acute), adjusted for multiple comparisons. Cyclic AMP values expressed 
as nM (nanomoles) per 10⁶ cells.  
 
             




Stable asthma  
There were 7 male and 7 female stable asthmatics. One of the male patients was excluded, because 
although his ACQ score was =1.5, his FEV1 was below 80 % predicted, therefore, he did not fulfil the 
study criteria for stable asthma.  
There were 6 males and 7 females included in the data analysis. ACQ scores were less than 1.5 
(median 0.67; IQR 0.17-1.0) and the median FEV1 was 95% of predicted (IQR 87-105%) which 
correctly categorized the patient’s asthma as stable. Short acting β-2 agonist use was less than 400mcg 
per day in the preceding week. ACQ scores (p<0.01) and SABA use were significantly less in stable 
asthmatics relative to acute asthmatics (<200mcg day vs. >1600mcg day; p<0.01). FEV1 was 
significantly less in acute relative to stable asthmatics (56% vs. 95%; p<0.01). 
Males did not use any SABA on a prn basis in the preceding week however, females did, although 
usage was low relative to acute asthmatics (p<0.05) (Table 3). There was a non-significant trend for 
males to have lower FEV1 values (87 vs. 100) and lower ACQ (0.17 vs. 0.69) scores relative to 
females. Atopy status was only documented in 6 patients hence, a comparison of atopy prevalence 
was not made (Table 4). 
 
 
Table 4. Baseline and demographic comparisons of stable asthmatics; males and females. 
 
IQR: interquartile range, BMI: body mass index, ICS: inhaled corticosteroid, LABA: long acting β-2 
agonist, SABA: short acting β-agonist, OCS: oral corticosteroid, FEV1: forced expiratory volume in 1 
second, mcg: micrograms 
Variables for stable asthma (n=13)
males                    
(n=6)
females               
(n=7)
p value
Age, median (IQR) 33.5 (32-35) 32 (27-39) 0.73
BMI, median (IQR) 28 (27-31) 27 (21-34) 0.37
Current smoker, n (%) 0 0
Preventer,  n (%)
ICS only 1 (16.7) 0 0.26
ICS+LABA 4 (66.7) 6 (87.5) 0.51
Other medications ~ ~
SABA use mcg/day , median (IQR) 0 (0-0) 300 (200-400) <0.05
OCS use in 24 hours prior to arrival , n (%) 0 0
Asthma Control Questionairre (0-6),  median (IQR) 0.17 (0- .17) 0.69 (.67-1) 0.13
Borg dyspnoea scale (0-10) , median (IQR) 0 0 1




Cyclic AMP production in lymphocytes of stable asthmatics was 75% greater with isoprenaline 
relative to salbutamol (p<0.01). In the lymphocytes from stable asthmatics, 1mM of magnesium had 
no significant effect on salbutamol stimulated cAMP, while 2mM of magnesium increased mean 
salbutamol stimulated cAMP by 20% relative to agonist alone (p<0.001) and produced a shift in the 
dose-response ratios to the left (Figure 4a). When adjusted for multiple comparisons, these differences 
were not statistically significant. In the lymphocytes from stable asthmatics, 1mM and 2mM of 
magnesium had no significant effect on isoprenaline stimulated cAMP production (Figure 4b). 
 
 
      4a)  4b)        
 
Figure 4. Dose response ratios cAMP stable asthmatics: the effects of different concentrations of 
magnesium on responses to stimulation with β-2 agonists. Effect of magnesium on increasing 
concentrations of β-2 agonist mM (millimolar) on cAMP production, expressed as fold increase in 
cAMP over baseline.  
4a) salbutamol, 4b) isoprenaline 
No added magnesium ●, 1mM added magnesium □, 2mM added magnesium ∆.  
 
Stable asthma vs. healthy controls  
There was greater variability in responses to the β-agonist in the healthy controls relative to stable 
asthmatics. There were no significant differences in salbutamol stimulated cAMP in stable asthmatics 
relative to healthy controls. Lymphocytes from stable asthmatics, when stimulated with isoprenaline, 
produced 10% less cAMP relative to healthy controls (p<0.05). When adjusted for multiple 
comparisons, these differences were not significant. There were no significant differences in mean 
baseline cAMP (5.53 vs. 5.3; p=0.8) or forskolin stimulated cAMP (12.06 vs. 10.4; p=0.48) between 




2.2.3 Beta-2 agonist stimulated cAMP production by sex 
Healthy controls 
When stimulated with salbutamol, lymphocytes of healthy females had a 38% greater increase in 
cAMP production relative to healthy males (Mann-Whitney-U; p<0.01). When stimulated with 
isoprenaline, lymphocytes of healthy females had a 79% greater increase in cAMP production relative 
to healthy males (p<0.001). When adjusted for multiple comparisons, the differences in mean cAMP 
between males and females were significant (Table 5).  
 
Table 5. Mean cyclic AMP production for females; each treatment condition by group. Mean 
difference in cAMP production between acute/stable asthma and healthy controls adjusted for 
multiple comparisons. Cyclic AMP values expressed as nM(nanomoles) per 10⁶ cells.  
    




There was no significant difference in mean baseline cAMP however, there was a difference in 
forskolin stimulated cAMP which was significantly higher in females (14.7 vs. 6.6; p<0.001).  
In the lymphocytes from healthy females, 1mM of magnesium increased the mean salbutamol 
stimulated cAMP by 18% (p<0.05), and 2mM of magnesium increased mean salbutamol stimulated 
cAMP by 16% relative to agonist alone (p<0.05) (Figure 5a). In lymphocytes from healthy males, 
1mM magnesium increased the mean salbutamol stimulated cAMP by 39% (p<0.001), and 2mM of 
magnesium increased mean salbutamol stimulated cAMP by 37% relative to agonist alone (p<0.001) 
(Figure 5b). 
 
     5a)  5b)  
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Figure 5. Dose response ratios cAMP healthy controls: the effects of different concentrations of 
magnesium on responses to stimulation with β-2 agonists. Effect of magnesium on increasing 
concentrations of β-2 agonist mM (millimolar) on cAMP production expressed as fold increase in 
cAMP over baseline. Comparison between the sexes.  
5a) salbutamol females, 5b) salbutamol males, 5c) isoprenaline females, 5d) isoprenaline males 




In the lymphocytes from healthy females, 1mM and 2mM magnesium had no significant effect on the 
mean isoprenaline stimulated cAMP but produced a shift to the left of the dose-responses (Figure 5c). 
In lymphocytes from healthy males, 1mM magnesium increased the mean isoprenaline stimulated 
cAMP by 13% relative to agonist alone (p<0.05), and 2mM of magnesium had no effect on mean 
isoprenaline stimulated cAMP (Figure 5d).  
Acute asthma 
The subgroup sample size for males was small (n=4) therefore, the effect of sex on β-2 agonist 
stimulated cAMP, the effect of acute asthma on cAMP production and the effect of magnesium on β-2 
agonist stimulated cAMP could not be formally assessed in males, however, there were some 
observed differences that are worthy of comment. When stimulated with salbutamol, lymphocytes of 
acute asthmatic males produced 46% more cAMP relative to asthmatic females. When stimulated 
with isoprenaline, acute asthmatic males produced 70% more cAMP relative to acute asthmatic 
females. Mean basal cAMP (6.2 vs. 1.4) and forskolin stimulated cAMP (11.8 vs. 2.9) were greater in 
asthmatic males relative to asthmatic females.  
In lymphocytes from asthmatic males, 1mM magnesium had no effect, but 2mM of magnesium 
increased mean salbutamol stimulated cAMP by 27% relative to agonist alone (Figure 6b). In 
lymphocytes from asthmatic males, 1mM magnesium increased mean isoprenaline stimulated cAMP 
by 10%, and 2mM magnesium increased the mean cAMP production by 19% relative to agonist alone 
(Figure 6d). 
In the lymphocytes from asthmatic females, 1mM and 2mM of magnesium had no significant effect 
on the mean salbutamol stimulated cAMP (Figure 6a). In the lymphocytes from asthmatic females, 
1mM and 2mM of magnesium had no significant effect on the mean isoprenaline stimulated cAMP 
(Figure 6c).  
When stimulated with salbutamol, lymphocytes from acute asthmatic males had a 40% less cAMP 
production relative to healthy male controls and when stimulated with isoprenaline, had 33% less 
cAMP production relative to healthy male controls. Basal and forskolin stimulated cAMP were 
similar between acute asthmatic and healthy male controls. 
When stimulated with salbutamol, lymphocytes from acute asthmatic females had 71% less cAMP 
production relative to healthy female controls (p<0.001), and when stimulated with isoprenaline, 
produced 78% less cAMP relative to healthy female controls (p<0.001). When adjusted for multiple 
comparisons these differences were significant (Table 5). Basal cAMP (1.4 vs. 6.4; p<0.01) and 
forskolin stimulated cAMP (2.9 vs. 14.7; p<0.01) were both significantly lower in acute asthmatic 
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Figure 6. Dose response ratios cAMP acute asthmatics: the effects of different concentrations of 
magnesium on responses to stimulation with β-2 agonists. Effect of magnesium on increasing 
concentrations of β-2 agonist mM (millimolar) on cAMP production expressed as fold increase in 
cAMP over baseline. Comparison between the sexes.  
6a) salbutamol females, 6b), salbutamol males, 6c) isoprenaline females, 6d) isoprenaline males 
No added magnesium ●, 1mM added magnesium □, 2mM added magnesium ∆.  
 
Stable asthma  
When stimulated with salbutamol, lymphocytes of stable asthmatic males had a 116% greater increase 
in cAMP production over baseline relative to females, but this was not significant. When stimulated 
with isoprenaline lymphocytes from stable asthmatic males had a 59% greater increase in cAMP 
production over baseline relative to females (p<0.05). When adjusted for multiple comparisons this 
difference was not significant. There were no significant differences in basal or forskolin stimulated 




Magnesium had no significant effect on salbutamol stimulated cAMP in stable female asthmatics, and 
2mM magnesium decreased the mean isoprenaline stimulated cAMP production by 17% relative to 
agonist alone (p<0.05) (Figures 7a, 7c). In lymphocytes of stable male asthmatics, 1mM magnesium 
had no effect, but 2mM magnesium, increased the mean salbutamol stimulated cAMP by 27% relative 
to agonist alone (p<0.01) (Figure 7b). In lymphocytes of stable male asthmatics, magnesium had no 
significant effect of isoprenaline stimulated cAMP (Figure 7d). 
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Figure 7. Dose response ratios cAMP stable asthmatics: the effects of different concentrations of 
magnesium on responses to stimulation with β-2 agonists. Effect of magnesium on increasing 
concentrations of β-2 agonist mM (millimolar) on cAMP production expressed as fold increase in 
cAMP over baseline. Comparison between the sexes.  
7a) salbutamol females, 7b), salbutamol males, 7c) isoprenaline females, 7d) isoprenaline males, 





When stimulated with salbutamol, stable male asthmatics had a 113% greater increase in cAMP 
production over baseline relative to healthy males (p<0.01) and when stimulated with isoprenaline 
had a 50% greater increase in cAMP production over baseline relative to healthy males (p<0.01). 
When adjusted for multiple comparisons these were not significant. Basal cAMP was not significantly 
different, but forskolin stimulated cAMP was greater in lymphocytes from stable male asthmatics 
relative to male healthy controls (16.7 vs. 6.6; p<0.05).  
When stimulated with salbutamol, lymphocytes from stable female asthmatics had 31% less increase 
in cAMP production over baseline relative to healthy female patients (p<0.001), and when stimulated 
with isoprenaline, had 47% less increase in cAMP production over baseline relative to healthy female 
controls (p<0.001). When adjusted for multiple comparisons, differences in cAMP were significant 
for isoprenaline-stimulated cAMP. Basal cAMP (3.6 vs. 6.4; p<0.01) and forskolin-stimulated cAMP 
(8.1 vs. 14.7; p<0.01) were lower in stable asthmatic females relative to healthy female controls  
(Table 5). 
 
2.2.4 Other factors affecting β-2 agonist responses 
Asthma control score (ACQ) and SABA use  
ACQ scores and preceding SABA use were significantly greater in the acute asthmatics relative to 
stable asthmatics (p<0.01, p<0.01). There were significant positive correlations between ACQ and 
SABA use (R2 0.790; p<0.01) and significant negative correlations between ACQ and FEV1 (R2 -
0.625; p<0.01) and FEV1 and SABA use (R2 -0.530; p< 0.05).  
There were significant negative correlations between SABA use and the mean cAMP production in 
asthmatics. Salbutamol-stimulated cAMP (R2 -0.508; p<0.01) and isoprenaline-stimulated cAMP (R2 
-0.464; p<0.01), were significantly negatively correlated with SABA use. ACQ score was 
significantly negatively correlated with salbutamol-stimulated (R2-0.349; p<0.01) and isoprenaline-
stimulated cAMP (R2-0.393; p<0.01) (Figure 8a, 8b). FEV1 was significantly correlated with 
isoprenaline-stimulated cAMP (R2 0.234; p<0.05) and more strongly correlated in acute asthmatics 
(R2 0.660; p<0.01). 
Use of oral corticosteroids 
The sample size was too small (n=9) to allow a meaningful statistical comparison between those using 
OCS and those not however, an effect of OCS use on salbutamol stimulated cAMP production was 




not taking OCS. This observed difference in cAMP may have been a confounding effect of sex, as 
there were more females using OCS relative to males. 
There did not appear to be any differences in the mean isoprenaline stimulated cAMP between 
asthmatics taking OCS relative to those who were not, nor any differences in basal and forskolin-
stimulated cAMP. Variability in salbutamol and isoprenaline stimulated cAMP was less in asthmatics 
taking OCS relative to those who were not. The use of OCS did not preserve the expected salbutamol 
dose response relationship.  
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Figure 8. The effects of ACQ score (asthma control questionnaire) on β-2 agonist stimulated cAMP 
production; β-2 agonist induced cAMP production, expressed nM (nanomoles) per 10⁶ cells 




Effect of atopy 
Atopic status was missing for much of the stable asthmatics, and the numbers of atopic vs. non-atopic 
asthmatics in the acute group were small, therefore, a statistical comparison was not made. It was 
observed in the acute asthma group, that all the non-atopic asthmatics were female and tended to be 
more obese relative to atopic asthmatics, who were all male. There appeared to be a much greater 
response to β-2 agonist in the atopic group relative to the non-atopic asthmatics, irrespective of sex. 
This difference in atopy-sex distribution of the acute asthma group may explain the apparent sex 
differences in cAMP production.  
Use of ICS/LABA 
There were only 2 asthmatics not taking ICS or combination ICS/LABA therefore, the effects of 




2.3.1 Overview of findings 
Interpretation of the findings in this study is limited by small sample sizes however, this study 
provides some information regarding the potential mechanism of magnesium’s effects on β-2 agonist 
induced cAMP production and hence, magnesium’s effect on bronchodilation. It also suggests that 
individual variation may influence treatment response. 
In this study, magnesium appeared to increase β-2 agonist stimulated cAMP. This effect may occur 
via augmented β-2 agonist stimulation of the β-2AR, due to an increase in receptor affinity for the 
agonist and an increase in receptor-G-protein coupling efficacy. Elevated cAMP is the mechanism for 
airway smooth muscle relaxation via numerous but not well-defined pathways. Given the ubiquitous 
nature of the β-2AR, it is likely that this is the mechanism via which magnesium may increase beta-2 
agonist induced smooth muscle relaxation. The serum levels at which Rolla and Bucca demonstrated 
augmented β-2 agonist bronchodilation [446], correlates with the in vitro environment of the 
lymphocytes and therefore, these results may be clinically significant.  
This study found that lymphocyte β-2 agonist stimulated cAMP production varies in relation to sex, 
asthma status, severity, and salbutamol use for the treatment of asthma. These factors contribute to 





For males and females in all groups studied, cAMP production over baseline was greater when cells 
were stimulated with isoprenaline than when stimulated with salbutamol. This is consistent with other 
studies in healthy lymphocytes [498]. The lymphocytes of stable male asthmatics appeared to be more 
responsive to salbutamol relative to isoprenaline when compared with healthy controls however, this 
could be explained by the preservation of β-2AR responsiveness and concomitant use of LABA which 
may have augmented salbutamol-stimulated cAMP production. 
 
2.3.2 The effects of magnesium on β-2 adrenergic receptor responses 
Magnesium in healthy cells 
Magnesium appears to increase the mean β-2 agonist stimulated cAMP production in healthy controls 
and produce a shift to the left of the dose-response ratios. This suggests that magnesium may enhance 
cAMP production through changes in β-2AR affinity for agonists. Binding studies would confirm this 
hypothesis. Previous studies in isolated frog erythrocyte (β-2) [469] and rat lung (β-1) [516] 
membranes, report that the effect of magnesium on agonist stimulated cAMP was increased by 
improved binding of the β-agonists to the receptor, as indicated by a shift to the left of the competition 
binding curves. This increase in binding was in proportion to potency of the agonist [469]. This effect 
of magnesium was dependent on the ability of the receptor to stimulate AC [469, 516]. Magnesium 
increased isoprenaline binding with greater efficacy relative to the partial agonist soterenol and had no 
effect on the binding of the β-2 antagonist propranolol [469].  
The mechanism by which magnesium could enhance binding of agonist and increase receptor affinity 
for agonist, may be via allosteric modification of the receptor. Previous studies have shown that 
magnesium can increase agonist affinity via allosteric modifications in a many G protein coupled 
receptors, including the µ,γ and κ opioid receptors in guinea-pig neurons [517] and M2 muscarinic 
receptors of the porcine heart [518]. This could be relevant to the β-2AR.  
In this study, the observed effect of magnesium on increasing β-2 agonist stimulated cAMP was 
inversely proportionate to agonist efficacy. This suggests that magnesium also increases agonist 
ability to form a stable high affinity agonist-receptor-Gsα complex. This could also be accomplished 
via allosteric modification of the receptor. Conformational changes in the β-2AR at the agonist 
binding site, were found to result in marked alterations in the conformation of the receptors 
cytoplasmic Gs interacting domain [519]. This conformational change influences agonist ability to 
couple with Gsα [140].  
A previous study of intact lymphocytes failed to show any effect of magnesium on cAMP production 




lymphocytes were incubated with a PDE inhibitor IBMX, prior to stimulation with β-2 agonist. PDE 
inhibitors increase cAMP by inhibiting cAMP degradation, which shifts the dose-response to the left 
[520] thus, use of a PDE inhibitor would mask any effect of magnesium on cAMP production. In this 
study the use of a PDE inhibitor was avoided, so as not to confound the results. These data taken 
together, suggest that magnesium may increase β-2 agonist stimulated cAMP in intact human β-2AR 
systems. The mechanism could be through the stabilization of an ‘active’ conformation via allosteric 
modifications, which increases the binding of the β-2 agonist to its receptor and/or coupling to its 
Gsα.  
Magnesium in acute asthma  
Lymphocyte β-2 agonist responses were reduced in asthmatics relative to controls and correlated with 
SABA use. In a study of peripheral lymphocytes, reduced β-2 agonist responses were demonstrated in 
asthmatic cells relative to non-asthmatic cells [488]. The differences in cAMP response could be 
attributed to increased exposure to β-2 agonist. Long term exposure to β-2 agonist stimulation in vitro 
[147-149] and in vivo [150, 521], resulted in a down regulation of lymphocyte β-2AR function as 
determined by isoprenaline stimulated cAMP, and receptor numbers as determined by radio-ligand 
binding studies. In exacerbating asthmatic patients, a reduction in the β-2AR response of lymphocytes 
to agonist stimulation was also shown to be proportionate to SABA exposure [491, 513]. In radio-
ligand binding studies of the lymphocytes of exacerbating asthmatic, a reduction in surface receptors 
relative to stable asthma and healthy controls has also been demonstrated [492, 522, 523].  
The effects of magnesium on β-2 agonist induced cAMP production were diminished in asthmatics. 
These data suggest that magnesium’s effect on cAMP production may be limited by the proportion of 
receptors lost via down regulation. Magnesium may enhance β-2 agonist-receptor interactions and 
improve β-2 agonist responsiveness, but this effect may be limited by the degree of down regulation 
i.e. less effective where receptors have been lost from the surface. This may be clinically relevant. 
Tachyphylaxis as determined by a reduction in bronchodilator response to inhaled β-2 agonist, has 
been demonstrated in vivo in healthy subjects [524, 525] and asthmatic patients [526-528]. Meta-
analysis has found that HASM tolerance to β-2 agonists occurs in asthma [529]. Studies have also 
correlated reduced responsivity with reduction in pulmonary β-2 receptors [530, 531].   
Magnesium in stable asthma 
In stable asthmatics, β-2AR function was well preserved. This would suggest that there was less 
down-regulation of β-2 receptor responses, which is consistent with the low SABA exposure, low 
severity scores and preserved FEV1, that was observed in the group of stable asthmatics in this study. 
The use of LABAs can also induce similar levels of tachyphylaxis as SABA [532]. Of the stable 




an ICS. Corticosteroids have been shown in vitro to reduce the effects of β-2 agonist induced 
tachyphylaxis on uncoupling and receptor down-regulation [514, 533]. Clinical studies also suggest 
that a significant loss of response to β-2 stimulation is prevented by concomitant use of inhaled 
corticosteroid [327, 534]. These data suggest, that preservation of β-2 receptor responses in stable 
asthmatics was due to low exposure to down-regulating stimuli and concomitant ICS use. 
Magnesium had almost no effect on β-2 agonist stimulated cAMP in this group of stable asthmatics. 
The reason for the efficacy of 2mM magnesium on salbutamol-stimulated cAMP is unclear. 
Magnesium’s relative inefficacy may be explained by an interaction between LABA and the β-2 
agonist, which may have masked any effect of magnesium in this group. The long acting β-2 agonist 
salmeterol has been shown to have extended receptor activation properties for the β-2AR and this may 
be due to binding to an ‘exosite’ on the receptor, thus, ‘anchoring’ salmeterol [535]. This is thought to 
be a property of other LABAs [536]. If magnesium were to increase agonist binding by allosteric 
modification of the receptor as proposed, the presence of another bound ligand such as a LABA, 
could inhibit magnesium’s effect on the SABA ligand binding through the LABA ligands own effects 
on the β-2AR. A larger sample size would have enabled the assessment of the effects of ICS/LABA in 
acute asthma and enabled a comparison of the effect of ICS/LABA on the efficacy of magnesium in 
acute and stable asthmatics and explained these findings.  
 
2.3.3 The effects of sex 
Small sample size limited the full assessment of the effect of sex on response to magnesium however, 
there were some sex some differences in β-2 agonist stimulated cAMP production. These differences 
may influence responses to magnesium.  
Healthy females produced more cAMP relative to males. In asthmatics the female sex was associated 
with a loss of β-2AR responses, as indicated by reduced cAMP production relative to healthy females. 
Stable asthmatic males had preserved β-2 agonist responsiveness. This effect was not confirmed in 
acute asthmatic males due to the small sample size. It is possible there are sex differences in β-2AR 
responses and a greater proportionate loss of surface receptors in females relative to males. This could 
limit magnesium’s efficacy in female asthmatics relative to male asthmatics. 
As discussed in chapter one, others have demonstrated sex differences in β-2AR stimulated cAMP in 
lymphocytes. Healthy females have been shown to have increased responses to β-2 agonist over time, 
associated with increased oestrogen and progesterone levels, relative to healthy males [300, 301]. 
Paradoxically, female asthmatics down-regulate β-2 responses in response to cyclic changes in sex 
hormones relative to non-asthmatic females [302]. Administration of exogenous progesterone during 




asthmatic females relative to non-asthmatics [537]. This difference between asthmatic and healthy 
females was not affected by the oral contraceptive pill [538]. These results are in keeping with the 
findings in this study and further support that there are sex differences in β-2AR function. These 
differences could influence magnesium’s efficacy, and the loss of surface receptors may limit the 
efficacy of magnesium in female asthmatic patients. These apparent sex differences in susceptibility 
may be clinically relevant, as there are numerous phenotypic sex differences as discussed in chapter 
one.  
In addition to β-2 agonist stimulated cAMP, there were sex differences in basal and forskolin 
stimulated cAMP, which would imply that the differences are not confined to the β-2AR but may also 
include post-receptor mechanisms. This data, however, may not be reliable due to the technical 
difficulties encountered in activating forskolin. Another study found that forskolin stimulated more 
cAMP in healthy females relative to males [301]. No other published studies comparing forskolin 
activation of cAMP between the sexes were found. 
 
2.3.4 Other factors influencing response to magnesium 
The effects of atopic status on magnesium’s efficacy and β-2AR function were not able to be assessed 
because of the small sample size. Another study in lymphocytes showed heterogeneity in down 
regulation of response to β-2 agonist among asthmatics however, atopic status was not documented 
[539]. Pre-treatment with desensitizing agonist, receptor density was identical in both groups of 
asthmatics. Atopic status may influence β-2AR responses in asthmatics, in that atopy may provide 
some protection against loss of receptors by down-regulation. In a clinical study, in vivo 
desensitisation to inhaled β-2 agonist was only observed in non-atopic asthmatics and not in atopic 
asthmatics [525]. This protective effect may represent an intrinsic difference in β-2AR function. A 
larger sample size is required to adequately assess the effect of atopy however, these differences may 
be clinically relevant. Taken together with the observations in this study, these data suggest that a 
difference in susceptibility to down-regulation may exist between atopic and non-atopic asthmatics 
and therefore, atopic status may influence response to magnesium.  
It is important to note in this study, that all male acute asthmatics were atopic, while all the non-atopic 
asthmatics were female. This is in keeping with relative frequencies of atopy among adult asthmatics 
described in the literature, as discussed in chapter one. Although atopic status may be another factor 
in determining the efficacy of magnesium in acute asthma exacerbations, there may be a sex-atopy 
interaction.  
The effect of OCS use on responses to magnesium was not able to be assessed. Others have shown in 




induced tachyphylaxis but have no effect in in untreated lymphocytes [493, 514]. Corticosteroids 
were also found to shift the equilibrium towards a greater proportion of “high affinity” receptors 
[514]. 
The effects of ethnicity on β-2AR function and response to magnesium could not be assessed, as all 
the controls and asthmatics were Caucasian. Others have shown ethnic differences in β-2AR function. 
A study of lymphocytes from healthy adults found African-Americans to have greater isoprenaline 
stimulated cAMP relative to Caucasians [540]. Healthy female African-Americans also been found to 
have greater isoprenaline stimulated cAMP relative to healthy African-American males and relative to 
healthy Caucasian males and females [301]. A study in predominately males found isoprenaline 
stimulated cAMP to be greater in Caucasians relative to African-Americans [541]. Studies of males 
only with hypertension, found African-Americans had greater isoprenaline stimulated cAMP [542] 
and less down-regulation of β-2AR responses [543] relative to Caucasians. These data suggest an 
interaction of race and sex in determining β-2AR responses to agonist stimulation which could also 
influence response to magnesium. 
 
2.3.5 Limitations 
The small sample size and missing data prevented a complete assessment of the effect of sex, and the 
effects of atopy and corticosteroids, on magnesium’s efficacy in acute asthma and a detailed 
assessment of any interactions between these factors. No distinction was made between self-reported 
atopy and doctor diagnosed atopy which may be an important factor in determining an effect of atopy. 
The methodology used may have limited the accuracy of some of the data. The methodology for β-2 
agonist stimulation of cAMP was subject to the influences of ambient temperature on enzyme 
activity, and there may have been a loss of cAMP by degradation prior to assay, causing potential 
errors in measurement. This is likely to have been consistent across all experiments. 
The low cAMP levels produced may have limited the accuracy of the data. The determination of 
cAMP concentration required interpolation from standards. The interpolated values were often 
calculated as zero, despite an absorbance value that was greater than zero. This occurred because the 
assay was not sensitive at cAMP concentrations ≤0.3 nM, and in some of the experiments, cAMP 
production was ≤0.3 nM. This resulted in data loss in two patients.  
Forskolin is a powerful direct activator of AC however, forskolin induced cAMP was much lower 
than expected. Some samples were exhausted due to poor cell viability, preventing repetition of the 
experiments. In many experiments where forskolin-stimulated cAMP levels were low, isoprenaline 




through degradation. It is more likely that forskolin activation was affected. Forskolin was stored as a 
stock solution in DMSO, which inhibits forskolin activation. This occurs at concentrations of ≥10% 
DMSO [544]. Given that the stock solution was diluted 1:100, it is unlikely that forskolin was 
inhibited by the DMSO. Stock solution was diluted in Milli-Q immediately prior to experimentation 
as forskolin is unstable in water. The amount of time taken to perform the experiments could have 
resulted degradation of forskolin.  
 
2.3.6 Future directions 
Further study of the effects of magnesium on the β-2AR  is warranted. Larger studies are needed to 
confirm the findings of the effects of magnesium on β-2AR responses and to assess the effects of sex 
on the efficacy of magnesium. More sample material is required to allow for the need to repeat 
experiments, should insufficient cAMP be produced. Larger quantities of cells could be used to ensure 
generation of adequate cAMP for ELIZA assays to be performed more accurately.  
Further study, with a larger sample size is required to assess the effects of atopy and corticosteroids 
with and without LABA, on β-2AR function and efficacy of magnesium. Larger studies would also 
allow assessment of any interactions between sex and these factors. Larger studies could also assess 
the effects of ethnicity on β-2AR function and efficacy of magnesium. 
Future study should include radio-ligand binding studies to quantitatively and qualitatively assess the 
β-2AR. Correlation between these laboratory findings and clinical outcomes within individuals would 




Magnesium may increase β-2 agonist stimulated cAMP through increasing receptor affinity for the 
agonist, possibly via allosteric modification of the β-2AR. This mechanism may also contribute to 
increased coupling efficacy between the β-2AR and its Gsα sub-unit, and hence, further increase β-2 
agonist efficacy. Magnesium’s effect is decreased where receptors are lost through down-regulation.  
Further work is required to confirm these results and to further assess the influence of sex, ethnicity 
atopy and asthma treatment on β-2AR function and magnesium’s efficacy. The relevance of these 





Chapter 3: Clinical trial of intravenous magnesium in 
acute asthma exacerbations 
 
3.1 Methods 
3.1.1 Trial design and setting 
This study was a randomised double-blind placebo-controlled clinical trial to assess the effects of the 
addition of 5g(20mmol) of intravenous magnesium sulphate as a single infusion, to standard treatment 
of nebulisations and oral steroids, in patients presenting to an emergency department with an acute 
exacerbation of asthma. The setting was an urban district emergency department of the Lyell McEwin 
Hospital in the northern suburbs of Adelaide, South Australia.  
The clinical trial was retrospectively registered with the Australian New Zealand Clinical Trials 
Registry ACTRN: ACTRN12612000838819  
Eligibility  
Patients with an acute exacerbation of asthma that presented to the emergency department were 
considered eligible for inclusion in the study if they complained of acute difficulty breathing, had a 
known diagnosis of asthma and required immediate treatment for their symptoms. 
Classification of patients 
Asthma was defined by reversible airways obstruction demonstrated clinically, diagnosed by a 
medical practitioner, or in a patient with symptoms of asthma at any time during their lifetime 
whether diagnosed or not (e.g. patient giving history of a recurrent cough and wheeze but had not 
sought medical assistance previously), or on asthma treatment as prescribed by a doctor. This 
treatment included regular inhaled corticosteroid, as needed inhaled salbutamol, or another 
bronchodilator. 
An acute attack was defined as the onset of symptoms in previously asymptomatic patient or an acute 
worsening of symptoms of diagnosed asthma, irrespective of treatment or acute respiratory distress 
due to asthma. 
Inclusion Criteria 
Inclusion criteria were age 18–50 years-old, the ability to give written consent to participation and an 
FEV1 of <70% predicted at least 15 minutes post ‘rescue treatment’. Those with features of life-




exhaustion, cyanosis, arrhythmia, hypotension, silent chest, poor respiratory effort, were excluded. 
Patients with an FEV1 of ≥70% predicted post rescue treatment were excluded. Patients were also 
excluded if; unable to perform a single forced expiratory manoeuvre for any reason, known to be 
pregnant, unwilling to provide written consent, unable to consent due to language barrier or 
intellectual impairment, known contra-indications to magnesium (hypermagnesemia, hypotension, 
heart block, allergy or sensitivity to magnesium, renal failure) were present, they had received 
magnesium in the previous 24 hours, or if they had been previously enrolled in the study. Patients 
were also excluded if they had a diagnosis of a pre-existing lung disease other than asthma at the time 
of enrolment (emphysema, chronic bronchitis, bronchiectasis, heart failure). Two patients were 
eligible for screening, however, were not screened, as they had already participated in the study.  
Withdrawal criteria 
Patients could withdraw voluntarily from the trial at any time for any reason. Involuntary withdrawal 
criteria were; a deterioration in the patient’s clinical condition, requiring nebulisations of salbutamol 
more frequently then every half hour, the need for non-invasive ventilation, or impending or actual 
respiratory arrest. If withdrawn from the trial treatment, that subject’s treatment was un-blinded for 
the purposes of determining further treatment including intravenous magnesium. Each bag of trial 
solution had a corresponding numbered sealed envelope with the information regarding the contents 
of the solution and was accessible to staff along with the trial solutions. This procedure was instituted 
to enable safe administration of magnesium should a patient deteriorate and be withdrawn from the 
trial, as our department guidelines included magnesium sulphate for treating severe-life-threatening 
exacerbations. The guidelines suggest 2.5g(10mmol) bolus for severe/life-threatening asthma which 
can be repeated up to 5g(20mmol) total whilst in the emergency department. 
Patients were withdrawn if an alternative diagnosis was proven from the time of enrolment to the time 
of discharge from hospital. The electronic case record was used to review the results of radiology and 
pathology to confirm the diagnosis of asthma and exclude an alternate diagnosis. The decision to 
retrospectively exclude patients was made by the principal investigator.  
Recruitment 
Patients were recruited from the population of asthmatics presenting to the emergency department for 
the treatment of an acute exacerbation of asthma. Recruitment of patients occurred 24 hours a day, 7 
days a week, provided that a nurse or medical officer who was accredited in the use of the 
‘EasyOne®’ spirometer was available. The principal investigator was, therefore, contactable 24 
hours/7 days a week, so as to be notified of any potential eligible recruits as per the inclusion criteria, 
and to recruit patients and collect data where onsite accredited staff were not available. This occurred 




3.1.2 Testing and treatment before consent  
Rescue treatment was given to those who were eligible for inclusion as part of the study protocol. 
Treatment consisted of three consecutive nebulisations of 5mg of salbutamol, one 500mcg 
nebulisation of ipratropium and 50mg of oral prednisolone, provided this had not been administered 
in the 24 hours prior to arrival. A baseline FEV1 measurement was then taken, prior to consent, to 
determine if the final of the inclusion criteria was met. Spirometry was performed with the EasyOne® 
hand held spirometer [n.d.d Medical Technologies US/Zurich]. The value of the best of three attempts 
was recorded although not all values were the best of 3 attempts. An FEV1 of <70% of the predicted 
value, from NHANES (III) values or best if known, was required for study entry.  
Testing was performed at least 15 minutes after the last of the three rescue nebulisations however, 
many of the acutely exacerbating asthmatics were unable to perform 3 attempts, therefore, an attempt 
was accepted if considered adequate. An attempt was considered adequate if the forced expiration 
lasted at least 2 seconds, there was a sharp early PEF and the patient did not cough during the first 2 
seconds of the manoeuvre. Repeated attempts were encouraged however, in cases where this was not 
possible, a single effort was accepted. This method of obtaining spirometry in acute asthma has been 
used in other published studies in acute asthma, where repeated attempts to obtain “quality” 
spirometry were not possible [383, 384].  
Those patients with an FEV1 of ≥70% predicted were excluded from the trial and managed by the 
treating physician. Those who met the inclusion criteria were then consented and randomised. 
Ethics and consent 
Ethics was approved by the Human Ethics Research Committee of the Lyell McEwin, and Queen 
Elizabeth hospitals [TQEH/LMH Approval No: 2010076]. An amendment for the collection of whole 
blood samples was later approved for the laboratory component of this study, to enable the isolation 
of lymphocytes for cAMP analysis. The treating physician or the principal investigator obtained 
informed consent in writing. Written information sheets were provided to patients, prior to consent. 
Randomisation and concealment of allocation 
Patients were randomised to receive either magnesium sulphate or placebo. The randomisation 
sequence was numerical and computer-generated in lots of 30. Randomisation was carried out by the 
hospital’s trial pharmacist, using a web-based free algorithm-based software program Urbaniak, G. 
C., & Plous, S. (2015): Research Randomizer (Version 4.0) [Computer software]; Retrieved on 




Trial solutions of placebo (0.9% saline) or magnesium sulphate (0.9% saline and 5g(20mmol) of 
magnesium) were made up in plain 100mL bags covered with an adhesive plain white label and 
allocated a number beginning with 1. Trial solutions in batches of 10 were distributed to the 
emergency department. These were stored at room temperature in accordance with pharmacy 
guidelines. Unused solutions were discarded after 3 months and replaced with new solutions to which 
new numbers were allocated. Each solution was allocated sequentially to each recruited patient in 
numerical order as labelled by the hospital pharmacy under direction of the trial pharmacist.  
Interventions 
After written consent was obtained, an intravenous cannula was inserted and 30mLs of blood was 
drawn. Samples were assayed for blood cell counts, serum electrolytes, serum magnesium and blood 
was set aside for isolation of PBMCs. Patients then received a 100mL intravenous infusion over 30-40 
minutes of either 5g(20mmol) of magnesium sulphate in 0.9% saline or 0.9% saline alone. The 
experimental solution was administered concurrently with a further 5mg salbutamol nebulisation.  
Further salbutamol nebulisations were administered on an as-needed basis, up to every half hour, for a 
further 3 hours. Supplemental oxygen was administered by the medical or nursing staff, as per usual 
practice, for a saturation below 92% on room air and titrated to effect. Other interventions and 
treatments were administered at the discretion of the treating medical officer during and after 
participation in the trial. 
Four hours after randomisation, the patients’ vital signs and FEV1 were assessed to determine 
disposition. Those fulfilling the requirements for discharge (n=6) and those that chose to leave against 
medical advice (n=2), were given standardised discharge medications and treatment. Discharge 
medications and follow-up were standardised and included 50mg oral prednisolone daily for 5-7days 
and salbutamol inhalations via an inhaler and spacer, 3-4 hourly as needed. A letter for GP follow-up 
and a respiratory nurse outpatient follow-up within 72 hours was provided to patients upon discharge 
or completion of the trial. Those who were admitted to hospital were reviewed by the hospital 
respiratory nurse and repeat FEV1 was performed within 24 hours of admission. 
 
3.1.3 Trial end point 
Discharge/admission  
Disposition as defined in the trial protocol was determined by FEV1, taken at least 15 minutes after 
the last nebulisation and four hours post-randomisation. Those whose FEV1was ≥75% of predicted 




signs of clinical instability. These included an oxygen saturation <92% on room air, signs of increased 
work of breathing i.e. subcostal or sternal recession, subjective symptoms of dyspnoea as defined by 
Modified Borg Score ≥ 2, abnormal vital signs including but not limited to a respiratory rate ≥22. 
Patients were then discharged provided none of the following applied; concerns of the treating 
physician regarding compliance, social isolation or restricted access to medical care, or a history of 
previous mechanical ventilation or cardio-respiratory arrest as the result of an acute asthma attack. 
Those unable to be discharged for these reasons or at the patient’s request, were further observed in 
the emergency department until the treating physician deemed it safe for the patient to be discharged. 
Those patients whose FEV1was < 75% of predicted at 4 hours post randomisation were referred to the 
inpatient medical team for admission. Patients were then admitted to either a medical ward or 
intensive care, as determined by the treating physician. Those whose FEV1 was < 75% of predicted 
and refused admission to hospital, were discharged from the emergency department if clinically stable 
as described above. Patients who were not clinically stable were encouraged to remain in hospital 
however, some chose to leave against medical advice. 
Patients who requested to be discharged prior to the four hours after randomisation, could attempt 
FEV1. Subjects with a FEV1 ≥ 75% of predicted were discharged from hospital, provided that there 
were no signs of clinical instability as described above. Patients with an FEV1 < 75% predicted at the 
time of request for discharge, were offered medical admission. Those whose FEV1 was < 75% of 
predicted and refused admission to hospital, were discharged from the emergency department if 
clinically stable as described above. Patients who were not clinically stable were encouraged to 
remain in hospital however, some chose to leave against medical advice. 
Outcome measures 
The primary outcome measure was discharge from the emergency department, which was determined 
on an intention-to-treat-basis by the treating physician at 4 hours after randomisation. At this time, the 
patient’s participation in the trial was concluded.  
Secondary outcome measures during participation were; adverse effects including flushing, injection 
site pain, hypotension and bradycardia, involuntary withdrawal from the trial and change in FEV1, 
respiratory rate and subjective dyspnoea score as measured by the Borg scale, from baseline at 
randomisation to 4 hours post randomisation. The patient’s length of stay in hospital from the time of 
randomisation to discharge from hospital was also obtained from the clinical case record. 
Data collection 
Outcome data was recorded separately to the clinical case record. Data sheets were collated by the 




baseline physiological parameters taken at randomisation post rescue treatment (respiratory rate, 
oxygen saturation, blood pressure, heart rate and FEV1% predicted) and at 4 hours post 
randomisation, regular asthma treatment, use of oral steroid in the preceding 24 hours prior to 
presentation, previous intensive care admissions or need for invasive ventilation and other medication 
usage in the week prior to presentation (anti-histamines, anti-reflux, antibiotics, oral steroids). 
Additional data included FEV1% predicted at follow-up either 24 hours or 72 hours after completion 
of the trial. An abbreviated Asthma Control Questionnaire (ACQ) was administered by the treating 
physician or self- administered by the patient at the time of randomisation (i.e. post rescue treatment). 
The questionnaire contained 6 questions relating to asthma symptoms and answers were scored on a 
scale of 0 to 6. The ACQ score was determined by dividing the total score by 6 (the number of 
questions). The inclusion the ACQ score provided the additional information of asthma 
control/presence of symptoms of active disease and SABA use, that spirometry alone could not 
provide [545, 546].  
Consent forms, patient information sheets, data collection sheets and a trial protocol flow diagram 
were available in the emergency department. Completed forms were sealed in envelopes that were 
provided by and collected by the principal investigator for safe storage in accordance with the 
Australian Code for the Responsible Conduct of Research 2007 (The Code).  
FEV1 measurements were performed by emergency department nurses accredited for use of the 
EasyOne® spirometer [n.d.d Medical Technologies US/Zurich]. Nurses and the principal investigator 
were accredited by the respiratory nurse practitioner accredited in training staff for the use of the 
EasyOne® spirometer. Ten of the 280 nursing staff and one of the 80 medical officers (the principal 
investigator) were trained in its use. Due to staff workloads and competing priorities in staff 
education, no other persons were trained. This limited the number of patients that were recruited. 
Consent form, data collection and patient information sheets are presented in the Appendix at the end 
of this document. Raw data is displayed in the Appendices at the end of this document. 
 
3.1.4 Statistical analysis 
The data analysis was on an intention-to-treat basis with the primary outcome variable of admission to 
hospital at first visit. A prior power calculation (X2 test for a 2x2 contingency table) determined that a 
study of n=390 per group would have 80% power to detect a 10% difference in admission rates with 
α= 0.05. A post-hoc power calculation (X2 test for a 2x2 contingency table) determined that with 
α=0.05 our study (n=24) had a 36% power to detect a 22% difference in outcomes. A sample size of 




The secondary outcomes analysed were; re-admission to hospital within 72 hours, total length of 
hospital stay in hours, changes in FEV1, change in respiratory rate and subjective dyspnoea rating by 
0-10 scale (Borg) and oxygen saturation from randomisation to 4 hours after randomisation. 
Differences in demographic variables and physiological parameters of heart rate and blood pressure 
were also compared between treatment groups. Primary and secondary outcomes were also compared 
between the sexes. 
Statistical analysis was performed using SPSS 24 (Statistical package software for students, IBM). A 
Chi-squared test was used to compare differences in categorical variables of the primary outcome of 
admission to hospital, demographic parameters of age, sex, smoking status and asthma treatment at 
home. Continuous variables (vital signs, ACQ and Borg scores, SABA use) were non-normally 
distributed, so non-parametric tests were used. The Mann-Whitney U test was used to compare 
independent variables i.e. between treatment groups, disposition groups and between the sexes. For 
dependent variables i.e. repeated measures (difference in Borg score, respiratory rate, blood pressure 
and heart rate from randomisation to 4 hours post randomisation), a Wilcoxon-Ranked sign test was 
used. Correlations were performed with Spearman’s Rho. Significance was considered at an alpha 




Forty-one patients were enrolled in the clinical trial over a period of 5 years. Seventeen of these were 
excluded from analysis. Of the 17 excluded patients, one was consented without an FEV1 
measurement, one was not randomised because the trial solution had expired, 7 patients were not 
randomised for reasons that could not be ascertained and 8 were withdrawn post-randomisation. One 
patient withdrew voluntarily for personal reasons, one was involuntarily withdrawn due to 
deterioration in asthma symptoms and six patients were withdrawn retrospectively post 
randomisation, due to an alternative primary diagnosis. Of the 6 that were retrospectively withdrawn, 
one had a diagnosis of bronchiectasis and 5 were excluded due to an alternative diagnosis of 
pneumonia. There were 24 patients suitable for inclusion and data analysis (Figure 9). 
Demographics and baseline characteristics 
There were 10 males and 14 females recruited. Twenty-two of the 24 patients were Caucasian. The 
remaining two were Aboriginal. The median age of patients was 35.5 years (interquartile range 26.3-
46) with 45.8% (n=11) over the age of forty. The average BMI of patients was 29.4 (range 23.1-39.5) 




59%), which classified them as having mild to moderate asthma according to BTS/SIGN guidelines. 
ACQ scores were high (3.5), indicating poor control of asthma symptoms in the week prior to 
presentation. The median number of SABA inhalations per day in the preceding week was 12, which 






Figure 9. Flow diagram of the outcome of enrolment of patients recruited for the clinical trial 
subsequent to their consent. 
1 withdrawn
deterioration
N=41 eligible for inclusion
15 analysed 9 analysed
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Table 6. Demographic and baseline variables (at randomisation); comparison between 
treatment and placebo. 
 
IQR: interquartile range, SE: standard error, BM: body mass index,  
ICS: inhaled corticosteroid, LABA: long acting β-2 agonist, OCS: oral corticosteroid, SABA: short 
acting β agonist, FEV1: forced expiratory volume in 1 second, mM (millimolar).   
 
 
Fifty four percent of patients (n=13) were taking inhaled corticosteroid (ICS), mostly in combination 
with a long acting β-2 agonist fluticasone 250-1000mcg/ salmeterol 25-100mcg daily, or budesonide 
400-800mcg/eformoterol 6-24mcg daily. There was no difference in ACQ scores between ICS users 
relative to non-users. The prevalence of OCS use was 29% (37.5 mg-50mg daily for 1-7 days), and 
45.8% (n=11) were atopic, as defined by having a history of allergic rhinitis (hay fever), eczema or 
hives, or a more serious reaction to another trigger such as eggs or latex. Serum magnesium levels 
were within normal limits.  
Fifteen patients were randomised to magnesium and nine were randomised to placebo. There were 8 
females and 7 males in the magnesium group and 6 females and 3 males in the placebo group. There 
were no statistically significant differences in any of the demographic or baseline physiological 
Demographic /baseline characteristic
magnesium            
(n=15)
placebo                 
(n=9)
p value
Caucasian ethnicity 14 (93.3) 8(88.9) 0.70
Age, median (IQR) 38 (25-46) 31 (27-48) 0.86
Female , n (%) 8 (53.3) 6 (66.7) 0.52
BMI, median (IQR) 33.6 (23.0-37.9) 27.3 (24.0-41.2) 0.93
Current smoker, n (%) 9 (60) 6 (66.7) 0.81
Serum magnesium (mM), mean (SE) 0.84 (0.02) 0.87 (0.02) 0.48
Preventer,  n (%) 8 (53.3) 5 (55.6) 0.92
ICS only 2 (13.3) 1 (11.1)
ICS+LABA 6 (40) 4 (44.4)
Other medications ( antibiotics, antihistamines, others), n (%) 6 (35.7) 2 (16.7) 0.31
Atopy ( hayfever/eczma/other), n (%) 6 (40) 5 (55.6) 0.47
OCS in 24 hours prior to arrival , n (%) 4 (26.7) 3 (33.3) 0.52
Asthma Control Questionairre (0-6),  median (IQR) 3.1 (2.0-4.8) 4.5 (2.5-5) 0.34
Preceding SABA use (mcg/day), median (IQR) 1400 (500-1800) 1200 (800-1600) 0.92
Borg dyspnoea scale (0-10) , median (IQR) 6 (6-7) 6.5 (5-8) 0.85
FEV1 % predicted, median (IQR) 54 (44-61) 40 (34-51) 0.06
Respiratory rate in breaths per minute , median (IQR) 24 (22-26) 24 (22-26) 0.56
Oxygen saturation %, median (IQR) 94 (93-96) 95 (93-96) 0.77
Pulse rate in beats per minute , median (IQR) 121 (100-130) 112 (94-122) 0.19
Systolic blood pressure mmHg , median (IQR) 115 (110-140) 115 (110-120) 0.64




parameters between the magnesium and placebo treatment groups (Table 6). There was a trend 
towards a greater baseline FEV1 in the magnesium group relative to the placebo group, which was 
near significant (p=0.06). 
The overall admission rate for the study group was 75% (n=18). The average length of stay in hospital 
for admitted patients was 36 hours (IQR 15-48 hours). Only one patient fulfilled the discharge criteria 
as defined in the protocol as a post treatment FEV1 of ≥ 75% predicted. The remaining six patients 
were discharged as they were considered clinically stable. Retrospective analysis of the clinical case 
record found that those discharged had a Borg scores <2 and respiratory rates ≤ 20. These patients 
required salbutamol nebulisations less frequently than every 2 hours, and none of these patients 
returned to an emergency department within the 7 days following discharge. These patients were 
considered to have been successfully discharged, and the outcome of discharge from hospital was 
evaluated on an intention-to-treat basis. 
Primary outcome 
The difference in admission rates between the magnesium group (66.7%; n=10) and placebo (88.9%; 
n=8) was not significant (p=0.22). Five of those patients admitted, discharged themselves from the 
emergency department against medical advice (20%). They had persistently elevated respiratory rates 
of > 22 breaths per minute, a requirement for nebulisations more frequently than 2 hours and an 
average FEV1 of 57% predicted. Four of these were in the magnesium treatment group and three of 
these patients returned within 48 hours and were re-admitted to hospital. 
Secondary outcomes 
No patients from either the magnesium or the placebo group required an intensive care admission. 
None of the patients discharged from the emergency department by the treating physician required re-
admission to hospital within 7 days.  
Those in the magnesium group had a significant decrease in heart rate (HR) at 4 hours post-
randomisation (p=0.02). The frequency of nebulisations 4 hours post-randomisation tended to be less 
in the magnesium group (2-4 hourly) relative to placebo group (1-2 hourly) (p=0.07) (Table 7). There 
were no significant improvements in FEV1 for either group, with a median improvement of 3% for 
both groups. 
Adverse effects  
There was a 20.8% (n=5) incidence of a sensation of body flushing in the magnesium group. In the 
placebo group, there was an 11.1% (n=1) incidence of pain at the cannula site and an 11.1% incidence 




Table 7. Secondary outcomes. 
  
Values given as median: (N), BORG: subjective dyspnoea ranking (0-10), FEV1: forced expiratory volume 
in 1 second.  
 
 
Table 8. Sex differences in baseline variables and outcomes. 
 
IQR: interquartile range, SABA: short acting β-2 agonist 
 
 
Table 9. Outcome variables affecting disposition. 
 
SABA: short acting β-2agonist, FEV1: forced expiratory volume in one second, IQR: interquartile range 
 
Secondary outcomes (4 hours post randomisation)
magnesium                   
(n=15) 
placebo                 
(n=9)  
p value
BORG score  (0-10) 2 (9) 1 (3) 0.86
FEV1 % predicted (%) 56 (11) 53(5) 0.74
Heart rate in beats per minute (bpm) 98(13) 104 (7) 0.02
Respiratory rate (breaths/min) 22 (11) 22 (5) 0.59
Oxygen saturation (%) 96 (13) 95(8) 0.88
Length of stay (hours) 28 (5) 41 (5) 0.76
Time between  nebulizations after randomization in hours (range) 2-4 (11) 1-2 (5) 0.12
Demographic variable/outcome
males                           
(n=10)
females                            
(n=14)
p value
Admission rate , n (%) 6 (60) 12 (85.7) 0.15
Length of stay (hrs), median (IQR) 28 (12-48) 62 (38-145) 0.08
Atopy, n (%) 7 (70) 4 (28.6) 0.1
Asthma Control Questionairre (0-6),  median (IQR) 3.0 (1.5 -4.2) 4.8 (2.5-5.0) 0.17
Preceding SABA use (mcg/day), median (IQR) 800 (200-1600) 1600 (1200-2000) 0.17
Factors affecting outcome of admission to hospital 
(baseline values at recruitment)
admitted             
(n=18)  
discharged        
(n=6)   
p value
Asthma control score (0-6) median (IQR) 4.7 (3.0-5.1) 0.6 (0.5-2.2) 0.001
Short acting B2 agonist use mcg/day , median (IQR) 1600 (900-1900) 200 (50-1600) 0.09
Initial FEV1 % predicted , median (IQR) 47.5 (37-56) 58.5 (44-63) 0.18
Oxygen saturations on arrival % , median (IQR) 94 (93-95) 95.5 (95-96) 0.14




Other factors affecting outcomes independent of treatment 
There were sex differences in admission rates, baseline and demographic characteristics but these 
were not significant (Table 8). The main factor affecting outcomes was severity as measured by ACQ 
score (Table 9). The ACQ score was correlated with the amount of SABA use prior to presentation 
(R2-680; p=0.001). There were no significant correlations between ACQ score and improvements in 
secondary outcomes. ACQ score was negatively correlated with a degree of improvement in 
subjective dyspnoea at 4 hours post randomisation but this did not reach significance (R2-.492; 
p=0.053). There was a negative association between SABA use and length of stay, which was 
significant (R2 -568: p<0.043). Systolic blood pressure was significantly associated with admission, 
though the reason for this is unclear. The sample size was too small to detect any other associations 
with hospital admission however, we observed that all non-atopic asthmatics were admitted. There 





When designing this study, it was identified that the Lyell McEwin emergency department had 90 
patients admitted over a 12-month period for asthma presentation in the 18-50-year age range (SA. 
Health-HASS/EDIS 1/1/2009-31/12/2009), suggesting that the study was feasible for patient numbers. 
The primary objective was not met however, due to insufficient numbers of patients. Acute asthma 
patients were also required for the laboratory study and therefore, recruitment continued despite low 
numbers. There were no alternatives to obtaining “original” data for the purpose of the thesis. This 
study demonstrates the difficulties in conducting clinical research in a busy emergency department 
where the focus is service provision.  
Potential benefits 
This study identified some potential benefits of magnesium, such as a reduction in heart rate and 
possibly a reduced requirement for nebulisations. Heart rate is important parameter in acute asthma as 
heart rate is an indicator of severity of the exacerbation [2-4]. Reduction in heart rate therefore 
represents a clinical improvement.  
A reduction in the requirement for nebulisations is important, as it reduces the risk of salbutamol 
toxicity and improves patient comfort. Only one other study has reported nebulised β-2 agonist use as 
an outcome and there was 10% reduction in nebulisations used in those treated with magnesium 




of magnesium to the treatment regimen may contribute to a reduction in admission rates relative to 
standard care alone. A larger sample size may have detected a difference in this outcome. 
The dose of magnesium used in this trial appears to be safe however, the small sample size may have 
been insufficient to detect any serious adverse effects. This is the first Randomised Controlled Trial to 
assess the effects of magnesium in adults with acute asthma at the dose of 5g(20mmol), although 
higher doses have been documented in case reports. Previous studies have used 1.2-2g(5-8mmol) of 
magnesium [377, 381, 382, 384, 387, 388]. Doses of 100mg/kg (0.4mmol/kg) have been used in 
paediatric asthma [414], and individual case reports in both males and females with life-threatening 
asthma have reported use of doses of up to 20g(80mmol) in one hour, without any serious untoward 
effects [398]. These data support the safety of the use of a 5g slow bolus infusion in acute asthma in 
adults however, care should always be taken in monitoring for potential adverse effects, such as 
respiratory muscle weakness. 
Subgroup analyses and other factors influencing admission 
The most significant contributing factor towards the primary outcome of disposition was a high ACQ 
score, which is indicative of poor control of asthma symptoms and instability. Two large international 
cohort studies also found poor asthma control to be a predictor of emergency department visits and 
hospital admissions [547, 548].  
Due to the small sample size it was not possible to examine these data for other sub-group benefits, 
nor was it possible to assess the effect of other individual factors on admission rates and response to 
magnesium, such as atopy/sex. Phenotypic distinctions in asthma were traditionally made based on 
atopy [269], however, no studies comparing admission rates between atopic and non-atopic adult 
asthmatics have been published to the best of our knowledge. It would also have been useful to assess 
the effects of sex and assess for any sex-atopy interaction as women have more severe asthma [285, 
289-294], are more likely to use oral steroids [291] and are more likely to be admitted to hospital 
relative to men [292, 296]. Additionally, the prevalence of non-atopic asthma is also greater in adult 
females relative to adult males [305].  
 
3.3.1 Limitations 
The main limitation of this study is the small sample size. The small numbers of recruited patients 
precluded an assessment of the effects of magnesium in this group. We were also unable to assess the 
effects of sex and atopy on outcomes. 
The reliance on emergency nursing staff to participate in training in the use of the spirometer, and 




significant limitation that reduced recruitment rates. This reduced the potential number of patients 
recruited as it was only possible to recruit patients on days where a nurse trained in the use of the 
spirometer, was available. The principal investigator was available either directly during normal 
clinical duties, or remotely on call; however, being the sole investigator with no external funding 
provided, limited my ability to attend out of rostered work hours due to requirements for recovery, 
and time to conduct the laboratory component and further literature reviews towards this thesis.  
The spirometry session quality varied greatly between individuals and the grading ranged from “A” to 
“D”, with 2 sessions graded as “F”. The inclusion of “poor quality spirometry” may have limited the 
accuracy of the data however, the rationale for including the low-quality data has already been 
discussed in the discussion in chapter 2, and the method of obtaining spirometry used in this study has 
been used in published studies in acute asthma where attempts to obtain “quality” spirometry were not 
possible [383, 384]. The rationale for including the “poor quality” data can be explained further.  
The spirometry was graded for diagnostic mode, which requires a 6 second expiratory effort to obtain 
the FVC/FEV1 ratio. A grade of “A” or “B” indicates 3 acceptable manoeuvres and a “C” indicates 2 
acceptable manoeuvres. A “D” indicates that 2 manoeuvres were adequate but non-reproducible, and 
“F” indicates there were no acceptable manoeuvres i.e. the patient was unable to sustain a 6 second 
effort. Thus, even if a patient was able to sustain a 2 second effort, the effort would not be acceptable 
and graded “F”. Additionally, when an FEV1 is measured in a bronchial challenge test in non-
exacerbating asthmatics, a best of three attempts is performed at only at baseline [549], and the FEV1 
is only measured once during active bronchoconstriction [549, 550]. This active constriction could be 
compared to an exacerbation hence, a single manoeuvre would be acceptable. 
There were 5 participants in this study, who on repeated attempts to obtain a ‘best of three’, showed a 
decline in FEV1 with each subsequent effort. This is due to deep inspiration-induced bronchospasm. 
In a study of acute asthma where FEV1 measures were made at 20-minute intervals, some were 
unable to perform three attempts, and some of the participants showed a decline in FEV1 values with 
repeated attempts [551]. This was thought to be due to worsening obstruction from the exacerbation 
or the effects of repeated inspiratory manoeuvres, rather than the interventions. The deep inspiration 
required for the manoeuvre can induce bronchoconstriction in asthmatics [196] and forced 
inspiratory/expiratory manoeuvre induced bronchoconstriction has been reported [552]. A decline in 
PEF with repeated attempts in acute asthma exacerbations has also been shown to occur [553]. Thus, 
repeated attempts at spirometry may reduce the accuracy of the measurements. 
Some data, particularly data regarding the secondary outcomes was missing, such as a Borg score, 
which was not retrievable retrospectively from the case notes. The inclusion of this and other data 




Only one of the patients discharged from emergency, was discharged according to the protocol 
requirements. The treating physician discharged patients if they were deemed clinically stable. None 
who were deemed to be ‘fit for discharge’ required re-admission at any time within the 7 days 
following discharge, therefore, this is unlikely to have influenced the overall results. 
 
3.3.2 Future directions 
Clinical studies in acute asthma with sufficiently large numbers of patients to assess the effects of sex, 
recent asthma control as measured by ACQ score, smoking and atopy on outcomes would be useful. 
Larger numbers of patients would also be useful to confirm the safety in administration of a 
5g(20mmol) dose of magnesium. A multicentre trial would be feasible; however external funding 
would be required to overcome many of the limitations that have been discussed. The use of PEF, as a 
means of selecting those with “severe” asthma, may be more appropriate for measurement of 
obstruction in acutely exacerbating asthmatics. Measurement of obstruction using a PEF meter is 





This trial was unable to demonstrate a significant effect of intravenous magnesium on admission rates 
or other outcomes in acute asthma as the sample size was inadequate. Poor asthma control over the 
preceding week was the most significant contributing factor, and a high ACQ score was associated 
with a greater the likelihood of admission to hospital. Larger numbers are required to assess the 
efficacy of magnesium in acute asthma and to determine whether other factors influence response to 
treatment. Simplification of the trial protocol and funding for a multicentre study could allow 






Chapter 4: The effectiveness of 2g of intravenous 
magnesium for the treatment of acute asthma on 
admission rate: a re-analysis of 3M clinical trial data 
 
Admission rates for acute exacerbations vary around the world [554], however, they are an important 
measure of outcome as hospital admissions represent a substantial cost to the health care systems. In 
Australia, $665 million dollars per year is spent on asthma with 20% of this total on hospital 
admissions [555]. In the UK, the most recent figure is £1.1 billion with 12% of this total on hospital 
care [556]. In addition to this, hospital admission has psychosocial implications for patients and 
families, including loss of work and isolation from family and friends. Treatments that reduce 
admission rates would have financial benefits for health systems as well as quality of life benefits for 
those individuals who are affected by asthma. Treatments or management practice change that 
consistently reduce ED presentations, would ideally produce maximum benefit for health systems and 
individuals with asthma.  
The 3M trial was a randomised double-blind placebo-controlled trial in acute asthma, that compared 
the effect of nebulised or intravenous magnesium sulphate to a placebo, on admission to hospital 
[388]. It is the largest clinical trial of magnesium in acute asthma to date and was conducted at 
multiple centres around the UK. The patient demographic was reported as largely (90%) ‘white’, with 
the remainder, a mixture of Asian, ‘Black’ or ‘other’.  
Patients were given standardised treatment according to national guidelines for the treatment of an 
acute asthma exacerbation, alongside the experimental treatment. Standardised treatment included 
oxygen, 5mg of nebulised salbutamol, 500mcg of nebulised ipratropium and oral prednisolone. The 
primary outcome measure was admission to hospital and the main secondary outcome was a change 
in subjective measurement of breathlessness.  
The group recruited 1109 (92%) of the 1200 proposed by the power calculation. They found that 
nebulised magnesium had no effect on the admission rate relative to placebo 79% (n=261) vs. 78% 
(281). The admission rate in the intravenous magnesium group was 72% (n=285), and intravenous 
magnesium was associated with an odds ratio of 0.73 (95% CI 0.51-1.04; p=0.083) for hospital 
admission relative to placebo. The overall admission rate in the combined placebo and intravenous 
magnesium groups was 74% (n=557). The prevalence of associated co-morbidity in this group was 
17.8% (n=134). This is possibly due to the inclusion of older asthmatics up to the age of 88 years-old 





In this analysis it was hypothesised that:   
• Intravenous magnesium would significantly reduce admission rates relative to placebo in 
adults aged 50 years-old or less experiencing an acute asthma exacerbation. 
• There may be differences in efficacy between categories of severity as defined by the 
predicted percent PEF values. 
• There would be sex differences in response to magnesium and that magnesium would have a 
greater effect on reduction in admission rates in male asthmatics relative to female asthmatics. 
• OCS use and active smoking would increase the likelihood of admission to hospital. 
 
The aim of this study was; to re-examine the data from the 3M study’s ‘white’ Caucasian population 
aged 18-50 years, who received either placebo or intravenous magnesium, to assess the effect of 
intravenous magnesium on admission rates and secondary outcomes, and to assess the effects of sex 
and severity of exacerbation on outcomes and response to treatment with intravenous magnesium. The 
sub-set data was chosen to remove any confounding variables, such as serious age -related co-
morbidity, that may influence outcomes. Non-whites were excluded as race was thought to be a 




The primary author was contacted via email and consented (via email) to a re-analysis of the data for 
this thesis. Data from a sub-set of 837 patients between the ages of 18 and 50 were obtained to 
correspond with the age of patients in my clinical trial. The data contained patient demographics of 
site recruited, age, sex, smoking status and ethnicity; physiological baseline parameters of heart rate, 
respiratory rate, systolic and diastolic blood pressure, temperature, oxygen saturations, oxygen flow 
rate, subjective dyspnoea score (VAS 0-100), repeated physiological parameters measured at 1 and 2 
hours post treatment; airways obstruction as measured by % predicted and actual peak expiratory flow 
(PEF) in L/min at baseline and at 1 and 2 hours. The use of asthma medications such as inhaled and 
oral corticosteroids was also recorded. Outcome data included admission to hospital at first visit and 
admission to hospital within 7 days. 
Data from patients in the intravenous magnesium and placebo treatment groups were selected and 
data from patients in the nebulised magnesium group were excluded, as the aim of this thesis was to 
study intravenous magnesium. Data from a total of 583 patients was then examined. There were 528 




selected so that ethnicity corresponded to my clinical trial. The data from these 528 patients was 
assessed.  
Primary outcomes assessed were admission to hospital at first visit and admission to hospital within 7 
days. Secondary outcomes assessed were changes in respiratory rate at 2 hours, changes in VAS at 2 
hours, changes in PEF at 2 hours as measured by the percent predicted. 
Baseline and demographic parameters, primary and secondary outcomes were assessed between 
magnesium and placebo groups and between male and female patients. A separate sub-group analysis 
by severity and by sex was undertaken. Severity sub-groups were categorised, according to the British 
Thoracic Society guidelines of severity, into mild-moderate (PEF >50% predicted), severe (PEF 33-
50% predicted) and life threatening (PEF <33% predicted) at baseline [4]. Sub-group analyses by 
severity and sex were also undertaken to determine if these factors affected response to magnesium 
treatment, as the data from the clinical and laboratory study suggested that they may influence the 
response to magnesium treatment.  
Statistical analysis was performed using SPSS 24 (Statistical package software for students, IBM). 
Primary and secondary outcomes between treatment and placebo groups were compared. Direct 
comparison of primary and secondary outcomes between the sexes was undertaken. Chi squared 
analysis was used to compare outcomes between categorical variables. Continuous variables were 
analysed using t-test for independent samples. Significance was considered at an alpha level of 0.05. 
Logistic regression analysis was used to assess for other variables that may have had a significant 




Of the 528 patients, 388 (73.5%) were female and 140 (26.5%) were male. There were 290 patients in 
the ‘active’ magnesium treatment group and 238 in the placebo group. There were no significant 
differences in age or frequencies of smoking status, or sex between active treatment and placebo 
groups. There were no significant differences in oral or inhaled corticosteroid between groups. The 
baseline percent predicted peak flow values were statistically greater in the magnesium group relative 
to the placebo group by 3% (p<0.05). There were no other significant differences in baseline 







Table 10. Baseline parameters 
 
ICS: inhaled corticosteroid, OCS: oral corticosteroid, SE: standard error, VAS: Visual analogue scale. 
PEF: peak expiratory flow. 
 
 
4.2.1 Overall effects 
Primary outcome measures 
There was a statistically significant greater admission rate of 8% in the placebo group relative to the 
magnesium group (χ2 (1, N=528) = 4.13, p<0.05). When the outcome was adjusted for re-admission 
within 7 days, the difference in admission rate was reduced by 0.4% (χ2 [1, N=528] = 3.78; p=0.052). 
Secondary outcomes 
There were no significant differences in VAS scores, respiratory rate or peak flow % predicted values 
between treatment and placebo groups. There was a trend towards a lower VAS in the magnesium 
group relative to placebo group (Table 11). 
Effect of variables on outcome of admission to hospital 
Direct logistic regression was performed to assess the effect of magnesium on the outcome of 
admission at first visit, correcting for other variables that may have affected the outcome of admission 
to hospital. Firstly, a model was constructed with all significant predictor variables. Bivariate logistic 
regression was performed separately for each variable, such as initial PEF, and any a-priori 




Table 11.  Secondary outcomes. Comparison of magnesium and placebo groups. 
 
SE: standard error, VAS: Visual analogue scale. PEF: peak expiratory flow L/min 
 
An initial multi-variate model was then tested by regressing outcome against treatment group and all 
variables and interactions where the p value was <0.2 in the bivariate regression. This model 
contained in addition to the treatment group, demographic variables of age, smoking status and sex 
and baseline physiological parameters of respiratory rate, heart rate, breathlessness (VAS), percent of 
predicted peak flow at baseline and use of oral and inhaled corticosteroid in the 24 hours prior to 
presentation. There were no significant interactions between any of the variables in the regression 
model. Backwards multivariate analysis of the model containing all significant factor variables was 
then performed to produce the most efficient and parsimonious logistic model. This was done by 
eliminating the variable with the highest p value and re-running the model. This step was repeated 
until only the variables with a p value of <0.05 remained.  
The final regression model was significant, with an overall p<0.001(Table 12). The Χ2 (N=483, 7) 
=69.1, and the model produced a –LLR=516.03. The model explained between 13.3% (Cox and Snell 
R2) and 19% (Nagelkerke R2) of the variance in admission rates.  
 
Table 12.   Logistic regression analysis: Acute asthma presentations aged 18-50. Effect of 
treatment on primary outcome of admission to hospital at first visit controlling for significant 
pre-randomisation variables. 
                                                                                                              
PEF: peak expiratory flow, OCS: oral corticosteroid 
Lower Upper
Group (placebo) -0.472 0.225 4.380 1 0.036 0.624 0.401 0.970
Age 0.033 0.013 6.732 1 0.009 1.034 1.008 1.060
Sex (Female) 0.638 0.248 6.649 1 0.010 1.894 1.165 3.076
Pulse rate (beats per minute) 0.013 0.006 4.220 1 0.040 1.013 1.001 1.025
PEF at baseline -0.017 0.006 9.100 1 0.003 0.983 0.972 0.994
OCS use in 24hrs 0.778 0.248 9.821 1 0.002 2.177 1.338 3.541
Combined oxygen saturation -0.213 0.055 14.842 1 0.000 0.808 0.725 0.901
Supplemental oxygen administration L/min 0.068 0.032 4.499 1 0.034 1.071 1.005 1.140
Constant 19.000 5.420 12.289 1 0.000 1.786E+08





In this regression model controlling for other factors in the model, treatment was significant with OR 
0.62 (CI 0.4-0.97), indicating a decreased likelihood of admission with magnesium treatment relative 
to placebo.  
The strongest predictor of admission was the use of oral corticosteroid prior to arrival with an OR of 
2.2 times increased risk of admission to hospital (CI 1.4 to 3.5), controlling for other factors in the 
model. Female sex was associated with an OR of 1.9 times increased risk of admission to hospital (CI 
1.16-3.1), controlling for other factors in the model. Oxygen saturation was associated with admission 
with an OR 0.81 (CI 0.7.2-0.9) reduced likelihood of admission for each percent increase in 
saturation. Age was associated with an OR of 1.03 times increased risk of admission (CI 1.01 to 1.06) 
for every year older than 18, controlling for other factors in the model. Higher PEF at baseline was 
associated with a OR of 0.98 times decreased risk of admission (CI 0.97 to 0.99) when controlling for 
other factors in the model. Supplemental oxygen flow rate was associated with an OR of 1.07 times 
increased risk of admission to hospital (CI 1.0-1.14). 
When the outcome was adjusted for re-admission within 7 days, the model was significant with an 
overall p<0.001. The Χ2 (N=483, 7) = 67.14 and the model produced a –LLR =503. The model 
explained between 13% (Cox and Snell R2) and 18.7% (Nagelkerke R2) of the variance in admission 
rates. Magnesium decreased the likelihood of re-admission with an OR 0.62 (CI 0.4-0.98).  
 
4.2.2 Sub-group analyses  
Severity defined by PEF% predicted 
Admission rates increased according to severity. For those with life-threatening asthma, the admission 
rate was 81.8% (n=66), for those with severe asthma 74.3% (n=187) and mild to moderate asthma 
64.5% (n=242). The proportion of cases within each of the severity categories was significantly 
different between the sexes. Females were more likely to have life-threatening asthma (53%, n=192) 
relative to severe asthma (36.5%, n=132) or mild-moderate asthma (10.5%, n=38). Males were more 
likely to have severe asthma (41.4%, n=55) relative to life-threatening asthma (37.6%, n=50) or mild 
–moderate asthma (21.1%, n=28) (p<0.01). There were no differences in frequency of OCS use 
between categories of severity (p=0.3). 
In the life-threatening sub-group, there were no significant differences in admission rates in the 
magnesium group (84.8%, n=28) relative to the placebo group (78.8%, n=26). There were no 
significant factors in determining the primary outcome of admission to hospital. In this sub-group 





In the severe category, magnesium significantly reduced the admission rate by 14.8% relative to 
placebo (χ2 [N=187, 1]=7.01; p<0.01). Significance was retained for the outcome of admission to 
hospital within 7 days (χ2 [N=173, 1] =5.22; p<0.05). There were no other significant factors 
identified in determining admission. There was a trend towards greater subjective improvement in 
VAS at 2 hours and a lower respiratory rate in the magnesium group relative to placebo group (Table 
13). 
 
Table 13. Secondary outcomes by severity, magnesium vs. placebo. 
SE: standard error, VAS: Visual analogue scale, PEF: peak expiratory flow. 
 
In the mild-moderate sub-group, there was a lower admission rate in the magnesium group (61.4%, 
n=88) relative to placebo (68.7%, n=68), but this was not significant (p=0.25). Logistic regression 
identified the predictor variables of age, PEF % predicted at baseline, OCS use and oxygen saturation 
(Χ2 [N=242, 4] =48.17, –LLR =265.9; p<0.01) (Table 14).  
 
Table 14.  Logistic regression analysis: Acute asthma presentations aged 18-50, mild-moderate 
severity. Effect of treatment on primary outcome of admission to hospital at first visit, 
controlling for significant pre-randomisation variables. 
 
OCS: oral corticosteroid, PEF: peak expiratory flow 
Lower Upper 
Age 0.056 0.017 10.521 1 0.001 1.058 1.022 1.094 
OCS use in 24 hours 1.462 0.349 17.589 1 0.000 4.314 2.179 8.542 
PEF at baseline -0.177 0.068 6.900 1 0.009 0.837 0.733 0.956 
Combined oxygen saturation  -0.023 0.011 4.670 1 0.031 0.977 0.957 0.998 




95% C.I. for  




The model explained between 18.1% (Cox and Snell R2) and 24.9% (Nagelkerke R2) of the variance 
in admission rates. The strongest predictor of outcome was OCS use with an OR of 4.3 times 
increased risk of admission to hospital (CI 2.18- 8.5) controlling for other factors in the model. There 
were no significant differences in secondary outcomes between treatment and placebo groups. 
Effect of sex 
There were 388 female and 144 male patients in the analysis. Baseline respiratory rate (p<0.01), pulse 
rate (p<0.05), breathlessness by VAS score (p<0.05) and baseline PEF (p<0.01), were greater in 
females relative to males. There were significantly more active male smokers relative to females 
(p<0.01). The frequency of OCS use was 6% greater in females relative to males but was not 
significant (p= 0.2). Other demographic variables were similar between the sexes (Table 15). 
 
Table 15. Difference in parameter variables between sexes. 
 
SE: standard error, ICS: inhaled corticosteroid, OCS: oral corticosteroid, VAS: Visual analogue 
scale, PEF: peak expiratory flow  
 
When outcomes between the sexes were compared, the admission rates were 8.5% greater in females 
relative to males, but this was not statistically significant (p=0.058). The improvements in secondary 







Table 16. Differences in secondary outcomes between sexes 
 




There were 213 in the magnesium group and 175 in the placebo group. PEFs were lower in the 
magnesium group (53.3%) relative to placebo group (56.9%) but not significantly. There were no 
other differences in demographic and baseline parameters between treatment groups. There was a 
5.7% greater admission rate in the placebo group relative to the magnesium group, but this was not 
statistically significant (p=0.21). When adjusted for re-admission within 7 days, the effect of 
magnesium was slightly greater with a 6% reduction in admission rate relative to placebo (p=0.18). 
There were no statistically significant differences in secondary outcomes between treatment and 
placebo groups in female patients.  
The logistic regression model identified 5 predictor variables of admission. These were age, 
supplemental oxygen flow rate, oxygen saturation, oral corticosteroid use and PEF at baseline. The 
model was significant (χ2 [N=352, 5] =61.08; p<0.001) with a –LLR 349.459 and explained between 
15.9% (Cox and Snell R2) and 23.1% (Nagelkerke R2) of the variance in admission rates (Table 17). 
 
 
Table 17. Logistic regression analysis: Female sex: Effect of treatment on primary outcome of 
admission to hospital first visit controlled for significant pre-randomisation variables.  
 
PEF: peak expiratory flow, OCS: oral corticosteroid  
 
Lower Upper
Age 0.041 0.016 7.058 1 0.008 1.042 1.011 1.075
Supplemental oxygen flow rate L/min 0.084 0.039 4.591 1 0.032 1.087 1.007 1.174
PEF at baseline -0.028 0.007 15.649 1 0.000 0.973 0.960 0.986
OCS use in 24 hrs 1.000 0.304 10.838 1 0.001 2.719 1.499 4.931
Combined oxygen saturation -0.234 0.066 12.521 1 0.000 0.792 0.695 0.901
Constant 23.349 6.391 13.348 1 0.000 1.382E+10
Sig. Exp(B)/OR
95% C.I.for EXP(B)/OR




The strongest predictor of outcome in females was oral corticosteroid use which was associated with 
an OR of 2.7 times greater risk of admission (CI 1.5 to 4.9) when controlling for other factors in the 
model. For each 1% increase in oxygen saturation, the risk of admission to hospital decreased by 79% 
(OR 0.79, CI 0.6 to 0.9). PEF% at baseline was associated with a slightly decreased risk of admission 
(OR.97, CI.96 to 0.99) and with each percent increase in PEF, there was a 97% decreased risk of 
admission. Age was associated with a 4% increase in admission for each year over 18 years (OR 1.04 
CI 1.01-1.07). When the outcome was adjusted for admission within 7 days, a similar model was 
produced. 
Male sex 
There were 77 males in the magnesium group and 63 in the placebo group. There were no significant 
differences in baseline parameters or demographic variables between treatment groups. PEFs were 
lower in the magnesium group relative to placebo but not significantly.  
There was a 14.6% greater admission rate in the placebo group relative to the magnesium group 
which was not significant (p=0.072). When adjusted for re-admission within 7 days, this effect 
decreased slightly to 12% (p= 0.14). There were no other significant factors contributing to 
admission. For males, there was a significantly lower respiratory rate at 2 hours in the treatment group 
relative to placebo group (Table 18). The sex difference in the effect of magnesium on admission 
rates was significant (5.7 vs 14.6, p<0.05). 
 
 
Table 18. Secondary outcomes: males only, comparison between magnesium and placebo 
 







The sub-set analysis of the 3M study was similar to my clinical study in ethnicity of the population, 
demographics, age and treatment, which was standardised according to the same acute asthma 
treatment guideline [4]. Thus, this data, potentially provided a similar patient group in which to 
further assess the effects of sex and severity on response to magnesium. Severity was also assessed by 
the degree of airways obstruction, but PEF was used, and patients were included irrespective of the 
degree of airways obstruction. This resulted in asthmatics with a wide range of severities included in 
the 3M study who would have been excluded from my study. These patients could have been 
excluded from my sub-set analysis however, a large sample size was needed to assess the effects of 
sex on response to magnesium. Current OCS use at presentation, an indicator of severity and poor 
asthma control, and smoking status were documented. A subjective dyspnoea assessment was also 
included in the secondary outcome measures.  
This 3M study therefore provided a comparable but larger sample of ‘white’ Caucasian adult 
asthmatics from which sub-group analyses could be performed. The limiting factor, however, was 
inclusion of all participants, irrespective of initial β-2 agonist responses. 
 
4.3.1 Main findings 
Magnesium’s effect on admission rates 
This sub-analysis of the 3M trial has identified that magnesium can reduce admission rates in white 
Caucasian adults aged 18-50 years, presenting to emergency with an acute asthma exacerbation. The 
finding of statistical significance in this cohort differs from that of the original 3M study, but the 
difference in admission rates between magnesium and placebo was only slightly greater. The 
exclusion of those over 50, would have removed many of those participants with significant co-
morbidities that may have had a significant impact on the outcome. By excluding these participants in 
re-analysis, it was expected that there would be a greater influence of magnesium on admission rates 
hence, a greater reduction in admissions. Data from a national health survey in the USA found that 
asthmatics over 54 years-old, had worse outcomes in terms of the number of hospital admissions and 
mortality relative to younger asthmatics [557]. The overall admission rate decreased by only 2.8% 
relative to the original study, and the overall effect of magnesium on decreasing admission rates in the 
re-analysis was only 1% more than in the original study, which is surprisingly small.  
The original 3M study also included recruitment site in their logistical regression analysis and found a 
small effect of site on outcomes and effect of magnesium (unadjusted OR 0.72, CI 0.51-1.0, p=0.051; 




numbers which precluded the inclusion of site as a covariate. Exclusion of this covariate may have 
influenced the result in this analysis. Admission rates varied greatly between sites (45-95%), with the 
greatest variations in admission rates between centres with the least recruits. This is likely to reflect 
non-standardized admission policies; therefore, this covariate may have been a confounder in the 
original analyses. Local admission policies may have influenced outcomes irrespective of the effect of 
magnesium. This illustrates the importance of having well-defined admission/discharge criteria in 
clinical studies.  
The ability to conclude definitively that magnesium is effective in this subset analysis is limited. It is 
likely that a larger data set is needed to confirm magnesium’s overall effect on admission rates. 
Other variables that influenced admission rates 
The use of OCS prior to arrival and female sex were the strongest predictors of the outcome of 
admission to hospital. Most subjects in this study were female (>70%), consistent with the literature 
on emergency department presentations [287, 289]. Large cohort studies in adult asthmatics in the 
USA and Canada, have also shown that female asthmatics relative to male asthmatics are more likely 
to be admitted to hospital [285, 287, 291, 292]. A small study in Spain found the same increase in 
admission rates in females relative to males [558]. 
In this analysis, prior OCS use was associated with the greatest increase in odds of admission, 
controlling for all other factors including magnesium. Current OCS use is another marker of severity 
and indicates initiation of an asthma action plan. Regular and current OCS use has also been 
associated with an increased risk of hospital admissions in studies in the USA [559, 560], Canada 
[561] and Australian [562]. Females tended to use more OCS relative to males, which is also 
consistent with the literature [291]. There may have also been a significant interaction between sex 
and OCS use, which a larger sample size may have been able to detect.  
In this study, a 1% decrease in oxygen saturation increased admission rate by 23%. In a small study in 
Canada of those aged 18 to 55 years, who presented to emergency departments with asthma 
exacerbations, a saturation of <95% was associated with an almost two-fold increase in admission rate 
[561]. BTS guidelines classify a saturation of <92% with life-threatening disease [4]. Hypoxia is life 
threatening and an indicator of severity of disease; hence, it increases the risk of hospital admission. 
Secondary outcomes 
PEF values 
The re-analysis did not find magnesium to have significant effect on improvements in lung function 
as measured by changes in PEF values. Magnesium was given alongside optimal standard care as 




participants with good initial bronchodilator responses may have masked any benefit from 
magnesium.  
 
4.3.2 Subgroup analyses 
Severity 
Despite magnesium’s small overall benefit, the results of the subgroup re-analysis suggest that 
magnesium may be beneficial in those with severe exacerbations as defined by PEF 33-50% 
predicted. The reduction in admission rates was accompanied by small improvements in VAS but not 
in PEF.  
This contrasts with other studies where magnesium was most effective in those with predicted values 
<25-30%. Magnesium was shown to be effective in reducing admission rates in those with a FEV1 
<25% predicted [381], FEV1 <30% predicted [383] or PEF <200L/min [382]. The reductions in 
admission rates were large at 42% [381] and 45% [382]. Studies of the severe sub-groups also found 
between 10 and 25% greater improvements in airways obstruction relative to placebo [381-384]. The 
study populations were largely female. The reason for the difference in outcome in this subset may 
relate to ethnic differences. The 3M subset in this analysis was entirely white” whereas, the 
populations in these studies were “non-white” The possible influence of ethnicity on response to 
magnesium has already been discussed in detail in chapter one. The reason for the apparent benefit on 
admission rate in this subgroup is not clear.  
Sex 
The effect of magnesium on reduction in admission rates was greater in males relative to females; 
however, the effect of magnesium on admission rates in male asthmatics was not statistically 
significant, due to small sample size. There was, however, an improvement in VAS and respiratory 
rate. Whether these sex differences in efficacy are independent, or confounded by severity, is 
important given the sex differences in severity. The small sample size however, precluded our 
assessment of this. A larger sample size may also have been able to detect an interaction between sex 
and severity. 
Previous clinical trials of intravenous magnesium in acute asthma have not assessed the effects of sex 
on response to magnesium, and sample sizes would have been insufficient in most studies. Sex 
differences in adult asthma phenotypes have been well characterised and may account for the 
differences in efficacy. These data suggest that there are intrinsic sex differences in phenotypic 




4.3.3 Potential clinical benefits of magnesium in acute asthma 
Magnesium’s apparent effect on outcome of admission to hospital was not associated with any 
improvements in airways obstruction as measured by improvements in peak flow. It may be that any 
effect was masked by the inclusion of “treatment responders”. 
It is also possible that magnesium has other benefits in acute asthma that are not measurable with 
spirometry. In HASM, the increase in cAMP is also associated with alteration in tension due to 
alteration in cytoskeletal dynamics, as demonstrated in HASM where isoprenaline induced actin de-
polymerisation [167]. Clinically this would result in a reduction in ‘stiffness’ via alteration in the 
dynamic properties of HASM. A pharmacological effect of a reduction in stiffness has been 
demonstrated in healthy porcine ASM [163]. A reduction in stiffness could reduce the sensation of 
chest tightness and dyspnoea experienced. This would not be measurable using PEF but would result 
in a subjective improvement in dyspnoea as measured on a VAS scale; however, magnesium had no 
effect on VAS overall and the subgroups were likely to have been too small to detect the differences 
observed. 
Beta-2 agonists have also been shown to have anti-inflammatory effects in vitro through inhibition of 
TNF-α from mast cells [323] via an increase in cAMP [565]. Cyclic AMP elevation has also been 
shown to have anti-inflammatory activity in other cell types, including human neutrophils [566], 
monocytes [567] and cultured HASM cells [568]. Thus, magnesium may reduce inflammation via 
augmented β-2 agonist induced cAMP production. This may be another mechanism whereby 
magnesium could decrease admission rates without an improvement in PEF.  
 
4.3.4 Limitations 
Despite the relatively large sample size relative to previous studies, the data sample size was 
insufficient for a complete assessment of sub-groups and differences in baseline demographic 
parameters, such as ICS and OCS use, oxygen saturation, and secondary outcome of respiratory rate, 
between treatment groups in the sub-groups. A larger sample size may have altered the outcomes. The 
sample size was too small to compare the effect of severity within each sex, which may have revealed 
important differences in outcomes. The sample size of this sub-set analysis was also too small to 
assess the effects of magnesium in life threatening asthma or the need for non-invasive or invasive 
ventilation and intensive care or high-dependency admissions. Given that this was a sub-group 
analysis, there was increased risk of a type I errors; however, the findings in this analysis are 




There was missing data from the original data set with regards to ethnicity, therefore, these data were 
not included in the sub-set analysis. These data could have influenced the results. There was also 
missing sub-set data for variables such as smoking, and secondary outcome data including PEF, 
respirations and VAS at 2 hours, which could have influenced the results. The data used in this re-
analysis was collected across multiple centres and hence, there may have been variability in the 
reliability of PEFs and other observations, relative to the experience of researchers across these 
centres.  
Asthma control scores and atopic status were not documented, hence, the effects of these variables on 
outcomes could not be ascertained. Information on the length of stay was available, however, was not 
obtained from the original 3M data, due to an oversight on my behalf. 
 
4.3.5 Future directions 
As this was a sub-group analysis, further prospective studies should be undertaken to confirm these 
findings. The effects of race and sex have already been recognised as influencing the disease 
expression, however, the effects of race and sex in determining a response to magnesium, appear to be 
relevant and warrant further study. The effect of atopy on disease expression is also well recognised 
and should be further assessed in terms of response to magnesium. Retrospective analysis of previous 
studies may be useful; however, any future studies should clearly document ethnicity and atopic 
status, as they are important demographics for further understanding of the effects of magnesium in 
asthma. Studies assessing the effects of severity should be consistent in classification methods. The 
PEF reference ranges used in the BTS guideline appear to be appropriate for stratifying patients based 
on severity. 
The reason for magnesium’s reduction in admission rates has not been clearly illustrated. The use of 
PEF is limited in its ability to measure lung function and requires a forced expiratory manoeuvre, 
which can alter airway tone. Inhaled β-2 agonist has been shown to abolish deep inspiration induced 
bronchoconstriction in asthmatics [198]. Augmentation of β-2 agonist responses by magnesium, could 
enhance this effect and influence airway tone and AHR and may improve asthma symptoms and 
contribute to a reduction in admission rate. This effect would be difficult to assess by standard 
spirometry however, other measures of lung function may detect an alteration in airway tone. 
Studies have found the forced oscillatory technique (FOT) to be a useful tool for study of lung 
function in asthma [567-569]. FOT was able to detect differences in levels of airway obstruction, 
abnormalities in dynamic compliance and airways reactivity between healthy and asthmatic subjects 




in the level of airway obstruction between healthy and asthmatics subjects with normal FEV1 values 
[567]. FOT has been shown to be sensitive in detecting bronchodilation in children, but sensitivity in 
adults varies [568]. This may be due to differences in methodology, as a time lag between pressure 
and flow measurements can reduce accuracy [570] which can be corrected with the appropriate choice 
of a FOT machine. Further studies using additional outcome measures as determined by FOT, such as 
dynamic compliance and airways reactivity in addition to obstruction, may reveal the mechanism of 
benefit from the use of magnesium in acute asthma. Recently, there have been recommendations for 
targeting regulatable stiffness in the treatment of asthma [571], suggesting that these measures may be 




Although my findings in this sub-set analysis support the role of magnesium in treating acute asthma 
exacerbations, in severe asthma, the ability to fully analyse subgroups was limited by sample size 
within these subgroups. The findings suggest that the benefits of magnesium are modest overall; 
however, there may be a greater benefit in males, as they are likely to present with more ‘acute’ 
presentations and those with severe exacerbations as defined by presenting PEF 33-50% predicted. 
These sub-group findings are relevant to Caucasian populations in whom the overall efficacy may 
differ from other ethnicities. The reasons for these differences may relate to bronchodilator 
responsiveness or genetic variation. Further study could be warranted to explore the effects of 












Chapter 5: Final discussion 
 
5.1 Summary 
This thesis was unable to conclusively show that magnesium was an effective in the treatment in the 
management of acute asthma exacerbations. By re-examining selective data from a larger study, it 
was possible to show that magnesium reduced hospital admission rates in the subgroup of severe 
asthma.  
Asthma is a heterogeneous condition with individual variations in immuno-pathological and 
phenotypic manifestations. It follows that clinical presentation and treatment responses also vary and 
are also influenced by individual factors such as sex, race and atopy. When assessing magnesium’s 
efficacy, these factors should be taken in to consideration as they may influence treatment response. 
Individual variation in response is likely to account for the modest overall effect. This means that 
larger sample sizes are required to fully assess the utility of magnesium in acute asthma. Magnesium 
may be effective in certain populations, despite a lack of conclusive evidence in the literature. Larger 
studies are needed to fully assess the influence of individual factors such as sex, race and atopy on 
response to magnesium in the treatment of acute asthma. 
The laboratory study illustrated a potential mechanism of action for magnesium in acute asthma and 
some explanation for its variable efficacy. This needs further study with larger numbers to confirm 
these observations and to fully explore the effects of individual factors, such as sex, ethnicity and 
atopy, on treatment response. Magnesium may increase β-2 agonist stimulated cAMP in a dose 
dependent manner and proportionate to agonist strength. The likely mechanism for the increase in 
cAMP, is via an increase in an agonist binding to the β-2AR. This requires ligand binding studies for 
confirmation. There were sex differences in lymphocyte responses to magnesium and overall cAMP 
production, and others have also demonstrated sex and racial differences in lymphocyte cAMP 
production as discussed in chapter two. This could explain the mechanism whereby the variation in 
response to magnesium occurs and hence, explain the heterogeneity of the results of previous studies 
of magnesium in asthma. Magnesium, when used as an adjunct to standard care, may improve clinical 
outcomes in some sub-groups of patients presenting with acute exacerbations.  
Magnesium is inexpensive and easy to administer, with few if any serious adverse effects at modest 
doses. The literature supports this, at least in theory. The overall effects of its usage may be difficult 
to appreciate, however, a small overall reduction in hospital admission rate would be beneficial due to 
the high demands on limited health care resources around the world. The impact of an 8% reduction 




national figures on health expenditure [556]. One ampule (2.5g) of magnesium costs around £2 and 
therefore, if found to be efficacious, would be a cost-effective addition to the treatment of acute 
asthma exacerbations. The benefits are likely to be more significant in a targeted population. 
 
5.2 Recommendations regarding the use of magnesium in acute asthma exacerbations 
 
Magnesium could be considered as an adjunct to standard treatment of an acute exacerbation in those 
that present with acute, sudden, severe symptoms. It may reduce admission rates and/or improve 
symptoms of breathlessness. It is unlikely to do any harm and may be of benefit. Guidelines 
recommend 2g however, a dose of 2.5g could be given and repeated, if there is limited response to the 
initial dose. Theoretically, an initial dose of 5g could be given in those with normal renal function. 
 
5.3 The mechanism of action of magnesium and its modification of efficacy by sex  
 
Beta-2 agonist stimulation of the β-2AR induces HASM relaxation and bronchodilation through 
production of cAMP [317] and causes a reduction in passive tension or ‘stiffness’[163] (Figure 10). If 
magnesium were to augment β-2 agonist stimulated cAMP, it could potentially increase HASM 
relaxation, reduce stiffness and perhaps, reduce airway hyper-responsiveness. Magnesium’s efficacy 
is, therefore, dependent on the properties and function of the  β-2AR.  
Sex differences in lymphocyte β-2ARs were demonstrated in stable asthmatics, where female 
asthmatics showed a greater degree of down-regulation of receptor response to SABA exposure 
relative to male asthmatics, as shown by the greater loss of β-2 agonist induced cAMP. Down-
regulation of β-2 responses in lymphocytes also occurs in mast cells [563], and the greater loss of 
receptor function could also occur in these cell types. A greater loss of responsiveness may result in 
the inability of magnesium to increase β-2 agonist stimulated cAMP in female asthmatics relative to 
male asthmatics. An increase in binding to the β-2 adrenergic receptor would have minimal effect 
where a greater loss of surface receptors reduces the capacity to generate cAMP. This lack of capacity 










Figure 10. Proposed mechanism of action of magnesium. Increased binding of β-2 agonist to β-2AR. 
Consequent increase in cAMP/PKA pathways and cAMP/PKA independent pathways. Reduction in 
intracellular calcium via inhibition of store operated calcium channels; IP3 induced release from 
sarcoplasmic reticulum and increased SERCA activity. Reduction in calcium oscillation frequency, 
reduced phosphorylation of myosin light chain. These mechanisms decrease acto-myosin cross bridge 







5.4 Future directions 
 
Magnesium appears to increase β-2 agonist stimulated cAMP however, a larger study is needed to 
confirm this. The potential mechanism appears to be that of increased affinity for the receptor. The 
use of radio-ligand binding assays may confirm the mechanism responsible for the observed effects of 
magnesium on cAMP production. Results of such studies may also explain the sex differences in 
cAMP response and further explain the sex differences in the effects of magnesium. Further study of 
the anti-inflammatory effects of magnesium and its effects on airway dynamics could also provide 
information about its mechanism of effect. 
Response to magnesium may vary with atopic status, and there may be an interaction between atopy 
and sex. Further studies in lymphocytes, comparing the effects of magnesium on β-2 agonist 
stimulated cAMP in male and female atopic, and male and female non-atopic asthmatics, may provide 
important information regarding differences in efficacy and further optimise the selection of 
asthmatics most or least likely to benefit from magnesium. 
Further clinical studies would be helpful in ascertaining the effects of sex, atopy and ethnicity on 
response to treatment with magnesium. Further clinical studies should document racial background, 
atopic status and an asthma control score. Studies should be adequately powered for the outcomes, 
such that small but clinically significant differences may be measured. It is also important to consider 
ethnic differences in response to treatment and it would be reasonable to report results of further 
studies based on race or ethnicity. Statistical advice should be sought to determine the sample sizes 
needed and as such, is it likely that larger numbers would be required. This would also require a 
multicentre approach and adequate funding. Further study into the effects of magnesium may provide 
evidence to support its more widespread use, and its potential to improve outcomes for those with a 
greater risk of adverse outcomes. 
 
5.5 Clinical recommendations  
 
Magnesium is safe, inexpensive, and easy to administer. It is included in current acute asthma 
treatment guidelines and therefore, may be considered as an adjunct to standard treatment of an acute 
asthma exacerbation, in an acute, sudden severe exacerbation, when the patient does not respond to 
standard treatment or deteriorates. It could also be considered early in the course of treatment of acute 
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